Archived Medical News Stories

RSSArchived Drug Trial News Stories - 2010

Date Title Comments Rating
2010-12-30 Immunitor reports positive safety imm01 clinical trial against tuberculosis 0 None
2010-12-30 Enrollment commences in belinostat-Tarceva combination trial for NSCLC 0 None
2010-12-29 Dosing initiated in combination Phase I study of palifosfamide with etoposide and cisplatin/carboplatin in SCLC 0 None
2010-12-29 Positive results from OMS201 Phase 1/2 trial in patients undergoing urologic procedures 0 None
2010-12-29 CEL-SCI initiates Multikine Phase III trail for head and neck cancer 0 None
2010-12-29 Merck confirms plans for developing vernakalant drug for atrial fibrillation 0 None
2010-12-28 Sinovac's inactivated EV71 vaccine clinical trial against HFMD receives Chinese SFDA approval 0 None
2010-12-28 Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease 0 None
2010-12-28 Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme 0 None
2010-12-28 Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia 0 None
2010-12-27 Emergent initiates AV7909 Phase I trail for Anthrax vaccine 0 None
2010-12-23 Target enrollment reached in belinostat Phase 2 study in Carcinoma of Unknown Primary 0 None
2010-12-23 Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand 0 None
2010-12-23 Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension 0 None
2010-12-23 Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM 0 None
2010-12-23 Medicago completes first part of H5N1 vaccine Phase II trial 0 None
2010-12-23 Gilead stops ARTEMIS-IPF ambrisentan Phase III clinical trial in idiopathic pulmonary fibrosis 0 None
2010-12-23 Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease 0 None
2010-12-23 Abbott, AstraZeneca discontinue CERTRIAD development collaboration 0 None
2010-12-22 Tekmira begins patient dosing in TKM-PLK1 phase 1 trail for cancer 0 None
2010-12-22 Antares Pharma submits NDA for Anturol Gel in patients with overactive bladder 0 None
2010-12-22 New era for anticoagulant therapy 0 None
2010-12-22 BioCryst commences BCX4208/allopurinol combination Phase 2b study in gout patients 0 None
2010-12-22 Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV 0 None
2010-12-22 Amorcyte reports AMR-001 phase I trial results in heart attack patients 0 None
2010-12-21 Anavex files regulatory submission in Germany for ANAVEX 2-73 Phase I trial in Alzheimer's disease 0 None
2010-12-21 Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia 0 None
2010-12-21 Biovest issues FAQ update on BiovaxID personalized cancer vaccine 0 5
2010-12-21 Emisphere, Novo Nordisk partner to develop and commercialize oral formulations of insulins 0 None
2010-12-21 Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy 0 None
2010-12-21 Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis 0 None
2010-12-20 Ambit commences Phase I advanced solid tumor trials for AC430 and AC480 inhibitors 0 None
2010-12-20 VistaGen reports successful completion of AV-101 Phase 1 safety study for neuropathic pain 0 None
2010-12-20 Bristol-Myers Squibb, Oncolys complete license agreement for festinavir 0 None
2010-12-20 Rexahn granted Japanese patent for preclinical compound RX-0047 0 None
2010-12-20 Oncothyreon commences combination PX-866/cetuximab Phase 1/2 trial in cancers 0 None
2010-12-20 Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients 0 None
2010-12-20 Fibrocell Science submits response to FDA CR letter for azficel-T BLA 0 None
2010-12-20 Aeterna Zentaris reaches agreement with FDA for Solorel SPA as a diagnostic test in AGHD 0 None
2010-12-20 Icagen, Pfizer commence Nav1.7 Phase I clinical studies for pain and related disorders 0 None
2010-12-20 Positive top-line results from VEGF Trap-Eye Phase 3 studies in macular edema due to CRVO 0 1
2010-12-20 Chelsea completes successful NORTHERA pre-NDA assessment with FDA 0 None
2010-12-20 SEEK announces new joint venture entity with Pernix Therapeutics for antitussive drug development 0 None
2010-12-20 Cardio3 BioSciences presents positive C3BS-GQR-1 results in patients with acute myocardial infarction 0 None
2010-12-20 Inspire's denufosol tetrasodium TIGER-1 Phase 3 trial for CF published in AJRCCM 0 None
2010-12-20 4SC AG's Phase IIb study evaluates efficacy of vidofludimus in RA patients 0 None
2010-12-19 CF patients with normal to mildly impaired lung function may benefit from new investigational drug 0 None
2010-12-17 Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients 0 None
2010-12-17 Catalyst receives $4.0M milestone payment from Pfizer under hemophilia Factor VIIa program 0 None
2010-12-17 MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA 0 None
2010-12-17 NovImmune obtains additional financing of CHF 20 million 0 None
2010-12-17 Repros prepares for dosing 3 mg cohort in low dose Proellex study in uterine fibroids and endometriosis 0 5
2010-12-17 GSK, Impax enter global development, commercialization agreement for PD investigational product, IPX066 0 None
2010-12-17 FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression 0 None
2010-12-17 Recordati, Nymox sign European licensing agreement for BPH investigational drug, NX-1207 0 None
2010-12-16 FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate 0 None
2010-12-16 Anacor Pharmaceuticals initiates AN2690 phase 3 program for onychomycosis fungal infection 0 None
2010-12-16 Researchers begin placebo-controlled trial to test drug treatment for Rett syndrome 0 None
2010-12-16 Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor 1 None
2010-12-16 Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels 0 None
2010-12-16 BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis 0 None
2010-12-16 CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer 0 None
2010-12-16 ADVENTRX seeks meeting with FDA to discuss ANX-514 docetaxel emulsion study findings 0 None
2010-12-16 Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea 0 None
2010-12-16 HealthLinx's OvPlex performs better over CA125 in part 1 of multinational ovarian cancer biomarker study 0 None
2010-12-16 Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth 0 None
2010-12-16 Ocera completes two studies of OCR-002 in patients with hyperammonemia, hepatic encephalopathy 0 5
2010-12-15 Clinical Investigation – ground-breaking new launch from Future Science 0 None
2010-12-15 Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma 0 None
2010-12-15 Charité begins implementation of MGN1601 clinical phase I/II study in renal cancer 0 None
2010-12-15 Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study 0 None
2010-12-15 Researchers introduce new class of drugs for HCV patients 0 None
2010-12-15 MHRA issues notice of acceptance for BioMarin's GALNS Phase 3 trial in MPS IVA 0 None
2010-12-15 Positive results from Creabilis CT327 Phase IIa study in atopic dermatitis 0 None
2010-12-15 Ipsen discontinues development of chimeric compound BIM 23A760 for acromegaly 0 None
2010-12-15 Myotec, Hybrid merge to form PsiOxus Therapeutics 0 None
2010-12-15 NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer 0 None
2010-12-15 Amira's clinical-stage DP2 receptor antagonist program data to be presented at Pacifichem 2010 0 None
2010-12-15 CGEN-15001 administration shows dramatic therapeutic potential in CIA animal model 0 None
2010-12-15 Hemispherx granted extension to modify Ampligen NDA for CFS indication 0 None
2010-12-15 DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients 0 5
2010-12-15 Abbott initiates ABT-806 Phase 1 trial in EGFR expressing tumors 0 4
2010-12-14 ISTA commences bepotastine besilate nasal spray Phase 2 study in seasonal allergic rhinitis 0 None
2010-12-14 Glycotope receives innovation award 2010 for GlycoExpress technology platform 0 None
2010-12-14 Tolerx commences TRX518 Phase 1 trial in malignant melanoma 0 None
2010-12-14 Provectus commences PH-10 Phase 2c trial for psoriasis 0 None
2010-12-14 VIVUS submits briefing document to FDA in effort to secure regulatory approval for QNEXA 0 None
2010-12-14 Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma 0 None
2010-12-14 Lexicon reports top-line results from LX2931 Phase 2a study in rheumatoid arthritis 0 None
2010-12-14 Pharmasset initiates dosing in PSI-7977 exploratory study in HCV 0 None
2010-12-14 Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced 0 None
2010-12-14 Unigene enters agreement with GSK to advance oral PTH Phase 2 program for osteoporosis 0 None
2010-12-14 Orexo announces successful completion of OX219 initial pharmacokinetic trial for opioid dependence 0 None
2010-12-14 Nektar reports positive results from NKTR-102 Phase 2 study in metastatic breast cancer at CTRC-AACR SABCS 0 None
2010-12-14 GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer 0 None
2010-12-14 Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV 0 None
2010-12-14 Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE 0 None
2010-12-14 Drug to reverse immunological decline in aging 0 None
2010-12-14 Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles 0 None
2010-12-14 Capstone presents AZX100 Phase 2a trial results for keloid and trocar site scarring 0 None
2010-12-14 FDA to review Lantheus' DEFINITY sNDA for use in stress echocardiography 0 None
2010-12-13 Lilly suspends tasisulam global Phase III study in metastatic melanoma 0 None
2010-12-13 PREZISTA/ritonavir once-daily dosing for HIV-1 receives FDA approval for treatment in no DRV RAM adults 0 None
2010-12-13 Intercell to stop further development of Travelers' Diarrhea Vaccine Patch 0 None
2010-12-13 Bionovo reports positive Menerba clinical program meeting with FDA 0 None
2010-12-13 New positive data on Generex Oral-lyn published in Diabetes, Obesity and Metabolism 0 None
2010-12-13 Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer 0 None
2010-12-13 GeparQuinto study data on bevacizumab plus chemotherapy in early breast cancer to be presented at 33rd CTRC-AACR 0 None
2010-12-13 Syndax reports promising results from entinostat preclinical studies in breast cancer 0 None
2010-12-13 Xeloda may reduce recurrence of faster growing breast cancers: Study 0 None
2010-12-13 Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC 0 None
2010-12-13 Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial 0 None
2010-12-13 Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients 0 None
2010-12-13 Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer 0 None
2010-12-10 Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer 0 None
2010-12-10 Pfizer withdraws Thelin for treatment of PAH, discontinues global clinical studies 0 None
2010-12-10 Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension 0 None
2010-12-10 Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results 0 None
2010-12-10 Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c 0 None
2010-12-10 Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer 0 None
2010-12-10 Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin 0 None
2010-12-10 GeoVax's phase 2a trial results indicate excellent safety profile for HIV vaccine 0 5
2010-12-10 Talecris initiates clinical trial to evaluate 2 doses of PROLASTIN-C for emphysema due to AAT deficiency 0 None
2010-12-10 Results of Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer to be presented at symposium 0 None
2010-12-10 Biovex announces OncoVEXGM-CSF Phase 3 study for head and neck cancer 0 None
2010-12-10 Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010 0 None
2010-12-09 Acorda initiates enrollment in GGF2 Phase 1 clinical trial in patients with heart failure 0 None
2010-12-09 BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain 0 None
2010-12-09 Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program 0 None
2010-12-09 Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting 0 None
2010-12-09 Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia 0 None
2010-12-09 Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients 0 None
2010-12-09 Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis 0 None
2010-12-09 VIRxSYS presents study results of VRX1116 at HIV DART 2010 0 None
2010-12-09 p53 activation offers a novel strategy for cancer therapy 0 None
2010-12-09 New technique jumpstarts growth of nerve fibers to reverse stroke damage 0 None
2010-12-09 Euthymics announces EB-1010 Phase II data for major depressive disorder at ACNP meeting 0 None
2010-12-09 Clinical data of pomalidomide for treating patients with multiple myeloma presented at ASH 2010 0 1.5
2010-12-09 Euthymics's EB-1010 effective in treatment of major depressive disorder: Study 0 None
2010-12-09 Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence 0 None
2010-12-08 Bavarian Nordic receives SPA for Phase 3 study of PROSTVAC for advanced prostate cancer 0 4
2010-12-08 Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH 0 None
2010-12-08 Low-dose diazepam with NS-398 combination has twice the neuroprotective effect of NS-398 alone 0 None
2010-12-08 AiCuris announces completion of AIC316 Phase II genital herpes trial 0 5
2010-12-08 Novel therapy against hepatitis C disease 0 None
2010-12-08 SEEK reports Phase I safety trail for investigational flu vaccine 0 None
2010-12-08 Three abstracts on Defibrotide presented at ASH Annual Meeting 0 None
2010-12-08 Journal of Hand Surgery publishes XIAFLEX CORD II phase III clinical trial 0 None
2010-12-08 Immunomedics reports CD22 antibody produced significant anti-tumor response 0 None
2010-12-08 Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH 0 None
2010-12-08 GlycoMimetics highlights clinical, preclinical progress of GMI-1070 in sickle cell crisis at ASH 2010 0 None
2010-12-08 FDA Advisory Committee votes in favor of Orexigen's Contrave for treatment of obesity 0 None
2010-12-08 QLT's oral synthetic retinoid granted orphan drug designation for treatment of Leber Congenital Amaurosis 0 5
2010-12-08 FDA grants QLT's QLT091001 orphan drug designation for treatment of Retinitis Pigmentosa 0 None
2010-12-07 Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma 0 None
2010-12-07 Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL 0 5
2010-12-07 John Theurer Cancer Center presents research findings at ASH meeting 0 None
2010-12-07 Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010 0 None
2010-12-07 Roche completes enrollment in Herceptin SC Phase 3 trial for HER2-positive breast cancer 0 None
2010-12-07 Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma 0 None
2010-12-07 Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma 0 None
2010-12-07 Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients 0 None
2010-12-07 Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH 0 None
2010-12-07 Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients 0 None
2010-12-07 Phase 1 study results of Aduro BioTech's CRS-207 presented at AACR Conference on Tumor Immunology 0 None
2010-12-07 Epratuzumab-rituximab combination therapy effective against previously untreated follicular lymphoma 0 None
2010-12-07 Lytix Biopharma, KAEL-GemVax initiate treatment in LTX-315/GV1001 combination anti-cancer vaccine trial 0 None
2010-12-07 Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH 0 None
2010-12-07 IMO-4200 dual agonist increases antitumor activity in lymphoma models: Study 0 None
2010-12-07 Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma 0 None
2010-12-07 Positive results from PROCHIEVE 8% vaginal progesterone gel Phase III trial to reduce preterm birth risk 0 None
2010-12-07 Global phase III study to provide novel extended release of topiramate 0 None
2010-12-07 Mayo Clinic scientists say JAK inhibitors may help treat patients with myelofibrosis 0 5
2010-12-07 Clinical trial results of ACY-1215 in multiple myeloma published in scientific journal of ASH 0 None
2010-12-07 Positive interim data from Phase I/II trial of CYT387 in myelofibrosis presented at ASH Annual Meeting 0 None
2010-12-07 rVWF safe in patients with type 3 and severe type 1 von Willebrand disease, suggests interim study data 0 5
2010-12-07 New drug appears to help patients with chronic myeloid leukemia 0 None
2010-12-07 Ascenta, LLS enter agreement to develop AT-406 IAP small molecule inhibitor for acute myeloid leukemia 0 None
2010-12-07 Sequella files SQ109 IND for Phase 2 studies in H. pylori-related duodenal ulcers 0 None
2010-12-07 New analysis of Soliris in patients with PNH presented at ASH Annual Meeting 0 5
2010-12-07 FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA 0 None
2010-12-07 VIVUS reports positive results from avanafil phase 3 study in erectile dysfunction 0 None
2010-12-07 GeoVax expands Phase 2a clinical trial for MVA62B HIV/AIDS vaccine 0 None
2010-12-07 No evidence of toxicity in hemophilia B patients enrolled in gene therapy trial 0 None
2010-12-07 ArQule initiates enrollment in ARQ 736 Phase 1 clinical trial for advanced solid tumors 0 None
2010-12-06 Achillion Pharmaceuticals to present clinical study data of ACH-1625 at APASL 2011 0 5
2010-12-06 Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010 0 None
2010-12-06 Fraunhofer USA CMB receives FDA approval to initiate Phase I clinical trial of H5N1 influenza vaccine 0 None
2010-12-06 Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL 0 None
2010-12-06 Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS 0 None
2010-12-06 Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH 0 None
2010-12-06 Genentech announces Phase II study results of RG1678 for treatment of schizophrenia 0 None
2010-12-06 New research focusing on VTE presented at ASH Annual Meeting 0 None
2010-12-06 Phase 1 clinical data: ARRY-520 shows positive preliminary results in treating multiple myeloma 0 None
2010-12-06 Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting 0 None
2010-12-06 Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010 0 None
2010-12-06 Cell Therapeutics announces new pixantrone EOS follow up results 0 5
2010-12-06 Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma 0 None
2010-12-06 Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010 0 5
2010-12-06 Immunomedics reports results of milatuzumab-based combination treatments for NHL patients 0 None
2010-12-06 Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases 0 None
2010-12-06 BioCryst reports Phase 2 trial data of forodesine in patients with CLL 0 None
2010-12-06 Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010 0 None
2010-12-06 Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody 0 None
2010-12-06 Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010 0 None
2010-12-06 Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression 0 4.5
2010-12-06 Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting 0 None
2010-12-06 Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS 0 None
2010-12-06 Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting 0 None
2010-12-06 Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting 0 None
2010-12-06 Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH 0 None
2010-12-06 Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting 0 5
2010-12-05 QRxPharma completes patient enrolment of pivotal MoxDuo IR phase 3 study 0 None
2010-12-04 Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition 0 None
2010-12-04 Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease 0 None
2010-12-04 Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A 0 3
2010-12-04 Pfizer plans regulatory submissions of bosutinib for CML based on BELA study 0 None
2010-12-04 Onconova announces three presentations on Estybon- (ON 01910.Na) at ASH 2010 0 None
2010-12-04 Merck to present multiple clinical studies of dinaciclib at ASH Annual Meeting 0 None
2010-12-04 Mitoxantrone increases survival for children with relapsed ALL, trial results show 0 None
2010-12-04 Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study 0 None
2010-12-04 FDA extends PDUFA review target date for BENLYSTA BLA to treat systemic lupus erythematosus 0 None
2010-12-04 Phase III studies should make meaningful difference in patients' quality of life: Commentary 0 None
2010-12-03 SuperGen to present SGI-110 data for MDS, AML at ASH annual meeting 0 None
2010-12-03 Arthritis drug reduces incidence of non-melanoma skin cancers 0 None
2010-12-03 MHRA issues notice of acceptance for BioMarin's BMN 673 for genetically-defined cancers 0 None
2010-12-03 FDA accepts IND application to initiate human clinical trial to evaluate BNC 0 None
2010-12-03 Sirnaomics cemented partnership with Chinese pharmaceutical to develop siRNA therapeutics 0 None
2010-12-03 Geron commences enrollment in imetelstat Phase 2 clinical trial for metastatic breast cancer 0 None
2010-12-02 Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL 0 None
2010-12-02 Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting 0 None
2010-12-02 Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes 0 None
2010-12-02 AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium 0 None
2010-12-02 Shire reports topline results from FAST-3 Firazyr Phase III trials for acute attacks of hereditary angioedema 0 None
2010-12-02 Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting 0 None
2010-12-02 Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders 0 None
2010-12-02 CytRx commences tamibarotene Phase 2b clinical trial in NSCLC 0 None
2010-12-02 Wake Forest University to begin clinical trial for low-grade gliomas 0 None
2010-12-02 Daiichi Sankyo completes patient enrollment in Phase III edoxaban study for AF 0 None
2010-12-02 Oncolytics initiates enrollment in Phase II ovarian cancer study 0 5
2010-12-02 Oramed announces publication of GLP-1 analog formulation in Journal of Diabetes 0 None
2010-12-02 Tolerx enters collaborative research agreement with Cancer Research Institute 0 None
2010-12-01 Pfizer to present data on hematology portfolio at ASH Annual Meeting 0 None
2010-12-01 SPARTAC study examines ways to limit immune system damage in HIV infection 0 5
2010-12-01 Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH 0 None
2010-12-01 Physician-scientists enroll patients with NSCLC cancer in MAGE-A3 Phase III trial 0 None
2010-12-01 Results of pixantrone phase III trial for non-Hodgkin's lymphoma to be presented at Hematology Meeting 0 None
2010-12-01 New brain imaging technique can trace effects of SYN115 drug in Parkinson's disease 0 None
2010-12-01 Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting 0 None
2010-12-01 Rush University enrolls first U.S. patient in international clinical trial for melanoma 0 None
2010-12-01 Array BioPharma achieves $10 million clinical research milestone in Celgene collaboration 0 None
2010-12-01 GenSpera expands G-202 Phase I safety trial to CTRC at University of Texas Health Science Center 0 None
2010-12-01 PhaseBio initiates Glymera Phase 1/2a clinical trial in patients with Type 2 diabetes 0 None
2010-12-01 Pfizer awards $2.1 million grant to NCCN to evaluate axitinib in solid tumors 0 None
2010-11-30 NSAID Celebrex may help prevent non-melanoma skin cancer development: Research 0 None
2010-11-30 Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients 0 None
2010-11-30 Ikaria initiates enrollment in LUCASSIN Phase III trial for HRS Type 1 0 None
2010-11-30 Argos commences dosing in Arcelis personalized immunotherapy Phase 2b clinical trial for HIV 0 None
2010-11-30 FDA approves Inspire to begin STAR clinical trial to evaluate UAS therapy for OSA 0 None
2010-11-30 Neuraltus reports positive results from NP001 Phase 1 study for ALS 0 1.8
2010-11-30 Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma 0 None
2010-11-30 Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain 0 None
2010-11-30 Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia 0 4.5
2010-11-30 Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia 0 None
2010-11-30 Pharmasset commences combination study of PSI-7977 and PSI-938 nucleotide analogs in HCV 0 None
2010-11-30 ImmunoGen initiates IMGN901 Phase I/II clinical trial in SCLC patients 0 None
2010-11-30 Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML 0 None
2010-11-30 ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting 0 None
2010-11-30 DATATRAK applauds Cosmo Pharmaceuticals for positive top-line results from budesonide MMX 0 None
2010-11-30 FG-2216 drug offers new treatment option for kidney disease-related anemia 0 None
2010-11-30 GeoVax supports Bionor's Phase 2b trial of therapeutic HIV/AIDS vaccine 0 None
2010-11-30 Sanofi Pasteur commences phase II clinical study of vaccine for Clostridium difficile infection prevention 0 None
2010-11-30 Long-term phase 3 trial confirms safety of lubiprostone in Japanese patients with chronic idiopathic constipation 0 None
2010-11-30 NIAID scientists confirm antiviral activity of two lead compounds against HPV 1 5
2010-11-30 Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer 0 None
2010-11-30 Array BioPharma to present data on ARRY-520 Phase 1 trial for multiple myeloma at ASH Annual Meeting 0 None
2010-11-30 Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting 0 None
2010-11-30 Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting 0 None
2010-11-29 Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting 0 None
2010-11-29 FDA approves Merit's phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere Microspheres 0 None
2010-11-29 Merck announces initial results from ISENTRESS Phase III study in HIV-1 0 None
2010-11-29 Hemispherx requests FDA time extension for Ampligen NDA data resubmission 0 None
2010-11-29 Positive results from Oncolytics' combination REOLYSIN-docetaxel Phase I trial in advanced cancer 0 None
2010-11-29 Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides 0 None
2010-11-25 Phase 3 trial: TYSABRI improves vision in MS patients 0 None
2010-11-25 Neptune, Acasti completes preclinical program comparing CaPre with Lovaza 0 None
2010-11-25 Response to PLX4032 drug short lived in BRAF-mutated metastatic melanoma patients 0 None
2010-11-24 Advaxis initiates ADXS11-001 clinical trial for cervix cancer 0 None
2010-11-24 A new treatment landscape for triple-negative breast cancer 0 None
2010-11-24 FTC/TDF tablet reduces HIV infection among high-risk individuals: iPrEx study 0 None
2010-11-24 GCM supports iPrEx Study to prevent HIV infection among MSM 0 None
2010-11-24 Important queries about PrEP, iPrEx trial for HIV infection 0 None
2010-11-24 HIV treatment drugs also help prevent HIV infection in high-risk men: Study 1 None
2010-11-24 iPrEx study: PrEP reduces HIV infection risk among gay, bisexual men 0 None
2010-11-24 iPrEx trial shows reduction in new HIV infections 0 None
2010-11-24 Provectus reports progress in PV-10 program for metastatic melanoma 0 None
2010-11-24 iPrEx oral PrEP study achieves major milestone in HIV prevention research 0 None
2010-11-24 CONRAD congratulates Global iPrEx study team for HIV prevention trial 0 None
2010-11-24 XenoPort receives grant from Michael J. Fox Foundation to support Parkinson's disease therapies 0 None
2010-11-23 ViiV Healthcare awards $20 million to Idenix for GSK2248761 clinical milestone 0 None
2010-11-23 CEL-SCI holds clinical investigator meeting for Multikine Phase III clinical trial in head, neck cancer 0 5
2010-11-23 DoD awards Regenicin and Lonza $18 million to develop PermaDerm for severe burns 0 None
2010-11-23 Compugen announces development of Protein Family Members Discovery Platform 0 None
2010-11-23 Preclinical trial shows Chimerix’s CMX001 inhibits HSV replication 0 None
2010-11-23 Hemispherx announces publication of Ampligen Phase III data in Journal of Applied Research 0 None
2010-11-23 Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program 0 None
2010-11-23 BioCancell raises $5.1 million by excess demand in public offering 0 None
2010-11-22 Winston announces Phase II study results of Dolorac for chronic migraine at Lazard Conference 0 None
2010-11-22 Stem cell trial for eye disease receives FDA approval 2 4.7
2010-11-22 Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides 0 5
2010-11-22 Neurocrine announces results from elagolix Phase II Daisy PETAL study in endometriosis 0 None
2010-11-22 FDA grants ACT clearance for Phase I/II clinical trial of hESC derived retinal cells in patients with SMD 0 None
2010-11-22 Mimetogen initiates MIM-D3 Phase II clinical trial for dry eye disease 0 None
2010-11-22 S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies 0 None
2010-11-22 Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy 0 None
2010-11-22 Acthar Gel may be a viable treatment option for resistant nephrotic syndrome 0 None
2010-11-22 Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions 0 None
2010-11-22 Cell Therapeutics announces preliminary results of phase II OPAXIO study for high-grade gliomas 0 None
2010-11-22 VYTORIN reduces major vascular events in patients with chronic kidney disease 1 3.5
2010-11-22 Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD 0 None
2010-11-22 SHARP study shows cholesterol-lowering effective for patients with kidney disease 0 None
2010-11-22 Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function 0 None
2010-11-21 Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints 0 None
2010-11-21 Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting 0 None
2010-11-20 Myrexis announces poster presentation on Azixa at Neuro-Oncology Scientific Meeting 0 None
2010-11-20 Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting 0 None
2010-11-20 Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting 0 None
2010-11-20 Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint 0 None
2010-11-20 VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies 0 None
2010-11-20 Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium 0 None
2010-11-19 Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix 0 None
2010-11-19 FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia 0 None
2010-11-19 Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting 0 None
2010-11-19 AVEO's RON antibody shows anti-tumor activity in human cancer xenografts 0 None
2010-11-19 ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium 0 None
2010-11-19 ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium 0 None
2010-11-19 Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium 0 None
2010-11-19 ACE-041 drug may provide new option to treat cancer 0 None
2010-11-19 DoD recommends funding for Synta's STA-9584 for prostate cancer study 0 None
2010-11-19 Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS 0 1
2010-11-19 GRAVITAS Trial finds high dose of clopidogrel does not reduce risk of ischemic events 0 None
2010-11-19 AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers 0 None
2010-11-19 COG to conduct Phase I REOLYSIN trial in pediatric patients with solid tumors 0 None
2010-11-19 Zalicus presents data on novel synergistic drug combinations for cancer at EORTC-NCI-AACR Symposium 0 None
2010-11-19 OXiGENE updates data on FALCON trial for non-small cell lung cancer 0 None
2010-11-19 YM BioSciences expands CYT387 Phase I/II clinical trial for myelofibrosis in five sites 0 None
2010-11-19 Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure 0 None
2010-11-19 Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A 0 None
2010-11-19 Spectrum to present four key belinostat data for solid cancers at ASH annual meeting 0 None
2010-11-19 Impax announces positive top-line results of Phase III IPX066 study for Parkinson's disease 0 2
2010-11-19 Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York 0 None
2010-11-19 Cerulean presents data on CRLX101, CRLX288 study for cancer at EORTC-NCI-AACR Symposium 0 None
2010-11-19 Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium 0 None
2010-11-18 Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium 0 None
2010-11-18 Circassia announces positive result from phase II T-cell vaccine study for house dust mite allergy 0 None
2010-11-18 Naurex's antidepressant shares efficacy mechanisms with NMDA receptor antagonist ketamine 0 5
2010-11-18 Researchers report results from Phase III DEFINE study for coronary heart disease 0 5
2010-11-18 Access Pharmaceuticals to present two oncology posters at CPR Conference 0 None
2010-11-18 Medivir AB reports positive interim data on Phase 2b ASPIRE study for hepatitis C 0 None
2010-11-18 MK-4827 drug candidate shows promising anti-tumour activity in first human trial 0 None
2010-11-18 Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer 0 3
2010-11-18 Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer 0 5
2010-11-18 Inovio achieves positive results in Phase I PENNVAX-B study for HIV 0 None
2010-11-18 Clinical trial shows dalfampridine tablets improve walking ability in MS patients 0 None
2010-11-18 Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression 0 None
2010-11-18 Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium 0 None
2010-11-18 Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo 0 None
2010-11-18 Idera presents data on TLR7, TLR9 antagonist candidate for hyperlipidemia at American Heart Association 0 None
2010-11-18 Regado presents poster on REG3 at AHA Scientific Sessions meeting 0 None
2010-11-18 VX-770 drug candidate improves lung function in people with cystic fibrosis 0 None
2010-11-18 Titan Pharmaceuticals presents data on Probuphine Phase 3 clinical program for opioid addiction at Neuroscience Meeting 0 None
2010-11-17 Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting 0 None
2010-11-17 New investigational drug improves lung function in CF patients 0 None
2010-11-17 Scientists investigate new class of drugs for treating kidney failure 0 None
2010-11-17 Aeterna Zentaris presents results of orally active compounds with anti-tumor effects at EORTC-NCI-AACR Symposium 0 None
2010-11-17 Cardio3 BioSciences announces positive results from C-Cure Phase II clinical trial for heart failure 0 None
2010-11-17 MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S. 0 None
2010-11-17 Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer 0 None
2010-11-17 Mirna to present data on miRNA Replacement Therapies for cancer at CPRIT Conference 0 None
2010-11-17 EMA approves CTI's Pixuvri Pediatric Investigation Plan for lymphoid malignancies and solid tumors 0 None
2010-11-17 Anthera places voluntary hold on A-623 Phase 2b study for lupus 0 None
2010-11-17 Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications 0 None
2010-11-17 Combination doxorubicin-sorafenib treatment improves survival in patients with inoperable advanced liver cancer 0 None
2010-11-17 Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium 0 None
2010-11-17 TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients 0 None
2010-11-17 Chimerix’s lipid-conjugated drugs reduces nephrotoxicity: Study 0 None
2010-11-17 JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes 0 None
2010-11-17 UMass, PolyMedix receive Phase 2 STTR contract to conduct test on antimicrobial compounds 0 None
2010-11-17 AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors 0 None
2010-11-17 ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases 0 None
2010-11-17 Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan 0 None
2010-11-16 Stem cells for stroke: Clinical trial commences 0 5
2010-11-16 Anti-stroke blood thinner shows promise in large clinical trials 0 None
2010-11-16 Diuretic lessens risk of death from mild heart failure: Study 0 None
2010-11-16 4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium 0 None
2010-11-16 Merrion prepares Phase III study for Orazol in breast cancer treatment 0 None
2010-11-16 BiovaxID lymphoma vaccine to be featured at ASH Meeting 0 None
2010-11-16 St. Jude presents results from ASSERT trial for stroke at American Heart Association 0 None
2010-11-16 Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association 0 4
2010-11-16 Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer 0 None
2010-11-16 Celladon presents data on Phase 2 CUPID clinical trial for advanced heart failure at American Heart Association 0 None
2010-11-16 PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association 0 5
2010-11-16 ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting 0 None
2010-11-16 Diffusion Pharmaceuticals presents positive results of TSC study for PAD at American Heart Association 0 None
2010-11-16 Oramed presents ORMD-0801 Phase IIb results for Type II diabetes at Annual Meeting in Bethesda 0 None
2010-11-15 Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting 0 None
2010-11-15 Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting 0 5
2010-11-15 New investigational drug is well tolerated in children with nmCF 0 None
2010-11-15 Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients 0 None
2010-11-15 Novel heart attack treatment results presented at premier USA cardiology forum 0 None
2010-11-15 No difference in risk of nonsuicide death between ziprasidone and olanzapine for schizophrenia 0 None
2010-11-15 SuperGen to present three abstracts at EORTC-NCI-AACR International Symposium 0 None
2010-11-15 Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal 0 None
2010-11-15 Scios announces results of ASCEND-HF trial for ADHF treatment 0 None
2010-11-15 Inovio third quarter total revenue decreases from $3.6 million to $1.3 million 0 None
2010-11-15 POZEN presents PA32540 Phase 1 study results for cardiovascular disease at AHA Session 0 None
2010-11-15 Immunitor completes V5 Phase IIb imm01 clinical trial enrollment for TB 0 None
2010-11-15 Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda 0 None
2010-11-15 Dyax to present data of KALBITOR inhibitor for Angioedema at ACAAI Meeting 0 None
2010-11-12 Clinical trial results of Threshold's TH-302 hypoxia-activated prodrug presented at 16th CTOS annual meeting 0 1
2010-11-12 Nile third quarter net loss decreases to $1.8 million 0 None
2010-11-12 Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000 0 None
2010-11-12 Results of RE-LY trial evaluating Pradaxa capsules to be presented at American Heart Association Session 0 None
2010-11-12 Inovio to update HVTN 080 Phase I clinical study for HIV at HVTN Conference 0 None
2010-11-12 Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference 0 None
2010-11-12 Acetylon receives two grants under QTDP program to advance HDAC6 inhibitor drug candidate 0 None
2010-11-12 Advaxis receives $244,479 QTDP credit for ADXS11-001 trial 0 None
2010-11-12 NexBio presents Fludase data for Influenza-Like Illness at ACAAI 2010 0 None
2010-11-11 SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors 0 None
2010-11-11 NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients 0 None
2010-11-11 Pevion announces positive results of PEV7 Phase I study for recurrent vulvovaginal candidiasis 0 None
2010-11-11 Study investigates long-term outcome of REYATAZ/ritonavir regimens in ARV-experienced patients 0 None
2010-11-11 Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting 0 None
2010-11-11 4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million 0 None
2010-11-11 Cyclacel announces publication of sapacitabine in British Journal of Cancer 0 None
2010-11-11 Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium 0 None
2010-11-11 Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies 0 None
2010-11-11 Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C 0 None
2010-11-11 Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility 0 None
2010-11-11 Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium 0 None
2010-11-11 Resolve Therapeutics enters license with University of Washington for autoimmune disease treatment 0 None
2010-11-11 Nplate reduces treatment failure and splenectomies in adults with chronic immune thrombocytopenia 0 None
2010-11-11 Watson’s Uracyst pilot study for interstitial cystitis fails to demonstrate efficacy endpoints 1 4
2010-11-10 Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV 0 None
2010-11-10 Amarin reports $31.4 million cash balance for third quarter 2010 0 None
2010-11-10 Positive results from XOMA 052 study in patients with uveitis of Behcet's disease 0 5
2010-11-10 Zalicus third quarter total revenue decreases to $1.2 million 0 None
2010-11-10 Abbott presents results of 2 pivotal HUMIRA studies at American College of Rheumatology meeting 0 None
2010-11-10 Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR 0 2
2010-11-10 TRU-016 abstracts to be presented at ASH meeting 0 None
2010-11-10 Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting 0 5
2010-11-10 Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study 0 None
2010-11-10 Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation 0 None
2010-11-10 BioInvent receives FDA IND clearance for BI-204 Phase II trial in cardiovascular disease 0 None
2010-11-10 TONIX Pharmaceuticals announces Phase 2a study results of cyclobenzaprine in Fibromyalgia Syndrome 0 None
2010-11-10 Silence Therapeutics' Atu027 RNAi drug prevents pulmonary metastasis formation 0 None
2010-11-10 Diamyd completes patient screening for DiaPrevent Phase III study 0 None
2010-11-10 New York Times examines HIV prevention products undergoing clinical trials 0 None
2010-11-10 Enrollment complete in Nabi's second NicVAX Phase III clinical trial for nicotine addiction 0 None
2010-11-09 Phytomedics awarded $244,000 QTDP grant for development of RA drug 0 None
2010-11-09 NeuroDerm commences enrollment in ND0801 Phase 2a clinical study of ADD/ADHD in adults 0 None
2010-11-09 EntreMed to present data of ENMD-2076 Phase 1 study in multiple myeloma and leukemia at ASH 2010 0 None
2010-11-09 Discovery Labs reports net operating loss of $6.2 million for third quarter 2010 0 None
2010-11-09 Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics 0 None
2010-11-09 Arena third quarter net loss increases to $36.3 million 0 None
2010-11-09 ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA 0 None
2010-11-09 ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs 0 None
2010-11-09 Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting 0 5
2010-11-09 Inspiration receives two grants under QTDP program to advance development of IB1001, OBI-1 products 0 None
2010-11-09 EVP-6124 receptor acts as co-agonist with ACh to enhance cognition 0 None
2010-11-09 Colcrys safe for treating gout flares 0 None
2010-11-09 Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer 0 None
2010-11-09 SIMPONI injection improves inflammation, structural damage in RA patients 0 None
2010-11-09 Merrimack receives $2.44 million under QTDP program to support cancer research 0 None
2010-11-09 Dabigatran etexilate benefits AF patients with previous stroke or transient ischemic attack 0 None
2010-11-09 EpiCept third quarter net loss decreases to $3.2 million 0 None
2010-11-09 BioCryst to present data on BCX4208 for gout at ACR Scientific Meeting 0 None
2010-11-09 Omthera initiates ECLIPSE study for treatment of high triglycerides 0 None
2010-11-09 New data on Soliris for PNH treatment to be presented at ASH Annual Meeting 0 None
2010-11-08 Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases: Study 0 None
2010-11-08 NUVO announces positive results from WF10 Phase 2 clinical trial for severe allergic rhinitis 0 None
2010-11-08 Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease 0 None
2010-11-08 Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout 0 None
2010-11-08 TB Alliance launches three-drug combination trial for drug-sensitive and multidrug-resistant TB 0 None
2010-11-08 MAP Pharmaceuticals reports positive results from LEVADEX QT trial for migraine 0 None
2010-11-08 TransTech Pharma, High Point receive $1.96 million grants under QTDP program 0 None
2010-11-08 Santarus's budesonide MMX drug shows positive result for active ulcerative colitis 0 None
2010-11-08 bitop includes first patient in Ectoin inhalation solution clinical trial for inflammation and airway obstruction 0 5
2010-11-08 Plexxikon's PLX4032 shows positive data in patients with metastatic melanoma 0 None
2010-11-08 Pervasis receives $920,000 in grants under QTDP program 0 None
2010-11-08 Synergy receives $244,479 grant under QTDP program to develop plecanatide for gastrointestinal disorders 0 None
2010-11-08 SGN-35 drug reduces tumor growth in Hodgkin's lymphoma 0 None
2010-11-08 Alder to present data of ALD518 two clinical studies for rheumatoid arthritis at American College Meeting 0 None
2010-11-08 Inviragen to present data on CHIKV vaccine at ASTMH meeting 0 None
2010-11-08 ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis 0 None
2010-11-08 Sanofi Pasteur's dengue vaccine enters phase III trial in Australia 0 None
2010-11-08 Genentech announces Phase II RG7204 clinical study results for metastatic melanoma tumors 0 None
2010-11-08 Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress 0 None
2010-11-08 Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R 0 None
2010-11-08 New malaria drug can save millions of lives: Study 0 None
2010-11-07 AiCuris to present data on AIC316 anti-HSV drug at Antivirals Congress 0 5
2010-11-07 Ortho-McNeil terminates collaboration agreement with Arena on APD597 trial program 0 None
2010-11-04 Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009 0 None
2010-11-04 NWBT receives $490,000 in two grants under QTDP program 0 None
2010-11-04 Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs 0 None
2010-11-04 AVEO third quarter total collaboration revenues increase to $6.2 million 0 None
2010-11-04 Pfizer's two new compounds may be effective in treating alcohol, nicotine dependence 0 None
2010-11-04 NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting 0 None
2010-11-04 New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data 0 5
2010-11-04 4SC's vidofludimus Phase IIa study in IBD meets primary endpoint 0 None
2010-11-04 Phase III study suggests CYCLOSET tablets improve glycemic control 0 None
2010-11-04 World's most clinically advanced dengue vaccine candidate enters first phase 3 clinical study 0 5
2010-11-04 Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer 0 5
2010-11-04 Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial 0 None
2010-11-04 Regado receives funding under QTDP grant program to advance treatment for cardiovascular diseases 0 None
2010-11-04 Coronado completes series of private financings 0 None
2010-11-04 Bolder BioTechnology receives $1.2 million in Qualifying Therapeutic Discovery Project Grants 0 None
2010-11-04 Afinitor tablets decrease size of SEGA associated with tuberous sclerosis 0 None
2010-11-04 Etanercept plus MTX improves height, weight, and BMI in children with juvenile idiopathic arthritis 0 None
2010-11-04 New antibody with SGN-35 drug produces remission in Hodgkin lymphoma 0 3.5
2010-11-04 Positive results from Lithera's LIPO-102 Phase IIb clinical study for abdominal fat reduction 0 None
2010-11-04 Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program 0 None
2010-11-04 Aeolus receives $489,000 grant under QTDP program for two lead compounds 0 None
2010-11-04 Bristol-Myers Squibb and Simcere partner to co-develop oncology compound 0 None
2010-11-04 Biogen Idec and Cardiokine terminate lixivaptan collaboration 0 None
2010-11-04 PolyMedix receives $488,958 grants under QTDP program 0 None
2010-11-04 Alnylam third quarter revenue increases from $24.2 million to $27.7 million 0 None
2010-11-03 Bortezomib reduces inflammation and promotes bone healing in arthritis models 0 None
2010-11-03 QLT third quarter sales decreases 12.9% to $20.5 million 0 None
2010-11-03 Incyte announces achievement of $50 million in INCB18424 clinical trial 0 None
2010-11-03 SYMBICORT improves lung function in African American asthma patients compared to budesonide alone 0 4
2010-11-03 Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis 0 None
2010-11-03 GenVec receives $244,479 grant under QTDP program 0 None
2010-11-03 Celsion receives $244,000 grant under QTDP program 0 None
2010-11-03 POZEN’s therapeutic development programs qualified to receive federal grant under PPACA 0 None
2010-11-03 Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study 0 None
2010-11-03 BioCryst receives $1.1 million in grants under QTDP program 0 None
2010-11-03 Immunomedics product candidates, technologies receive recognition from QTDP program 0 None
2010-11-03 Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting 0 None
2010-11-03 Enzon receives $1.2 million in funding under IRS Qualifying Therapeutic Discovery Project program 0 None
2010-11-03 ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium 0 None
2010-11-03 Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint 0 None
2010-11-03 BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer 0 5
2010-11-03 Bristol-Myers extends time to review BLA for ipilimumab in melanoma 0 None
2010-11-03 NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia 0 5
2010-11-03 CytRx receives nontaxable grant under Qualifying Therapeutic Discovery Project Program 0 None
2010-11-03 Nile announces results of CD-NP Phase 2 study in renally compromised ADHF patients 0 None
2010-11-03 Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C 0 3.5
2010-11-02 Asthmatx presents 2-year results from AIR2 Trial of bronchial thermoplasty in severe asthma 0 None
2010-11-02 NPS third quarter net loss increases to $15.7 million 0 None
2010-11-02 RegeneRx announces positive results from RGN-259 non-clinical study for Dry Eye Syndrome 0 None
2010-11-02 Inhibitex to present INX-189 data for HCV infections at AASLD Meeting 0 None
2010-11-02 TriRima shows positive result in food-induced cardiovascular effects associated with MAO inhibitors 0 None
2010-11-02 Soligenix completes enrollment in RiVax Phase 1B ricin toxin clinical trial 0 None
2010-11-02 Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease 0 None
2010-11-02 ADVANCE Phase 3 study confirms clinical benefits of telaprevir regimen in patients with HCV infection 0 None
2010-11-02 Boceprevir combinational therapy improves SVR rate in patients with HCV genotype 1 0 None
2010-11-02 BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer 0 None
2010-11-02 EMA issues Scientific Advice to Genta's clinical development plan for tesetaxel in patients with gastric cancer 0 None
2010-11-02 PPACA program provides $733,438 grant to Inovio 0 1
2010-11-02 Positive results from linaclotide Phase 3 trial in patients with IBS-C 0 None
2010-11-01 Telbivudine prevents HBV transmission from mothers to newborns: Study 0 None
2010-11-01 Neogenix Oncology's ensituximab granted FDA orphan drug designation for pancreatic cancer treatment 0 None
2010-11-01 GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer 0 None
2010-11-01 Lab study shows nanoviricide drug candidate improves survival rate in influenza viral infection 0 None
2010-11-01 Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine 0 None
2010-11-01 Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium 0 None
2010-11-01 FDA grants Clinical Data's PRX-8066 Orphan Drug Designation for pulmonary arterial hypertension 0 5
2010-11-01 Inhibitex announces initiation of INX-189 Phase 1b clinical trial for HCV infection 0 5
2010-11-01 Catalyst’s CPP-115 improves retinal safety profile than vigabatrin 0 None
2010-11-01 Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C 0 None
2010-11-01 Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain 0 None
2010-11-01 Shield signs strategic commercialization agreement for ST10-021 iron therapy product 0 None
2010-11-01 Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV 0 None
2010-11-01 Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection 0 None
2010-11-01 Boehringer to present data of SOUND-C1 Phase Ib study for HCV treatment at AASLD Meeting 0 None
2010-11-01 NeurAxon’s NXN-188 compound effective for acute migraine treatment 0 None
2010-11-01 Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting 0 None
2010-11-01 Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting 0 3
2010-11-01 Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting 0 None
2010-11-01 Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010 0 3
2010-11-01 Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010 0 None
2010-11-01 Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting 0 None
2010-10-30 OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International 0 None
2010-10-30 Presidio to present PPI-461 data for HCV infection at AASLD meeting 0 None
2010-10-30 CONCERTA improves handwriting performance in children with ADHD: Study 0 None
2010-10-30 Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne 0 None
2010-10-30 Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting 0 None
2010-10-30 Idera presents data on TLR 3 agonist as vaccine adjuvants at Immunological Meeting 0 None
2010-10-30 AVEO to raise $61 million through private placement 0 None
2010-10-30 OHSU to lead next phase of HuCNS-SC trial for NCL in children 0 None
2010-10-29 Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne 0 None
2010-10-29 MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress 0 None
2010-10-29 GSK and Amicus announce Amigal development and commercialization agreement 0 None
2010-10-29 Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder 0 1
2010-10-29 57% of ALK-positive advanced non-small cell lung cancer patients respond to crizotinib: Study 0 None
2010-10-29 ImmuneRegen's Homspera enhances survival of animals vaccinated with experimental melanoma vaccine 0 None
2010-10-29 Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms 0 None
2010-10-29 Forest, Almirall report topline results from aclidinium bromide comparative Phase III study in COPD 0 None
2010-10-29 StemCells initiates HuCNS-SC second clinical trial for Batten disease in children 0 None
2010-10-29 Geron 2010 third quarter revenue increases from $494,000 to $546,000 0 None
2010-10-29 ImmunoGen first quarter net loss increases to $12.9 million 0 None
2010-10-29 Amira initiates AM152 Phase 1 clinical study for fibrotic diseases 0 None
2010-10-28 Antigenics third quarter net loss decreases from $10.8 million to $5.9 million 0 None
2010-10-28 Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment 0 None
2010-10-28 QLT expands QLT091001 Phase 1b LCA study to include patients with Retinitis Pigmentosa 0 4
2010-10-28 Octapharma initiates Human-cl rhFVIII clinical study for severe hemophilia A 0 None
2010-10-28 Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine 0 2.5
2010-10-28 Curemark adds two sites in California for CM-AT Phase III clinical trial program 0 None
2010-10-28 Laureate enters agreement with AVEO to produce AV-203 monoclonal antibody against ErbB3 0 None
2010-10-28 Epigenomics presents data on Septin9 biomarker clinical study for colorectal cancer at UEGW 0 3
2010-10-28 Evotec grants Jingxin Pharma rights to develop, market EVT 201 insomnia drug candidate in China 0 None
2010-10-28 ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients 0 None
2010-10-28 EpiCept, FDA reach agreement on regulatory path forward for Ceplene 0 None
2010-10-28 Nymox updates NX-1207 Phase 3 pivotal trials for benign prostatic hyperplasia 0 5
2010-10-28 New oral drug shrinks IMT sarcoma driven by abnormally activated protein 0 None
2010-10-28 BDSI to initiate BEMA Buprenorphine Phase 3 program following positive End-of-Phase 2 meeting with FDA 0 None
2010-10-28 Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials 0 None
2010-10-27 Vical to present preclinical results of HSV-2 vaccine program at Keystone Symposium 0 5
2010-10-27 Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease 0 None
2010-10-27 MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients 0 None
2010-10-27 Oramed to present data on oral insulin formulation for Type II diabetes at Annual Meeting in Bethesda 0 None
2010-10-27 Oncolytics presents REO 013 clinical trial data for colorectal cancer at International Symposium in Spain 0 None
2010-10-26 Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia 0 None
2010-10-26 Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program 0 None
2010-10-26 Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM 0 None
2010-10-26 TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment 0 None
2010-10-26 Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange 0 None
2010-10-26 Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium 0 None
2010-10-26 Genmab begins Phase III head to head study of ofatumumab vs. rituximab in follicular NHL 0 None
2010-10-26 Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome 0 None
2010-10-26 Sanofi-aventis commences teriflunomide Phase III study in RMS patients treated with interferon beta 0 None
2010-10-26 Trius receives patent protection for torezolid phosphate in the U.S. 0 None
2010-10-26 TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium 0 None
2010-10-26 Chemoradiotherapy can reduce bladder cancer recurrence 0 None
2010-10-26 ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer 0 5
2010-10-26 LigoCyte presents Phase I/II study results of NoV vaccine for gastroenteritis at IDSA Meeting 0 None
2010-10-26 Dual antiplatelet therapy study expanded into Australia and New Zealand 0 None
2010-10-26 Sanofi Pasteur presents Fluzone quadrivalent Phase II trial data for influenza at IDSA Annual Meeting 0 None
2010-10-26 Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV 0 None
2010-10-25 Repros commences randomization in Androxal Phase II study in T2DM men with low testosterone 0 None
2010-10-25 Inviragen commences Phase 1 clinical trial of DENVax dengue vaccine in Colombia 0 None
2010-10-25 Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction 0 None
2010-10-25 Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze 0 None
2010-10-25 Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium 0 None
2010-10-25 Soligenix reports Phase 2 clinical trial results of orBec for GVHD 0 None
2010-10-25 NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting 0 None
2010-10-25 Antigenics expands HSPPC-96 Phase 2 clinical study in glioma 0 None
2010-10-25 Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint 0 None
2010-10-25 Chimerix to present CMX001 data for viral infections at IDSA Annual Meeting 0 None
2010-10-25 Novartis informs Emisphere on First Interpretable Results of two-year Phase III Study 2301 in osteoarthritis 0 None
2010-10-25 Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting 0 None
2010-10-25 Pharmaxis announces combined results of Bronchitol Phase III trial for cystic fibrosis 0 None
2010-10-25 Revance presents results of RT001 two Phase 2b clinical trials for lateral canthal lines at Chicago annual meeting 0 None
2010-10-22 Astellas suspends patient enrollment from ACT 5 study of KYNAPID 0 None
2010-10-22 Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference 0 3
2010-10-22 Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal 0 None
2010-10-22 Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients 0 5
2010-10-22 TOBI reduces mortality in patients with cystic fibrosis, Pa lung infection 0 None
2010-10-22 AiCuris’ AIC246 inhibitor treats patient with multi-organ HCMV disease 0 None
2010-10-22 Myrexis to present Phase 2 monotherapy study results of Azixa in patients with GBM 0 None
2010-10-22 Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories 0 5
2010-10-22 Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease 0 None
2010-10-22 Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia 0 None
2010-10-21 Astellas suspends enrollment in ACT 5 study of KYNAPID in atrial fibrillation patients 0 None
2010-10-21 Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study 0 None
2010-10-21 PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology 0 None
2010-10-21 BioCryst to present intravenous peramivir data for influenza treatment at IDSA meeting 0 None
2010-10-21 ISCTM to develop solutions for CNS clinical trial methodology 0 None
2010-10-21 OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS 0 None
2010-10-21 Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV 0 None
2010-10-21 MAP Pharmaceuticals to present nine analyses on LEVADEX for migraine therapy at 2010 EHMTIC congress 0 None
2010-10-21 Quark initiates dosing NAION patients in QPI-1007 Phase I study for ocular neuroprotection 0 None
2010-10-21 Agensys and Seattle Genetics initiate ASG-5ME phase I clinical trial for castration-resistant prostate cancer 0 None
2010-10-21 Aastrom submits SPA for Phase 3 clinical development program in critical limb ischemia to FDA 0 5
2010-10-21 DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy 0 None
2010-10-21 Genzyme third quarter revenue increases to $1.0 billion 0 None
2010-10-21 Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment 0 5
2010-10-21 Genzyme reports results of Clolar combination Phase 3 trial in adult AML 0 None
2010-10-21 IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer 0 None
2010-10-20 Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy 0 5
2010-10-20 Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate 0 None
2010-10-20 Aradigm reports positive data from DRCFI, ARD-3150 Phase 2b bronchiectasis study 0 None
2010-10-20 European Commission grants Ipsen's OBI-1 orphan drug status for treatment of hemophilia 0 None
2010-10-20 LANL's researcher to implement first human trial of mosaic HIV vaccine candidate 0 None
2010-10-20 Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS 0 None
2010-10-20 NIAID announces four new contracts for clinical trials to address problem of antimicrobial resistance 0 None
2010-10-20 MannKind begins MKC1106-MT Phase 2 trial for advanced melanoma 0 None
2010-10-20 Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease 0 None
2010-10-19 BioMarin announces BMN-111 program for treatment of achondroplasia 0 4.2
2010-10-19 Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data 0 None
2010-10-19 Acorda announces data of GGF2 preclinical studies for focal ischemic stroke 0 None
2010-10-19 Adolor initiates ADL5945 Phase 2 proof-of-concept study for patients with OIC 0 None
2010-10-19 Cytheris initiates ORVACS Phase II clinical trial to study HIV infection 0 None
2010-10-19 Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC 0 None
2010-10-19 Positive results from Diamyd Medical's NP2 Enkephalin Phase I trial for chronic pain 0 5
2010-10-19 Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis 0 None
2010-10-19 Study investigates effectiveness of potential treatment for Non-alcoholic steatohepatitis 0 None
2010-10-19 New research coalition to design first human trial of mosaic HIV vaccine candidate 0 None
2010-10-19 Transcept announces Intermezzo tablet preliminary data for insomnia 0 None
2010-10-19 Salix presents two Phase 3 pivotal clinical trials data for non-C IBS at ACG Meeting 0 None
2010-10-19 New clinical trial to treat brain cancer launched 0 None
2010-10-19 UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting 0 None
2010-10-18 Groundbreaking melanoma clinical trial initiated by Patrys 0 None
2010-10-18 BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease 0 None
2010-10-18 Studies explore impact of upper GI conditions on sleep 0 None
2010-10-18 Sequella to develop SQ109 further with EDCTP, LMU, and TB experts in PanACEA 0 None
2010-10-18 Vertex commences VX-770 and VX-809 combination Phase 2a clinical trial for cystic fibrosis 0 None
2010-10-18 Fluticasone gets rid of eosinophils in the esophagus, but does not improve symptoms 1 3
2010-10-18 Hyperion's HPN-100 granted FDA Fast Track Designation for urea cycle disorders 0 None
2010-10-18 FDA grants fast track designation for Aastrom's CLI cell therapy development program 0 None
2010-10-18 14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010 0 None
2010-10-18 BioSante enrolls 2,500th woman in LibiGel Phase III cardiovascular and breast cancer safety study 0 None
2010-10-18 EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis 0 None
2010-10-18 Alcon concludes 'proof of concept' clinical trial of NovaBay's Aganocide for viral conjunctivitis treatment 0 None
2010-10-18 Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium 0 None
2010-10-18 Preliminary Phase 2 data of TZP-102 for diabetic gastroparesis to be presented at ACG annual meeting 0 None
2010-10-18 Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver 0 5
2010-10-18 Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting 0 None
2010-10-18 PTC announces ataluren Phase 2b efficacy data at International Congress 0 None
2010-10-18 Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis 0 None
2010-10-18 Teva Pharmaceutical announces new data from PreCISe study 0 None
2010-10-15 Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress 0 3
2010-10-15 EC grants orphan medicinal product designation to Allos' pralatrexate for Hodgkin lymphoma 0 None
2010-10-15 Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study 0 None
2010-10-15 Oseltamivir reduces mortality in influenza A/H5N1 patients 0 None
2010-10-15 Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients 0 None
2010-10-15 NovaBay to present two poster presentations at IDSA Annual Meeting 0 None
2010-10-15 Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress 0 5
2010-10-15 Discovery Labs to present lucinactant Phase 2a clinical study results at NACFC Conference 0 None
2010-10-15 Knopp Neurosciences forms new parent entity 0 5
2010-10-15 Emerging Healthcare anticipates results of FDA-approved human embryonic stem-cell treatment 0 None
2010-10-15 Journal of Clinical Oncology publishes IPI-504 Phase 2 study results 0 None
2010-10-15 Sanofi-aventis announces TEMSO phase III study results for relapsing multiple sclerosis 0 None
2010-10-15 FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis 0 5
2010-10-15 Genzyme reports five-year patient data from Phase 2 multiple sclerosis trial 0 None
2010-10-14 Omeros receives additional NIDA grant for clinical studies in Addiction program 0 None
2010-10-14 Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress 0 4
2010-10-14 Sunshine Biopharma to enter Adva-27a Phase I clinical trial for Multi-Drug Resistant breast cancer 0 5
2010-10-14 Acceleron announces ACE-031 Phase 1b study results 0 None
2010-10-14 XenoPort to present XP23829 preclinical data at ECTRIMS meeting 0 None
2010-10-13 Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD 0 None
2010-10-13 Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer 0 None
2010-10-13 Threshold announces TH-302 Phase 1/2 clinical trial interim results 0 None
2010-10-13 JAMA publishes Probuphine Phase 3 clinical trial data 0 None
2010-10-13 Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug 0 None
2010-10-13 Archimedes publishes results from FPNS Phase III clinical study for breakthrough cancer pain 0 None
2010-10-13 Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment 0 None
2010-10-13 CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer 0 None
2010-10-13 MTN-007 phase trial evaluates vaginal microbicide to prevent rectal transmission of HIV 0 None
2010-10-13 US Oncology enrolls 1,000th patient in Phase I clinical trial 0 None
2010-10-13 HSV1716 clinical trial for childhood cancer receives FDA grant 0 None
2010-10-13 Combination of cetuximab and cisplatin chemotherapy benefits women with triple-negative breast cancer 0 None
2010-10-12 USPTO issues Watson Notice of Allowance for key progesterone patent to treat or prevent preterm birth 0 None
2010-10-12 Alimera to present Iluvien Phase 3 clinical trial data at AAO annual meeting 0 None
2010-10-12 First presentation of anti-HER2 antibody-drug conjugate as first-line therapy for advanced breast cancer 0 None
2010-10-12 Albireo reports positive results from A3309 Phase IIb study in chronic idiopathic constipation 0 None
2010-10-12 Helix completes GLP toxicology study milestone in L-DOS47 development program 0 None
2010-10-12 UCB, Synosia Therapeutics announce new strategic partnership in neurology 0 None
2010-10-12 Halozyme Therapeutics to advance core proprietary programs through key clinical inflection points 0 None
2010-10-12 Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors 0 4
2010-10-11 Early cancer drug trials flawed by inconsistencies in prohibited drug lists, study finds 0 None
2010-10-11 Access highlights clinical benefits of MuGard at ESMO conference 0 None
2010-10-11 Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer 0 None
2010-10-11 Abbott presents data from 4 briakinumab pivotal studies in psoriasis 0 None
2010-10-11 Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO 0 None
2010-10-11 COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate 0 None
2010-10-11 ArQule announces SPA with FDA for ARQ 197 Phase 3 trial design for NSCLC 0 None
2010-10-11 Innate Therapeutics initiates MIS416 Phase 2a clinical study in patients with progressive multiple sclerosis 0 4.5
2010-10-11 Genentech initiates GDC-0449 Phase II clinical trial in BCC patients 0 None
2010-10-11 Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer 0 None
2010-10-11 AVEO presents tivozanib Phase 2 study results at ESMO Congress 0 None
2010-10-11 Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury 0 None
2010-10-11 ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer 0 None
2010-10-11 Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting 0 None
2010-10-11 ArQule announces ARQ 197 Phase 2 clinical trial results at ESMO annual meeting 0 None
2010-10-11 Allos announces favorable survival data from FOLOTYN Phase 2b study 0 None
2010-10-11 MOH approves BrainStorm's NurOwn stem cell therapy for Phase I/II clinical trial 0 None
2010-10-11 BioSante presents update on LibiGel clinical study at NAMS Annual Meeting 0 None
2010-10-11 OXiGENE announces ZYBRESTAT Phase 2/3 study results at ESMO Congress 0 5
2010-10-11 Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors 1 5
2010-10-11 Combination of MET and erlotinib delays lung cancer progression: Study 0 None
2010-10-11 Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference 0 None
2010-10-11 Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial 0 None
2010-10-11 Seattle Genetics reports SGN-75 phase I clinical trial data 0 None
2010-10-11 Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease 1 2
2010-10-11 BiondVax commences Multimeric-001 flu vaccine Phase IIa clinical study 0 None
2010-10-11 Phase-II clinical trial of MLN8237 drug shows promising results for treating ovarian cancer 0 None
2010-10-11 First-line treatment with erlotinib drug improves progression-free survival in patients with advanced lung cancer 0 None
2010-10-11 Infinity announces preliminary results of IPI-926 Phase 1 study in patients with solid tumors 0 None
2010-10-11 Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research 0 5
2010-10-08 Phase I study of Shigella dysenteriae bioconjugate vaccine meets primary, secondary endpoints 0 None
2010-10-08 Abiraterone Phase III clinical data to be presented at ESMO meeting 0 5
2010-10-08 Roskamp to initiate RCP-006 clinical trials for Alzheimer's disease 1 5
2010-10-08 Pfizer announces tasocitinib Phase 2 data for plaque psoriasis 0 None
2010-10-08 StemCells provides update on PMD Phase I clinical trial 0 None
2010-10-08 Innovative trial designs may improve efficiency of clinical trials 0 None
2010-10-08 VentiRx announces VTX-1463 trial results for allergic rhinitis treatment 0 None
2010-10-08 Phase 3 study of D-tagatose in Type 2 diabetes shows significant reduction in HbA1c levels 0 None
2010-10-08 Targacept announces top-line results from AZD1446 Phase 2 clinical trial for ADHD 0 None
2010-10-07 Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress 0 None
2010-10-07 Vivaglobin therapy effective for patients with primary immunodeficiency 0 None
2010-10-07 Myrexis to present MPI-0485520 preclinical data at Annual Scientific Meeting 0 None
2010-10-07 Integra to present multi-center study of peripheral nerve repair at Mexico joint meeting 0 None
2010-10-07 Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study 0 None
2010-10-07 Hizentra therapy effective for primary immunodeficiency patients 0 None
2010-10-07 Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers 0 4
2010-10-07 Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB 0 None
2010-10-07 Neoprobe completes pre-NDA assessment for Lymphoseek with FDA 0 None
2010-10-06 Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress 0 None
2010-10-06 Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID 0 None
2010-10-06 ISTA Pharmaceuticals announces Phase 1/2 clinical study results of bepotastine besilate nasal spray 0 None
2010-10-06 Synergy reports positive results from plecanatide Phase IIa clinical trial for chronic constipation 0 None
2010-10-06 Adeona completes enrollment in Part 2 CopperProof-2 clinical study 0 None
2010-10-06 Innovacell invests 10 million Euros for clinical development 0 None
2010-10-06 Repinotan blocks respiratory depressant effects of morphine without altering pain-relieving effects 0 None
2010-10-06 Aeterna Zentaris' AEZS-130 demonstrates potential as oral diagnostic test for AGHD 0 None
2010-10-06 Aegerion Pharmaceuticals’ MTP-I Phase III trial published in Atherosclerosis online supplement 0 None
2010-10-06 Rochester General Hospital Research Institute awarded $7M for Prevnar 13 study of ear infections in children 0 None
2010-10-06 IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial 0 None
2010-10-06 Lixte, NCI collaborate for clinical evaluation of LB-100 compound 0 None
2010-10-05 Liquidia commences dosing in LIQ-001 Phase 1 trial for seasonal influenza 0 None
2010-10-05 ISTO announces completion of enrollment in NuQu Phase I clinical study for discogenic back pain 0 None
2010-10-05 Archimedes publishes FPNS clinical study results in Pain journal 0 None
2010-10-05 Preclinical data of Enzon's PEG-SN38 in pediatric neuroblastoma published in Clinical Cancer Research 0 None
2010-10-05 ImmunoCellular Therapeutics to present ICT-107 clinical data at World Stem Cell Summit 0 None
2010-10-05 Neuraltus achieves last patient out for NP001, NP002 studies 0 4
2010-10-05 Merck Serono to present Erbitux data at ESMO Congress 0 None
2010-10-05 BioSante to present LibiGel clinical trial update at NAMS Annual Meeting 0 None
2010-10-05 Amgen announces PRIME '203' and '181' Phase 3 trial results 0 None
2010-10-05 Seattle Genetics to present SGN-75 phase I data at ESMO Congress 0 None
2010-10-05 CrystalGenomics to present Phase I MAD study data at Arrowhead Summit 0 5
2010-10-05 Celldex Therapeutics presents initial clinical data on CDX-1401 cancer vaccine candidate at iSBTc meeting 0 None
2010-10-05 Onconova announces agreement with FDA for Estybon- MDS Phase 3 trial 0 None
2010-10-04 Enzo commences clinical trial of Optiquel for chronic non-infectious uveitis 0 None
2010-10-04 Onconova enters agreement with FDA for Estybon Phase 3 trial SPA 0 5
2010-10-04 Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD 1 None
2010-10-04 Neupro improves quality of life in Parkinson's disease patients 0 None
2010-10-04 AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium 0 None
2010-10-04 Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article 0 5
2010-10-04 Array BioPharma to present positive interim results of Phase 1 ARRY-380 trial at ASCO Symposium 0 None
2010-10-03 Celsion presents Phase I/II DIGNITY trial data at 2010 Breast Cancer Symposium 0 None
2010-10-03 Bristol-Myers Squibb to present multiple compounds’ data at AASLD annual meeting 0 None
2010-10-03 Isotechnika announces CONFIRM1 clinical trial results at TCT 2010 Symposium 0 None
2010-10-01 Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma 0 None
2010-10-01 LSUHSC-S receives $3.9M NIDA grant to develop EMB-001 drug for cocaine dependence 0 None
2010-10-01 AcelRx completes ARX-02 End-of-Phase 2 meeting with FDA for cancer breakthrough pain management system 0 None
2010-10-01 Benicar better than Cozaar in reducing blood pressure: Study 0 None
2010-10-01 Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD 0 None
2010-10-01 FDA grants Emergent Fast Track Designation for AVP-21D9 anthrax monoclonal antibody development program 0 None
2010-10-01 Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer 0 None
2010-10-01 Herpevac Trial for Women finds experimental vaccine ineffective in prevention of genital herpes disease 0 5
2010-10-01 Achillion initiates ACH-1625 Phase II dosing for HCV infection 0 None
2010-09-30 NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis 0 None
2010-09-30 Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases 0 None
2010-09-30 Repligen Corporation completes patient enrollment in RG2417 Phase 2b clinical trial 0 None
2010-09-30 sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes 0 None
2010-09-30 Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen 0 None
2010-09-30 AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate 0 None
2010-09-30 FDA grants Type B meeting to review Phase III pivotal efficacy protocols for Androxal 0 None
2010-09-30 NIH awards $3.1 million to further fund Inovio's universal SynCon flu vaccine development 0 None
2010-09-30 Circassia announces advancement in T-cell allergy vaccines development 0 None
2010-09-30 ThromboGenics enters 10-year supply agreement with MSD Biologics for microplasmin 0 None
2010-09-30 Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study 0 None
2010-09-30 Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis 0 None
2010-09-30 ACT updates myoblast program for heart failure treatment 0 5
2010-09-30 Duke receives approval to initiate NPC-1C Phase I trial for advanced pancreatic and colorectal cancer 0 None
2010-09-30 Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results 0 None
2010-09-30 Memantine enhances language and communication skills in patients with Alzheimer's disease 0 None
2010-09-29 NEUROKIN accentuates its leadership in the treatment of acute neurological diseases 0 None
2010-09-29 Unique genetic markers point to patient response to SCV-07 treatment 0 None
2010-09-29 Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer 0 5
2010-09-29 Keryx commences Zerenex Phase 3 study for hyperphosphatemia in patients with ESRD on dialysis 0 None
2010-09-29 Rigel earns $25M milestone payment from Astrazeneca for clinical development of fostamatinib 0 None
2010-09-29 Pulmokine receives NIH SBIR grants to develop novel treatments for PAH 0 None
2010-09-29 XOMA completes patient enrollment in XOMA 052 Phase 2a trial 0 None
2010-09-29 NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent 0 None
2010-09-29 ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial 0 None
2010-09-29 Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study 0 None
2010-09-29 Study finds broader statin use as a cost-effective way to prevent heart attack and stroke 0 None
2010-09-29 Blood journal publishes GMI-1070 pre-clinical data in sickle cell disease model 0 None
2010-09-29 Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study 0 None
2010-09-29 Combination therapy reduces radiographic evidence of joint destruction in rheumatoid arthritis: Study 0 None
2010-09-29 XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting 0 None
2010-09-29 Further trials needed to determine clinical application of Abatacept in SLE 0 None
2010-09-29 RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV 0 None
2010-09-29 HUYA, Quintiles announce agreement to develop HBI-8000 cancer drug 0 None
2010-09-29 NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate 0 None
2010-09-28 PolyMedix begins PMX-30063 Phase 2 clinical trial for bacterial infections 0 None
2010-09-28 Galapagos initiates phase II clinical study of GLPG0259 drug in RA patients 0 None
2010-09-28 GenMark’s eSensor technology selected for Warfarin clinical study 0 5
2010-09-28 PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity 0 None
2010-09-28 Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting 0 None
2010-09-28 Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC 0 None
2010-09-28 Rockland receives Phase I SBIR grant to develop assay for monitoring Akt pathway activity 0 None
2010-09-27 KAI Pharmaceuticals enrolls patients in Phase 1b study of KAI-4169 for treatment of SHPT 0 None
2010-09-27 Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients 0 None
2010-09-27 REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference 0 None
2010-09-27 S*BIO initiates SB939 Phase 2 clinical trial for metastatic prostate cancer 0 None
2010-09-27 MediciNova receives FDA approval to proceed with initial trial of ibudilast 0 None
2010-09-27 Takeda announces SGN-35 ADC trial results in Hodgkin lymphoma patients 0 None
2010-09-27 OncoGenex initiates OGX-427 Phase 2 trial for metastatic prostate cancer 0 None
2010-09-27 Clinical Data announces Stedivaze agonist data at ASNC2010 meeting 0 None
2010-09-27 Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session 0 None
2010-09-24 Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer 0 None
2010-09-24 Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia 1 None
2010-09-24 Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium 0 None
2010-09-24 Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma 0 4
2010-09-24 Cylene commences CX-4945 Phase I trial in multiple myeloma 0 None
2010-09-24 Phase 3 clinical study demonstrates efficacy of metformin therapy in type 2 diabetes 0 None
2010-09-24 Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer 0 5
2010-09-23 Tolerx presents otelixizumab preclinical research at 46th EASD 0 None
2010-09-23 FDA grants ZIOPHARM's darinaparsin Orphan Drug Designation for peripheral T-cell Lymphoma treatment 0 None
2010-09-23 Linagliptin clinical trial data shows positive result for type 2 diabetes treatment 0 3
2010-09-23 Athersys presents MultiStem phase I study results at TCT Conference 0 None
2010-09-23 Vaxonco initiates Phase I clinical trial of novel DNA-based polyepitope vaccine against malaria 0 5
2010-09-23 Phase II study: Fostamatinib improves outcomes in RA patients 0 4.3
2010-09-23 Biogen Idec concurs with FDA on safety monitoring for Gilenya through REMS 0 5
2010-09-23 DSMB authorizes Oxygen Biotherapeutics' next cohort of Oxycyte emulsion study in severe non-penetrating TBI 0 None
2010-09-23 Infinity Pharmaceuticals to present IPI-926 inhibitor Phase 1 data at ESMO Congress 0 5
2010-09-23 Weight-based taribavirin reduces anemia, increases sustained virologic response 0 None
2010-09-23 Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes 0 None
2010-09-22 Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD 0 None
2010-09-22 Titan completes enrollment in Probuphine Phase 3 study for opioid addiction 0 None
2010-09-22 Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC 0 5
2010-09-22 Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology 0 None
2010-09-22 Phase I/II DIGNITY trial abstract of ThermoDox accepted for poster session at 2010 Breast Cancer Symposium 0 None
2010-09-22 Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC 0 None
2010-09-22 FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma 0 None
2010-09-22 Aeras and Crucell commence Phase II study of TB vaccine candidate in infants 0 5
2010-09-22 Novartis' SOM230 reduces cortisol levels in Cushing's disease patients 1 5
2010-09-21 ChemoCentryx presents CCX140 clinical data at EASD 0 None
2010-09-21 NIDA awards 5-year, $3.7M research grant for development of drug to treat cocaine addiction 0 None
2010-09-21 VIVUS announces QNEXA study results for obesity treatment 1 None
2010-09-21 Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV 0 None
2010-09-21 ImmunoGen commences clinical testing with SAR566658 anticancer compound 0 None
2010-09-21 Annals of Internal Medicine publishes GRACE study data on HIV therapy 0 None
2010-09-21 ProtAffin presents impressive efficacy data for PA401 in COPD 0 None
2010-09-21 Inovio Pharmaceuticals completes enrollment for PENNVAX-B vaccine Phase I clinical study 0 None
2010-09-21 Multinational study demonstrates positive effects of laquinimod in patients with RRMS 0 None
2010-09-21 Lixisenatide experimental diabetes drug shows potential in trial 0 None
2010-09-20 Dengue fever vaccine in the pipeline 0 5
2010-09-20 Seven abstracts on Lantheus' PET imaging candidates to be presented at ASNC2010 0 None
2010-09-20 Celldex commences CDX-011 Phase 2b trial in advanced breast cancer patients expressing GPNMB 0 5
2010-09-20 Micromet initiates MT103 phase 2 trial in adult ALL patients 0 3
2010-09-20 Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients 0 None
2010-09-20 Sanofi-aventis releases Lantus(R) study results for type 2 diabetes 0 None
2010-09-20 Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD 0 None
2010-09-20 Myrexis releases MPC-9528 cancer metabolism inhibitor preclinical study results 0 None
2010-09-20 Chelsea Therapeutics' Phase III NORTHERA Study 301 meets primary endpoint 0 None
2010-09-18 ONS trial results show promise for treating medically refractory chronic migraines: ONSTIM study 0 None
2010-09-18 Emisphere’s SNAC drug successful in reducing food intake; increasing satiety 0 None
2010-09-18 Minocycline plus N-acetylcysteine may help treat TBI 0 None
2010-09-18 Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer 0 None
2010-09-17 Aradigm to present Phase 1 studies of inhaled liposomal ciprofloxacin at 2010 ERS Congress 0 4
2010-09-17 Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes 0 None
2010-09-17 Scott & White Healthcare recruits patients for Phase III lung cancer trial 0 2
2010-09-17 LigoCyte to enroll 98 subjects in first clinical trial for bivalent IM norovirus vaccine 0 None
2010-09-17 FDA grants AGTC $1M for Phase II human clinical trial in alpha-1 antitrypsin deficiency 0 None
2010-09-16 ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease 0 None
2010-09-16 BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout 0 None
2010-09-16 Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment 0 4
2010-09-16 Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC 0 None
2010-09-16 ViroPharma presents Phase 1 study data of VP20621 at ICAAC 2010 0 None
2010-09-16 Relypsa announces positive results from Phase 2 clinical trial of RLY5016 0 None
2010-09-16 Spirogen, Celtic Therapeutics announces initiation of Phase II ovarian cancer trial with SG2000 0 None
2010-09-15 BioCryst reports results from forodesine studies for CTCL and CLL 0 None
2010-09-15 Abstract on ACH-1625 accepted as late breaking poster presentation at The Liver Meeting 2010 0 None
2010-09-15 Phase II clinical trial shows GTx-758 reduces serum free testosterone 0 None
2010-09-15 COTI selected for Canadian life sciences partnering mission 0 None
2010-09-15 ADVENTRX announces Exelbine 12-month stability test results 0 None
2010-09-15 AVANIR's AVP-923 Phase III STAR trial results published in 'Annals of Neurology' website 0 None
2010-09-15 ITS commences treatment in synthetic universal influenza vaccine Phase I trial 0 None
2010-09-15 AMRI selects compound for advanced preclinical testing in treatment of IBS 0 None
2010-09-15 Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer 0 None
2010-09-15 Optimer Pharmaceuticals to present fidaxomicin Phase 3 clinical trial data at ICAAC Conference 0 None
2010-09-15 Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder 0 None
2010-09-15 RAB-1 monoclonal antibody study shows positive result for rabies 0 None
2010-09-15 FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy 0 None
2010-09-15 PLX-PAD therapy improves quality of life in CLI patients 0 None
2010-09-15 Wintherix announces WX04554 molecule can cause bone healing 0 None
2010-09-15 Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer 0 5
2010-09-15 Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis 0 None
2010-09-14 Data from Phase II trial of zanolimumab in PTCL published in British Journal of Haematology 0 None
2010-09-14 Gentium announces defibrotide presentations at 33rd World Congress of International Society of Hematology 0 None
2010-09-14 Enrollment in Derma Sciences DSC127 Phase 2 trial in diabetic foot ulcer healing to conclude September end 0 None
2010-09-14 VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment 0 None
2010-09-14 TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes 0 None
2010-09-14 Icagen suspends further enrollment in ICA-105665 study 0 None
2010-09-14 AACR, EmergingMed collaborate to connect cancer patients with clinical trials in connection to SU2C broadcast 0 None
2010-09-14 OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia 0 None
2010-09-14 Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation 0 2.5
2010-09-14 Ironwood, Forest Laboratories announce positive results for linaclotide Phase 3 clinical trials in IBS-C patients 0 5
2010-09-14 Capstone Therapeutics reaches overall progress in AZX100 Phase 2a clinical trials for keloid scarring 0 None
2010-09-13 High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients 0 None
2010-09-13 Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA 0 None
2010-09-13 Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress 0 None
2010-09-13 North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer 0 None
2010-09-13 Ticagrelor exhibits potential for prevention of heart attacks 0 None
2010-09-13 Synta expands STA-9090 Phase 2 clinical trial in NSCLC 0 None
2010-09-13 Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer 0 5
2010-09-13 Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial 0 None
2010-09-13 Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor 0 None
2010-09-13 ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia 0 None
2010-09-13 XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis 0 None
2010-09-13 Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients 0 None
2010-09-13 Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML 0 None
2010-09-13 Seattle Genetics' lintuzumab phase IIb clinical trial for AML does not meet primary endpoint 0 None
2010-09-13 Diamyd Medical reports potential results on NP2 Phase I clinical trial for chronic pain 0 None
2010-09-13 Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study 0 None
2010-09-13 Genmab announces Phase II ofatumumab study results in RRMS patients 0 None
2010-09-10 Resverlogix announces key changes to Phase 2 ASSURE trial 0 None
2010-09-10 Bioniche reduces net loss per share from $0.15 in fiscal 2009 to $0.02 in fiscal 2010 0 None
2010-09-10 Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients 0 None
2010-09-10 Purdue Pharma to present Butrans Transdermal System CIII clinical program data at PAINWeek 2010 0 None
2010-09-10 FerroKin BioSciences initiates international Phase 2 study of FBS0701 0 None
2010-09-10 Allos Therapeutics to present FOLOTYN trial results at ESMO Congress 0 None
2010-09-09 Seaside reports positive data from STX209 Phase 2 study in ASD 2 None
2010-09-09 Acceleron Pharma and Shire announce joint development of ACE-031 for DMD 0 None
2010-09-09 DARA BioSciences presents KRN5500 study results at World Congress on Pain 0 None
2010-09-09 Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion 0 None
2010-09-09 Researchers find minocycline antibiotics effective for fragile X syndrome 0 3
2010-09-09 NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference 0 None
2010-09-09 Insulin may reduce life-threatening bacterial infections in intensive care patients 0 None
2010-09-09 Team of scientists issues HIV vaccine strategy 0 None
2010-09-09 Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010 0 None
2010-09-09 Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop 0 None
2010-09-09 ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM 0 None
2010-09-09 EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients 0 3
2010-09-09 Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children 0 None
2010-09-09 GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL 0 None
2010-09-09 Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference 0 None
2010-09-09 GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology' 0 None
2010-09-08 Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation 0 None
2010-09-08 MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial 0 None
2010-09-08 MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE 0 None
2010-09-08 Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors 0 None
2010-09-08 Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic 0 None
2010-09-08 Trius Therapeutics announces presentations from drug development programs at 50th ICAAC 0 None
2010-09-08 PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage 0 None
2010-09-08 Phase 3 REALIZE study shows milestone in treatment development for hepatitis C 0 4
2010-09-08 Gemcitabine does not improve survival compared with fluorouracil plus folinic acid in resected pancreatic cancer 0 None
2010-09-08 Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy 0 None
2010-09-08 Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program 0 None
2010-09-08 Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment 0 None
2010-09-08 ESPAC-3 trial shows promising results to prevent pancreatic cancer 0 None
2010-09-08 Can-Fite BioPharma opens IND with US-FDA for CF101 Phase 3 study in Dry Eye Syndrome 0 None
2010-09-07 Methylphenidate facilitates recovery from drug addiction 0 None
2010-09-07 Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder 0 None
2010-09-07 CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer 0 None
2010-09-07 Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery 0 None
2010-09-07 Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera 0 None
2010-09-07 TenX Biopharma recommences enrollment in suspended Phase III trial for cutaneous T-cell lymphoma 0 None
2010-09-07 Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study 0 None
2010-09-07 Axelar AB publishes first AXL1717 data on phase I/II cancer study 0 None
2010-09-06 Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA 0 None
2010-09-04 AVAC calls for economic and political support for CAPRISA 004 microbicide trial's critical follow-up studies 0 None
2010-09-03 Researchers complete INX-189 clinical trials for Hepatitis C virus 0 5
2010-09-03 ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders 0 None
2010-09-03 Data from ESC confirms reduction in adverse events with CYPHER Stent 0 None
2010-09-03 GOG to conduct Phase II trial on primary peritoneal cancer 0 None
2010-09-03 Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection 0 None
2010-09-03 Iroko Cardio International Sàrl announces data on HDB dosing of tirofiban, abciximab in interventional cardiology 0 None
2010-09-03 Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer 0 None
2010-09-03 Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan 0 None
2010-09-02 Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress 0 None
2010-09-02 Halozyme initiates Ultrafast Insulin combination Phase 2 studies with rHuPH20 0 None
2010-09-02 Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections 0 None
2010-09-02 First Phase I/II clinical trial to test MK-0752 in patients with advanced pancreatic cancer 0 None
2010-09-02 Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints 0 None
2010-09-02 Inhibitex completes INX-189 Phase1a trial for HCV 0 None
2010-09-02 ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint 0 5
2010-09-02 Estradiol prevents vascular permeability following hemorrhagic shock: Study 0 None
2010-09-02 Agensys commences AGS-16M8F ADC Phase I clinical trial for renal cancer 0 None
2010-09-02 Sangart reports positive MP4OX Phase IIa study data in severely injured trauma patients with hemorrhagic shock 0 None
2010-08-31 Sangart reports positive data from MP4OX Phase IIa study in trauma patients 1 None
2010-08-31 Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study 0 None
2010-08-31 Phase 3 AVERROES trial reveals apixaban effective for atrial fibrillation patients unsuitable for warfarin 0 None
2010-08-31 ANTIPAF trial reveals ARBs do not reduce number of AF episodes in paroxysmal AF patients 0 None
2010-08-31 Data monitoring committee recommends early termination following impressive results of AVERROES study 0 None
2010-08-31 Unfractionated heparin standard dose may be optimal treatment strategy in PCI patients on fondaparinux 0 None
2010-08-31 Telmisartan and amlodipine combination therapy helps achieve high BP control/response rates 0 2
2010-08-31 Phase 3 EINSTEIN-DVT clinical trial data can transform deep vein thrombosis treatment 0 None
2010-08-31 Study: IV ibuprofen decreases pain, morphine use in pre and post-operative orthopedic surgery patients 0 None
2010-08-31 Reduced heparin dose lowers bleeding risk after PCI without increasing risk of ischaemic complications 0 None
2010-08-31 J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events 0 None
2010-08-31 Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study 0 None
2010-08-30 Heparin enoxaparin may provide better outcomes than unfractionated heparin 0 None
2010-08-30 Phase 2 INNOVATE PCI trial results for elinogrel presented 0 None
2010-08-30 Smoked cannabis relieves chronic neuropathic pain 1 None
2010-08-30 BioMarin's BMN-701 receives FDA orphan drug designation for treatment of Pompe disease 0 5
2010-08-30 BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010 0 None
2010-08-30 Trius commences oral torezolid phosphate Phase 3 clinical study for ABSSSI 0 None
2010-08-30 Selective lowering of heart rate reduces risk of death and hospitalization: Study 0 None
2010-08-30 Low doses of n-3 fatty acids do not reduce overall rate of major cardiovascular events 0 None
2010-08-30 RLY5016 potassium binder helps to regulate hyperkalemia in heart failure patients 0 None
2010-08-30 Large clinical trial does not confirm benefits of erythropoieitin for first ST-elevation myocardial infarction 0 None
2010-08-30 Boehringer Ingelheim announces sub-analysis result of RE-LY trial 0 None
2010-08-30 ATOLL study favors enoxaparin over UFH for primary Percutaneous Coronary Intervention 0 None
2010-08-30 Forest Laboratories reveals top-line results from cariprazine Phase II clinical trial for bipolar depression 0 None
2010-08-30 TEMSO Phase III Trial shows ARR reduction in multiple sclerosis patients 0 None
2010-08-27 Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera 0 None
2010-08-27 Experimental drug PLX4032 holds promise against cancers with faulty BRAF gene 0 None
2010-08-27 FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer 0 5
2010-08-26 Vanda Pharmaceuticals initiates tasimelteon Phase III clinical trial for Non-24-Hour Sleep Wake Disorder 0 None
2010-08-26 Lotus Pharmaceuticals initiates R-Bambuterol Clinical Trial I on-schedule 0 None
2010-08-26 NeoPharm second-quarter net loss decreases to $0.8 million 0 None
2010-08-26 Dose-defining Phase IIa trial of CXL-1020 initiated for treating patients with ADHF 0 None
2010-08-26 FDA approves Chelsea Therapeutics' Phase II protocol for CH-4051 antifolate in rheumatoid arthritis 0 None
2010-08-26 Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published 0 None
2010-08-26 Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma 0 None
2010-08-26 FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL 0 None
2010-08-26 Impax Pharmaceuticals completes enrollment in IPX066 Phase III trial for Parkinson’s disease 0 None
2010-08-26 Nabi receives US patent for treatment and prevention of nicotine addiction with NicVAX conjugate vaccines 0 None
2010-08-26 Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity 0 None
2010-08-25 CHX reports positive results from final pivotal trial of Prevora antibacterial tooth coating for cavity prevention 0 None
2010-08-25 NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera 0 None
2010-08-25 Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010 0 None
2010-08-25 ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial 0 None
2010-08-25 Tranzyme Pharma to present ulimorelin Phase 2 data at NGM Meeting 0 5
2010-08-25 Eisai's Phase III trial of Perampanel for epilepsy shows positive results 0 None
2010-08-24 First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090 0 None
2010-08-24 FDA clears PROLOR Biotech's Phase II clinical trial of hGH-CTP 0 None
2010-08-24 Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C 0 None
2010-08-24 USPTO grants Taligen patent for TT30 lead product candidate 0 None
2010-08-24 Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC 0 None
2010-08-24 FDA OOPD awards Soligenix $1.2M for orBec Phase 3 study in acute gastrointestinal Graft-versus-Host-Disease 0 None
2010-08-23 Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease 0 5
2010-08-23 InSite Vision initiates Phase 1/2 clinical trial of ISV-303 0 None
2010-08-21 Jazz Pharmaceuticals disappointed with FDA Advisory Committee recommendation for JZP-6 in fibromyalgia 0 3.5
2010-08-21 'Yakult' effective in reducing acute diarrhea in young children: Study 0 None
2010-08-20 Protalex initiates dosing in multicenter PRTX-100 Phase 1b clinical study in RA 0 None
2010-08-20 Knopp Neurosciences enters $345 million worldwide licensing agreement with Biogen Idec 0 3
2010-08-20 Trial shows positive results for radioembolisation technique for colorectal cancer liver metastases treatment 0 None
2010-08-20 SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program 0 None
2010-08-20 Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug 0 None
2010-08-20 Bioniche provides update on Urocidin clinical development program for non-muscle-invasive bladder cancer 0 None
2010-08-20 Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa 0 None
2010-08-20 FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD 0 None
2010-08-19 Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study 0 None
2010-08-19 FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer 0 None
2010-08-18 Bolder BioTechnology receives $600,000 NIH SBIR grant to study long-acting IL-11 analog in ARS 0 None
2010-08-18 Rush University Medical Center tests new drug therapy for West Nile fever 0 None
2010-08-18 Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease 0 None
2010-08-18 Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate 0 4
2010-08-18 Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002 0 None
2010-08-18 Repros Therapeutics requests Type B Meeting to review Androxal Phase III protocols 0 None
2010-08-18 USPTO grants Neogenix Oncology patent for DNAs encoding novel molecular aspects of NPC-1 antibody 0 None
2010-08-18 AMT's MAA for LPLD gene therapy product Glybera on schedule 0 None
2010-08-18 Lilly to halt development of potential Alzheimer's disease drug semagacestat 0 None
2010-08-18 Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology 0 None
2010-08-18 BioMarin commences Phase 3b study of Kuvan's neuropsychiatric effects in phenylketonuria patients 0 None
2010-08-17 Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction 0 None
2010-08-17 Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN 0 None
2010-08-17 Hospitals save $284 million through Premier's Quality Connect quality improvement program 0 None
2010-08-17 Intercell reports significant increase in second quarter revenue 0 None
2010-08-17 Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC 0 5
2010-08-17 Experimental drug benefits women with advanced ovarian or breast tumours caused by BRCA gene faults 0 None
2010-08-17 Oral contraceptives equally effective for obese women 0 None
2010-08-17 Antidepressant alleviates depression in peri- and postmenopausal women: Study 0 None
2010-08-16 Emisphere second-quarter net loss increases to $13.7 million 0 None
2010-08-16 Liverpool scientists create new drug for malaria 0 4
2010-08-16 Enrollment open in Phase I clinical study of Morphotek's MORAb-028 for advanced melanoma 0 None
2010-08-16 Titan Pharmaceuticals second-quarter net loss increases to $1.84 million 0 None
2010-08-16 NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies 0 None
2010-08-16 NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention 0 None
2010-08-16 Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009 0 None
2010-08-16 Belatacept study data to be presented at 23rd International Congress of The Transplantation Society 0 None
2010-08-13 CeNeRx BioPharma raises $13 million through Series C financing to support TriRima Phase II trial 0 None
2010-08-13 Achillion second-quarter net loss increases to $6.4 million 0 None
2010-08-13 Humanetics Corporation secures license to provide treatment for ionizing radiation exposure 0 None
2010-08-13 Neurologix second-quarter net loss increases to $4.5 million 0 4
2010-08-13 NovaBay second-quarter net loss increases to $1.2 million 0 None
2010-08-13 Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer 0 None
2010-08-13 BioSante second-quarter net loss increases to $10.8 million 0 None
2010-08-13 CPF urges people to consider clinical trials for pulmonary fibrosis 0 None
2010-08-13 Study finds Olaparib can reduce tumor size in ovarian cancer women 0 5
2010-08-13 OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009 0 None
2010-08-13 Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma 0 None
2010-08-13 Emergent BioSolutions enters agreement to acquire Trubion Pharmaceuticals 0 None
2010-08-13 Arrowhead third-quarter 2010 net loss decreases to $0.4 million 0 None
2010-08-13 Antares Pharma second-quarter total revenue increases 78% to $3.1 million 0 None
2010-08-12 FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients 0 None
2010-08-12 Aeterna Zentaris second-quarter revenues decrease to $5.6 million 0 None
2010-08-12 FDA grants BioMimetic Therapeutics orphan drug designation for rhPDGF-BB in treatment of OCD 0 None
2010-08-12 AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma 0 None
2010-08-12 Pathway's drug development milestone triggers $4.5M tranche of Series A private equity placement 0 None
2010-08-12 Early administration of TXA reduces death from bleeding without increase in complications: Study 0 None
2010-08-12 FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine 0 None
2010-08-12 Syndax raises $6 million to support ENCORE 301 study in breast cancer 0 None
2010-08-12 Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer 0 None
2010-08-11 HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies 0 5
2010-08-11 PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints 0 None
2010-08-11 Agile initiates Phase 3 NEW CHOICE Study of AG200-15 contraceptive patch 0 None
2010-08-11 Depomed announces SPA agreement with FDA for Serada Phase 3 trial for menopausal hot flashes 0 None
2010-08-11 OptiNose's bi-directional nasal device delivering fluticasone effective in reducing nasal polyps in CRS patients 0 None
2010-08-11 Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma 0 None
2010-08-11 Trigemina reports positive results from TI-001 Phase IIa clinical trial for Chronic Daily Headache 0 None
2010-08-11 FDA clears Curemark's CM – 4612 IND for Phase III clinical trial in ADHD 0 None
2010-08-11 TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug 0 2
2010-08-11 NIAID launches clinical trials of dengue vaccine 0 None
2010-08-11 Omeros net loss for second-quarter 2010 increases to $7.8 million 0 None
2010-08-10 Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C 0 5
2010-08-10 China Pharma second-quarter revenue increases 22% to $16.6 million 0 None
2010-08-10 Amarin provides progress update on MARINE and ANCHOR trials for treating elevated triglyceride levels 0 None
2010-08-10 Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting 0 None
2010-08-10 Transcept Pharmaceuticals second-quarter net loss decreases to $2.06 million 0 None
2010-08-10 Pharmasset third-quarter net loss increases to $16.0 million 0 None
2010-08-10 Synta second-quarter net loss increases to $9.1 million 0 3
2010-08-10 Array BioPharma fiscal 2010 revenue increases to $53.9 million 0 None
2010-08-10 Elan and Transition Therapeutics report results of ELND005 Phase 2 study for Alzheimer's disease 0 None
2010-08-10 Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011 0 None
2010-08-10 NIH begins human clinical testing for dengue virus vaccine 0 None
2010-08-10 Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial 0 None
2010-08-10 ACADIA second-quarter net loss decreases to $4.3 million 0 None
2010-08-10 Poniard second-quarter net loss decreases to $6.5 million 0 None
2010-08-09 Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer 0 None
2010-08-09 Bellus Health reports net loss of $5.8M for second-quarter vs. net income of $14.27M for previous year 0 None
2010-08-09 Isis second-quarter pro forma net operating loss increases to $15.5 million 0 None
2010-08-09 Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine 0 5
2010-08-09 Fibrocell Science submits clinical study report to FDA for azficel-T Phase II/III trial for acne scars 0 None
2010-08-09 Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada 0 4.5
2010-08-09 Clinical Data first-quarter gross revenue increases 52% to $6.2 million 0 None
2010-08-09 Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer 0 None
2010-08-09 GTx second-quarter net loss increases to $12.9 million 0 None
2010-08-09 Anti-viral drug addition to standard treatment regimen increases cure rate for hepatitis C 0 None
2010-08-07 Ironwood provides investor update for second-quarter 2010 0 None
2010-08-07 EpiCept second-quarter net loss decreases to $4.9 million 0 None
2010-08-07 Ardea Biosciences second-quarter total revenues decline to $3.5 million 0 None
2010-08-07 Orexigen second-quarter net loss decreases to $11.9 million 0 None
2010-08-07 Halozyme second-quarter revenue increases to $3.2 million 0 None
2010-08-07 Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone 0 None
2010-08-07 U.S. Senate passes I-ACT to enable patients with rare disease to participate in clinical trials 0 None
2010-08-07 NeurogesX net loss for second-quarter 2010 increases to $10.2 million 0 None
2010-08-07 Cyclacel second-quarter net loss decreases to $6.5 million 0 None
2010-08-07 Catalyst announces $1.5 million registered direct offering 0 None
2010-08-06 Cornerstone Pharmaceuticals includes Mary Crowley Research Centers in CPI-613 clinical trials 0 None
2010-08-06 V-101 shows safety profile in treating erythema of rosacea: Clinical study 0 None
2010-08-06 Dyax announces first Phase 3 trial results of KALBITOR for acute HAE 0 None
2010-08-06 Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study 0 None
2010-08-06 TEMPO study recommends early administration of Azilect in PD patients 0 4
2010-08-05 Ligand second-quarter net loss reduces to $0.3 million 0 None
2010-08-05 Biovail second-quarter total revenues increase 23% to $238.8 million 0 None
2010-08-05 Incyte second-quarter total revenues increase to $49.8 million 0 None
2010-08-05 YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis 0 None
2010-08-05 Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million 0 None
2010-08-05 Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer 0 None
2010-08-05 Micromet second-quarter 2010 total revenues increase to $6.5 million 0 None
2010-08-05 Inspire second-quarter total revenue increases 18% to $27.3 million 0 None
2010-08-05 BioCryst second-quarter total revenues increase to $7.6 million 0 None
2010-08-05 CEL-SCI produces and fills first lot of Multikine 0 5
2010-08-05 Affymax, Takeda announce preliminary strategy for Hematide to treat anemia in chronic renal failure patients 0 None
2010-08-05 Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint 1 3
2010-08-05 CTI second-quarter total net operating expenses decrease to $20.0 million 0 None
2010-08-05 ARIAD reports $159.3 million second-quarter net income 0 None
2010-08-05 Genzyme, Isis announce results of two mipomersen phase 3 studies 0 None
2010-08-05 Alnylam second-quarter revenues increase to $26.6 million 0 None
2010-08-05 ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million 0 None
2010-08-05 Anthera second-quarter total operating expenses increase to $7.9 million 0 None
2010-08-05 FDA issues Lux Biosciences Complete Response letter for Luveniq NDA 0 None
2010-08-05 Acceleron's ACE-031 protein therapeutic for DMD receives FDA Fast Track designation 0 1
2010-08-04 Infinity reports $18.4 million total revenue for second-quarter 2010 0 None
2010-08-04 NCI panel recommends Celsion's Phase III ThermoDox HEAT Study as Priority Clinical Trial for HCC 0 1
2010-08-04 Contrave added to diet and exercise regimen can induce significant weight loss 0 1
2010-08-04 Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine 0 None
2010-08-04 Advaxis receives India’s DCGI approval for ADXS11-001 Phase II clinical trial for cervical cancer 0 None
2010-08-04 Glycotope receives German, Italian regulatory approval for CetuGEX Phase I study for solid cancers 0 None
2010-08-04 CTI files SPA with FDA for new pixantrone phase III trial in relapsed or refractory aggressive B-Cell NHL 0 None
2010-08-04 ZymoGenetics second-quarter net loss declines to $3.8 million 0 None
2010-08-04 Excaliard reports positive results from EXC 001 Phase 2 clinical trial for reducing scar severity 0 None
2010-08-03 Titan completes 60% enrollment in confirmatory Phase 3 clinical study of Probuphine for opioid addiction 0 None
2010-08-03 Vical second-quarter revenues decrease to $2.1 million 0 None
2010-08-03 First patient treated in Phase Ib expansion study of CUDC-101 0 None
2010-08-03 NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM 0 None
2010-08-03 Researchers call for more public disclosure about clinical drug trials 0 None
2010-08-03 Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma 0 5
2010-08-03 ArQule, Daiichi Sankyo announce decision to advance ARQ 197 into Phase 3 clinical trial for NSCLC 0 None
2010-08-03 FDA approves N30 Pharma's NDA for N6022 GSNOR 0 None
2010-08-03 Methods to boost neutralizing antibody may prevent HIV-1 transmission 0 None
2010-08-03 Idera announces $15 million registered direct offering 0 None
2010-08-03 Etoricoxib better than opioid drug tramadol for postoperative pain: Study 0 None
2010-08-03 BioMarin provides update on PEG-PAL Phase 2 clinical study for phenylketonuria 0 5
2010-08-03 BioMarin reports $0.5 million GAAP net loss for second-quarter 2010 0 None
2010-08-03 BioMarin completes BMN 195 Phase 1 clinical trial for Duchenne muscular dystrophy 0 None
2010-08-02 Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF 0 5
2010-08-02 Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research 0 None
2010-08-02 Study: hGH linked to PROLOR's CTP technology increases half-life, bioactivity 0 None
2010-08-02 HDL does not predict heart attack risk after dramatic statin therapy: Study 0 None
2010-07-30 FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury 0 None
2010-07-30 Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released 0 None
2010-07-30 Anadys Pharmaceuticals reports SVR12 data for ANA598 0 None
2010-07-30 SynCo Bio Partners extends collaboration with Versartis 0 None
2010-07-30 Bio-Path commences dosing in Liposomal Grb-2 Phase I cancer study 0 None
2010-07-30 Curaxis completes reverse merger with Auto Search Cars 0 1
2010-07-30 Anthera initiates PEARL-SC Phase 2b study of A-623 for lupus 0 None
2010-07-30 Orexigen's Contrave COR-I trial results published online in journal Lancet 0 None
2010-07-30 Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint 0 5
2010-07-30 ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis 0 None
2010-07-29 Anadys second-quarter net loss decreases to $3.0 million 0 None
2010-07-29 Celgene second-quarter non-GAAP total revenue increases 36% to $850 million 0 None
2010-07-29 AVEO second-quarter total revenues increase to $15.6 million 0 None
2010-07-29 Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment 0 None
2010-07-29 Bionovo receives EMA final guidance for advancing Menerba to Phase 3 clinical trials 0 None
2010-07-29 Rotigotine provides clinically relevant improvements in RLS symptoms: Study 0 None
2010-07-29 Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia 0 None
2010-07-29 Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer 0 None
2010-07-29 Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine 0 None
2010-07-29 Generex reports positive trends in ongoing Oral-lyn buccal insulin spray global Phase III trial 0 None
2010-07-29 Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis 0 5
2010-07-29 Etubics enters Phase I trials for next generation vector vaccines 0 None
2010-07-29 CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial 0 None
2010-07-29 Limerick to announce new results from LIM-0705 human trials at 23rd Transplantation Society congress 0 None
2010-07-28 Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis 0 5
2010-07-28 Kyowa Hakko Kirin initiates Phase 2 trial of ARQ 197 for gastric cancer: ArQule 0 None
2010-07-28 Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC 0 None
2010-07-28 Allos reports net loss of $20.0 million for second-quarter 2010 0 None
2010-07-28 Pharmasset announces data from PSI-352938 single ascending dose study 0 None
2010-07-28 BiondVax receives 2010 European Influenza Vaccines Technology Innovation Award 0 None
2010-07-28 Regeneron second-quarter total revenues increase to $115.9 million 0 None
2010-07-28 GSK awards NCCN $4 million grant for study of ofatumumab and pazopanib 0 None
2010-07-28 Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients 0 None
2010-07-28 InterMune second-quarter total revenue decreases to $5.9 million 0 None
2010-07-28 MabCure's MAbs 94% accurate in identifying ovarian cancer 0 None
2010-07-27 Omeros initiates enrollment in OMS302 Phase 2b clinical trial in patients undergoing cataract surgery 0 None
2010-07-27 Iverson Genetic Diagnostics receives CMS approval for Warfarin clinical study 0 None
2010-07-27 Study on interactions between new antitubercular drug candidates SQ109 and TMC207 0 None
2010-07-27 Idenix second-quarter total revenues decrease to $1.3 million 0 None
2010-07-26 QRxPharma reports positive outcome of European Scientific Advice meetings on MoxDuo IR pain therapy 0 None
2010-07-26 Seaside Therapeutics reports positive data from STX209 Phase 2 study in fragile X syndrome 0 None
2010-07-26 Can-Fite's CF102 decreases HCV viral load in liver cancer patients 0 5
2010-07-26 Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia 0 None
2010-07-26 AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA 0 None
2010-07-26 Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma 0 None
2010-07-26 Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model 1 5
2010-07-26 ESC concerned over interpretation of JUPITER sub-analysis trial results about HDL cholesterol 0 5
2010-07-26 Cerenis, Novasep awarded French Government funding for development of CER-001 HDL mimetic 0 None
2010-07-26 L2FU reports 100% recovery of recent study's lost clinical trial patients 0 None
2010-07-26 North Shore-LIJ Health System seeks oropharynx patients for phase I clinical trial 0 None
2010-07-26 Experimental treatment for sickle cell disease enters Phase 3 clinical trials 3 2
2010-07-23 First patient enrolled in Phase 3 SyNAPSe study of BHR-100 for TBI 0 4
2010-07-23 Tarsa Therapeutics completes patient enrollment in Phase III ORACAL trial of oral calcitonin 0 None
2010-07-23 Update on Phase III Study of oral calcitonin for treatment of osteoarthritis 0 None
2010-07-23 Novartis, Nordic Bioscience to continue oral calcitonin Phase III study in osteoarthritis patients 0 None
2010-07-23 Early HAART during TB treatment prolongs survival of untreated HIV-infected adults: CAMELIA study 0 None
2010-07-23 Boehringer Ingelheim's VERxVE study of nevirapine meets primary endpoint 0 None
2010-07-23 NPS completes patient randomization in GATTEX Phase 3 study for PN dependent short bowel syndrome 0 None
2010-07-23 Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia 0 None
2010-07-23 Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles 0 None
2010-07-22 Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults 0 None
2010-07-22 Achillion nominates ACH-2928 NS5A clinical candidate for treatment of HCV 0 None
2010-07-22 Tarsa completes enrollment in Phase III ORACAL trial for postmenopausal osteoporosis 0 None
2010-07-22 Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study 0 None
2010-07-22 Repros granted IRB approval to commence low dose Proellex study 0 None
2010-07-22 Somaxon's Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals 0 None
2010-07-22 Fera acquires investigational new drug for treatment of fungal otitis externa 0 None
2010-07-22 Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma 0 4
2010-07-22 Ampio Pharmaceuticals commences Optina Phase II clinical trial for diabetic macular edema 0 4
2010-07-21 AMRI initiates enrollment for Phase I study of ALB-127158 for obesity 0 None
2010-07-21 Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials 0 None
2010-07-21 NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo 0 None
2010-07-21 PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone 0 None
2010-07-21 AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop 0 5
2010-07-21 AIDS 2010: Study finds microbicide containing HIV drug lowers infection risk in women by 39% 1 None
2010-07-21 Major turning point in antiepileptic drug testing, development 0 None
2010-07-20 Arcion reports top-line results from ARC-4558 Phase 2b clinical trial for painful diabetic neuropathy 0 None
2010-07-20 Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma 0 None
2010-07-20 KAI Pharmaceuticals completes enrollment in Phase 1 study of KAI-4169 for SHPT 0 None
2010-07-20 Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer 0 None
2010-07-20 Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study 0 None
2010-07-20 Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention 0 None
2010-07-20 Aegera reports data from Phase 1 portion of combination AEG35156 Phase 1-2 study for primary liver cancer 0 None
2010-07-20 AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection 0 None
2010-07-20 Argos' Arcelis immunotherapy reduces viral load in interim analysis of Phase 2 HIV trial 0 None
2010-07-20 Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel 0 None
2010-07-20 USAID Administrator issues statement on CAPRISA 004 trial for preventing HIV infection in women 0 None
2010-07-20 MDMA (Ecstasy) holds promise for chronic treatment-resistant PTSD 0 None
2010-07-20 Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events 0 None
2010-07-20 CytRx updates on progress in clinical development of bafetinib in three oncology indications 0 None
2010-07-20 Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program 0 None
2010-07-20 ZIOPHARM Oncology commences palifosfamide Phase III clinical trial for metastatic soft tissue sarcoma 0 None
2010-07-20 Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference 0 None
2010-07-20 Benefits of drug L-methionine for neurogenic bladder disorders unclear 0 None
2010-07-19 Amira achieves two clinical development milestones in FLAP program for asthma 0 None
2010-07-19 Oncolytics Biotech receives Canadian approval for combination REOLYSIN Phase 3 trial in head, neck cancer 0 None
2010-07-19 Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC 0 5
2010-07-19 Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint 0 None
2010-07-19 Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference 0 5
2010-07-19 ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna 0 1
2010-07-19 FIT Biotech to present results of FIT-06 Phase II clinical trial at XVIII International AIDS 2010 Conference 0 1
2010-07-17 Pacific Shore releases clinical trial results for Burner Balm lip balm 0 None
2010-07-17 Amgen granted FDA priority review designation for denosumab BLA 0 None
2010-07-16 VIVUS disappointed with FDA Advisory Committee's vote on QNEXA for obesity treatment 0 None
2010-07-16 JDD publishes long-term efficacy and tolerability study of PyratineXR Moisturizing Lotion 0 None
2010-07-16 Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010 0 None
2010-07-15 QR Pharma to present positive clinical data from mechanism of action study in MCI at ICAD 2010 0 2
2010-07-15 Positive microplasmin Phase II trial results published in journal Retina 0 None
2010-07-15 Scientists comment on two clinical trials that use Rituximab to treat small-vessel vasculitis 1 None
2010-07-15 PPMD to provide grant to clinical sites participating in Phase 2 study of ACE-031 0 None
2010-07-15 Two patents issued for GlycoMimetics lead drug candidate, related compounds 0 None
2010-07-15 Enrollment complete in Nabi's first NicVAX Phase III clinical trial for nicotine addiction 0 None
2010-07-15 Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma 0 None
2010-07-14 Aastrom commences extension study for control patients from Phase 2 IMPACT-DCM clinical trial 0 None
2010-07-14 Phase 1/2 clinical study of bepotastine besilate nasal spray initiated for seasonal allergic rhinitis 0 None
2010-07-14 Presidio Pharmaceuticals completes Phase 1a clinical trial of PPI-461 in healthy subjects 0 4
2010-07-14 Supernus initiates SPN812 Phase IIa clinical trial for ADHD in adults 0 None
2010-07-14 ChemGenex agrees with FDA on potential regulatory path to progress OMAPRO for CML 0 None
2010-07-13 Fredericksburg Oncology invites participants for new metastatic melanoma clinical trial 0 None
2010-07-13 SCENESSE reduces, prevents phototoxic reactions experienced by EPP patients in Phase III trial 0 None
2010-07-13 MAP Pharmaceuticals reports results from LEVADEX PK and safety clinical trial in smokers, non-smokers 0 None
2010-07-13 Innocoll submits SPA for phase 3 clinical trial of Cogenzia for adjuvant treatment of infected diabetic foot ulcers 0 None
2010-07-13 EntreMed announces publication of preclinical data for ENMD-2076 0 None
2010-07-13 Clinical trial initiated to evaluate LibiGel on cognitive function in menopausal women 0 None
2010-07-13 AlphaRx reports positive preclinical results of GAI-122 injectable nanoemulsion for Acute Ischemic Stroke 0 None
2010-07-13 Biodel reports preclinical test results of BIOD620 glucose-regulated or "smart" basal insulin product candidate 0 None
2010-07-13 BioSpecifics' partner Auxilium provides update on XIAFLEX 0 None
2010-07-12 Report on program to develop, test nasally delivered H5N1 vaccine filed with Japan's MHLW 0 None
2010-07-12 Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial 0 None
2010-07-12 Reata funds second pivotal trial of bardoxolone with $78 million equity financing 0 None
2010-07-12 Medivir reports 24-week interim Phase 2b results of TMC435 in treatment-naïve patients with HCV genotype-1 0 None
2010-07-12 Interim progress from Phase III TeloVac study of GV1001 vaccine announced 0 None
2010-07-12 Biogen Idec, Swedish Orphan Biovitrum present results from rFIXFc Phase 1/2a study in hemophilia B 0 5
2010-07-12 bitop's Ectoin allergy nasal spray reduces symptoms of acute allergic rhinitis in two-week crossover study 0 None
2010-07-12 Biogen Idec, Swedish Orphan Biovitrum announce advancement of rFVIIIFc into registrational study 0 None
2010-07-12 Study results show no improvement in overall survival for combination of gemcitabine and Amplimexon 0 None
2010-07-12 Mesoblast schedules formal meeting with FDA to discuss proposed Phase 3 clinical trial program 0 None
2010-07-09 Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference 0 None
2010-07-09 Phase II trial results of TB-402 presented at International Congress on Thrombosis 0 None
2010-07-09 Bayer HealthCare to present BAY86-6150 rFVIIa Phase I clinical data at XXIX WFH International Congress 0 None
2010-07-08 Rockwell Medical completes End of Phase II meeting with FDA regarding SFP 0 3
2010-07-08 Advanced Life Sciences announces positive results from preclinical studies of Restanza IV 0 None
2010-07-08 Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR 0 None
2010-07-08 Selvita, Orion collaborate to develop and commercialize SEL103 Alzheimer’s disease program 0 None
2010-07-08 Nymox reports positive new results from pooled analysis of NX-1207 clinical trials for BPH 0 None
2010-07-08 GSK, XenoPort disappointed with GSK1838262/XP13512 phase 2b study for migraine headaches 0 None
2010-07-08 Olaparib shows promising results against inherited forms of breast and ovarian cancer 0 None
2010-07-07 NOXXON to commence multiple ascending dose study of MCP-1 targeting anti-inflammatory Spiegelmer NOX-E36 0 None
2010-07-07 Neoprobe initiates third multi-center Phase 3 clinical study of Lymphoseek 0 None
2010-07-07 Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01 0 None
2010-07-07 Nile completes dosing in CD-NP Phase II study for acute decompensated heart failure 0 None
2010-07-07 Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress 0 None
2010-07-07 Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients 0 None
2010-07-07 Capstone Therapeutics to continue AZX100 Phase 2a trial in dermal scarring to planned 12-month endpoints 0 None
2010-07-07 Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer 0 None
2010-07-07 Debiopharm's achievement of Phase I milestone in Debio 0932 trial triggers $3M milestone payment to Curis 0 None
2010-07-07 Initial Phase II study results of ofatumumab in patients with RRMS announced 0 None
2010-07-07 FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy 0 None
2010-07-07 Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed 0 None
2010-07-07 Crux Biomedical commences enrollment in Retrieve 2 pivotal U.S. IDE trial of new Vena Cava Filter 0 None
2010-07-07 PuraMed BioScience completes clinical study of LipiGesic M for treating acute migraine 0 None
2010-07-07 FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations 0 5
2010-07-06 Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study 0 2
2010-07-06 CTI submits expanded PIP to EMEA for pixantrone MAA for relapsed or refractory, aggressive NHL 0 None
2010-07-06 Nottingham researchers undertake new clinical trial on hearing loss 0 None
2010-07-06 EC approves change in posology of Circadin from 3 weeks to 3 months of treatment 0 None
2010-07-02 Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks 0 5
2010-07-02 Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients 0 None
2010-07-02 Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia 0 2.7
2010-07-02 QR Pharma to present clinical data from mechanism of action study in MCI patients at ICAD 2010 0 None
2010-07-02 Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS 0 None
2010-07-02 Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint 0 None
2010-07-01 ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress 0 None
2010-07-01 Studies on VIAject and Vialog presented at 70th American Diabetes Association sessions 0 None
2010-07-01 Oxycyte PFCE decreases mortality after onset of decompression sickness in porcine model study 0 None
2010-07-01 Study results of triple combination therapy in patients with diabetes and hypertension presented at ADA 2010 0 None
2010-07-01 Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study 0 None
2010-07-01 Sepracor announces preliminary results from OMNARIS HFA Phase III study for seasonal allergic rhinitis 0 None
2010-07-01 Evotec commences EVT 101 proof-of-concept Phase II study in treatment-resistant depression 0 None
2010-07-01 CBio achieves recruitment milestone in XToll clinical trial 0 None
2010-07-01 Biospherics acquires worldwide patent rights to Dtagatose from UKRF 0 None
2010-07-01 XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052 0 None
2010-07-01 Eisai reports preliminary results from Dacogen for Injection Phase III study in AML 0 None
2010-07-01 Threshold Pharmaceuticals initiates Phase 2 clinical trial of TH-302 in patients with first line pancreatic cancer 0 None
2010-07-01 Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections 0 None
2010-06-30 SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication 0 None
2010-06-30 Calistoga Pharmaceuticals closes $40 million Series C financing 0 None
2010-06-30 Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension 0 None
2010-06-30 BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive 0 None
2010-06-30 Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI 0 None
2010-06-30 Data published in Cancer Research demonstrates proof of concept for Mirna's tumor suppressor miRNAs 0 None
2010-06-30 European Congress of Nephrology unveils results of various clinical trials 0 3
2010-06-30 Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs 0 None
2010-06-30 Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives 0 None
2010-06-30 Aeolus AEOL 10150 study confirms ability to rescue skin from deleterious effects of CEES 0 None
2010-06-30 Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases 0 None
2010-06-30 Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress 0 None
2010-06-30 Sangart completes enrollment for MP4OX Phase IIa study in severely injured trauma patients 0 None
2010-06-30 FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics 0 None
2010-06-30 Cardio3 BioSciences reports positive data from C-Cure stem cell therapy clinical trial for heart failure 0 None
2010-06-29 Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias 0 None
2010-06-29 Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR 0 None
2010-06-29 Alimera submits Iluvien NDA for DME to FDA 0 None
2010-06-29 Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD 0 None
2010-06-29 Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer 0 None
2010-06-29 Vitae earns $14M milestone payment from Boehringer Ingelheim 0 None
2010-06-29 PROLOR Biotech receives EU GMP certification for hGH-CTP biobetter version of human growth hormone 0 None
2010-06-29 Tranzyme reports positive results from TZP-102 Phase 2 study in diabetic patients with gastroparesis 1 None
2010-06-29 Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics 0 None
2010-06-29 Pluristem advances toward PLX-PAD Phase IIb clinical trials for CLI and Moderate-severe Claudication 0 None
2010-06-29 Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer 0 None
2010-06-29 Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients 0 5
2010-06-29 Astellas presents ASP1941 selective SGLT2 inhibitor Phase 2 study results at 70th ADA 0 None
2010-06-29 Quark reports results from QPI-1007 siRNA drug study in rat ocular hypertension model of glaucoma 0 None
2010-06-29 AFREZZA provides long-term glucose control in Type 2 diabetics: Study 0 None
2010-06-29 Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis 0 None
2010-06-29 Marcadia, Eli Lilly sign development, license agreement for short-acting glucagon program 0 None
2010-06-29 MGH, Iacocca Foundation complete Phase I BCG clinical trial in type 1 diabetes 0 3
2010-06-29 BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium 0 None
2010-06-29 Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain 0 None
2010-06-29 Cell>Point completes cancer diagnostic phase 2 trial; reports favorable trends in primary tumor imaging 0 None
2010-06-28 ITMTX treatment effective in late stages/progressive forms of MS: Study 0 None
2010-06-28 Intarcia presents ITCA 650 Phase 2 study results at 70th ADA 0 None
2010-06-28 Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsia 0 3
2010-06-28 Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis 0 None
2010-06-28 MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program 0 None
2010-06-28 Clinical study results show no increased risk of CV events associated with SYMLIN injection 0 None
2010-06-28 Tolerx presents data from otelixizumab Phase 3 DEFEND-1 clinical trial in type 1 diabetes patients 0 None
2010-06-28 First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010 0 None
2010-06-28 Aeterna Zentaris, Almac collaborate on study of AEZS-108 doxorubicin LHRH targeted conjugate compound 0 5
2010-06-28 Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes 0 None
2010-06-28 RiVax intradermal administration protects from mucosal, systemic ricin intoxication 0 None
2010-06-28 ADVANCE study provides new insights into the management of SHPT in CKD patients 0 None
2010-06-28 Linagliptin mono- and combination therapy improves blood glucose control 0 None
2010-06-28 Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis 0 None
2010-06-28 Final results of VIAject vs. RHI Phase 3 study in type 2 diabetes patients presented at 70th ADA 0 None
2010-06-28 Halozyme presents new data from Ultrafast Insulin development program at 70th ADA 0 None
2010-06-28 Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA 0 None
2010-06-28 Orexigen Therapeutics announces data from CORDiabetes trial for Contrave 0 None
2010-06-28 Arena's lorcaserin reduces body weight across patient subgroups 0 None
2010-06-28 Tolerx presents preclinical data on TRX518 anti-GITR immunotherapy for cancer 0 None
2010-06-28 Phase 2 proof-of-concept data for Novo Nordisk's degludec presented at ADA 2010 0 None
2010-06-28 Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study 0 None
2010-06-28 Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar 0 None
2010-06-28 Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010 0 5
2010-06-28 Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE 0 None
2010-06-25 CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial 0 None
2010-06-25 Sanofi-aventis' Phase I clinical trial with SAR650984 triggers $1M milestone payment to ImmunoGen 0 None
2010-06-25 Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease initiated 0 None
2010-06-24 Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin 0 None
2010-06-24 Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease 0 None
2010-06-24 Infinity commences enrollment in IPI-493 Phase 1 clinical trial for advanced hematologic malignancies 0 None
2010-06-24 Palatin announces completion of patient dosing, database lock in bremelanotide study for ED 0 None
2010-06-24 AVEO receives EMA orphan medicinal product designation for tivozanib 0 None
2010-06-24 DMARDs should be used early and aggressively at the first sign of RA: Researchers 0 None
2010-06-24 Spherix to explore triglycerides for D-tagatose therapy 0 None
2010-06-24 Pfizer announces suspension of osteoarthritis clinical program for tanezumab 0 1
2010-06-24 Positive results from Phase II PK study for Topical Interferon Alpha-2b announced 0 None
2010-06-24 BioSante closes $15 million registered direct offering 0 None
2010-06-24 Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia 0 None
2010-06-23 Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib 0 None
2010-06-23 SIGA completes fourth human clinical trial of ST-246 smallpox antiviral drug candidate 0 None
2010-06-23 AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD 0 None
2010-06-23 Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors 0 None
2010-06-23 MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial 0 None
2010-06-23 New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer 0 None
2010-06-23 Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment 1 4
2010-06-23 Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH 0 None
2010-06-23 MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award 0 None
2010-06-23 Phase I/II clinical trials show crizotinib reduces lung cancer tumors 2 None
2010-06-23 Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology 0 None
2010-06-23 Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients 0 None
2010-06-22 Nuon study confirms potential utility of tranilast as uricosuric agent 0 5
2010-06-22 Affymax's database lock achievement in Phase 3 Hematide trial triggers $30M milestone payment from Takeda 0 None
2010-06-22 Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD 0 None
2010-06-22 Biovest targets mantle cell lymphoma as next indication for BiovaxID 0 5
2010-06-22 Protea Biosciences, Mayoly-Spindler commence Phase I/IIA human clinical trial for new recombinant Lipase 0 None
2010-06-22 QLT reports final 24-month results from Phase II RADICAL study in patients with wet AMD 0 None
2010-06-22 SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates 0 None
2010-06-22 Novel MC4R agonist exhibits potential as new treatment for obesity, diabetes 1 5
2010-06-22 Oral micronized progesterone effective for women with symptomatic hot flashes 0 4
2010-06-22 Omega-3 effective for treating depression in patients without anxiety disorders 0 None
2010-06-22 FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante 0 None
2010-06-22 Enobia reports positive interim data from ENB-0040 enzyme replacement therapy study for children with HPP 0 None
2010-06-22 Ipsen reports top line results from European study of GuidAge for Alzheimer's Dementia 0 None
2010-06-22 Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia 0 None
2010-06-22 Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010 0 None
2010-06-22 Celator announces expansion of research agreement with Cephalon 0 None
2010-06-21 Sinapis initiates dosing in Phase I trial of intravenous infusion of methamphetamine 0 None
2010-06-21 Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study 0 None
2010-06-21 Palatin reports preclinical study results of PL-3994 in respiratory tissue for asthma indications 0 None
2010-06-21 NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection 0 None
2010-06-21 Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010 0 None
2010-06-21 Ostarine increases muscle mass and strength in postmenopausal women: Study 0 4
2010-06-21 Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting 0 None
2010-06-21 ZIOPHARM Oncology announces guidance on palifosfamide Phase III trial in metastatic soft tissue sarcoma 0 None
2010-06-21 Results of two clinical proof-of-concept studies for CER-627 program to be presented at EAS Congress 2010 0 None
2010-06-21 OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial 0 None
2010-06-21 Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients 0 None
2010-06-21 Staloral 300 demonstrates efficacy in phase III study for control of asthma in China 0 5
2010-06-21 Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1 0 4
2010-06-19 New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James 0 5
2010-06-19 Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010 0 None
2010-06-18 Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome 0 None
2010-06-18 Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR 0 None
2010-06-18 Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS 0 None
2010-06-18 InteKrin Therapeutics to present INT131 SPPARM Phase 2b data at American Diabetes Association meeting 0 None
2010-06-18 BioSante announces presentation of LibiGel safety update at ENDO 2010 0 None
2010-06-18 Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010 0 None
2010-06-18 Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010 0 None
2010-06-18 DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications 0 None
2010-06-18 Roche implements risk mitigation plan in taspoglutide Phase III programme 0 None
2010-06-18 First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer 0 None
2010-06-18 EC grants Allos Therapeutics' pralatrexate orphan medicinal product designation for CTCL treatment 0 None
2010-06-17 First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010 0 None
2010-06-17 Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders 0 None
2010-06-17 Teva exercises option to invest additional $11.9M in Andromeda Biotech 0 None
2010-06-17 Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting 0 None
2010-06-17 Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes 0 None
2010-06-17 VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR 0 None
2010-06-17 Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR 0 None
2010-06-17 HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010 0 None
2010-06-17 Stimuvax clinical program resumed in patients with NSCLC 0 None
2010-06-17 Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC 0 None
2010-06-17 Curis reports topline results from GDC-0449 Phase II clinical trial for metastatic colorectal cancer 0 4
2010-06-17 DURECT reports European POSIDUR Phase IIb hysterectomy clinical trial results 0 None
2010-06-16 The utility of observational studies in clinical decision making: Lessons learned from statin trials 0 None
2010-06-16 Trius Therapeutics reaches agreement with FDA under SPA for Phase 3 study of torezolid phosphate for ABSSSI 0 None
2010-06-16 Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease 0 None
2010-06-16 OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC 0 None
2010-06-16 Phase 3 U.S. registration study of LODOTRA shows improvement in patients with RA 0 5
2010-06-16 RG7204 holds promise for metastatic melanoma with V600E BRAF mutation 0 None
2010-06-16 Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE 0 5
2010-06-16 Nuon Therapeutics NU1618 phase 2a study in hyperuricemia meets primary endpoint 0 None
2010-06-16 AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib 0 None
2010-06-16 Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain 0 None
2010-06-16 Independent SMB recommends continuance of Allovectin-7 Phase 3 trial for metastatic melanoma 0 None
2010-06-16 Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist 0 None
2010-06-16 NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex 0 5
2010-06-16 Nymox near completion of new NX-1207 follow-up study for BPH 0 None
2010-06-16 New data from Phase 2a trial support further development of BMS-945429/ALD518 monoclonal antibody for RA 0 None
2010-06-16 Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress 0 None
2010-06-16 Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress 0 None
2010-06-16 Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma 0 5
2010-06-15 Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis 0 None
2010-06-15 Anacor's AN3365 novel systemic antibiotic achieves proof of concept 0 None
2010-06-15 Positive clinical trial results for Anacor Pharmaceuticals' AN2728 announced 0 None
2010-06-15 Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation 1 None
2010-06-15 Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine 0 None
2010-06-15 Pieris commences PRS-050 anti-VEGF Anticalin Phase I clinical trial for cancer 0 None
2010-06-15 First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma 0 None
2010-06-15 Early administration of tranexamic acid to patients with severe bleeding injuries saves lives 0 None
2010-06-15 Aeterna Zentaris to present poster on AEZS-130 growth hormone secretagogue/ghrelin receptor agonist at 92nd ENDO 0 None
2010-06-15 Micromet's blinatumomab demonstrates potential to change outcome for patients with ALL 0 None
2010-06-15 Trubion announces Pfizer's decision to discontinue development of TRU-015 for RA 0 None
2010-06-15 Celator presents new data on CPX-351 liposome injection at European Hematology Association congress 0 None
2010-06-15 FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS 0 None
2010-06-14 MultiCell retains CDSS to manage MCT-125 Phase IIb clinical trial for PMSF in UK 0 None
2010-06-14 Upsher-Smith commences global USL255 Phase III clinical trial for management of epilepsy 0 None
2010-06-14 Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress 0 5
2010-06-14 Lantheus Medical Imaging reports new Phase 4 data from DEFINITY study 0 None
2010-06-14 Updated Phase 1 trial results of blinatumomab in patients with relapsed NHL presented at EHA 2010 0 4
2010-06-14 Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC 0 None
2010-06-14 Abstract on Phase I/II DIGNITY trial of ThermoDox in RCW Breast Cancer accepted at ASTRO 2010 0 None
2010-06-14 ARCA receives approval to commence enrollment of first therapeutic trial using HIV vaccine candidate 0 None
2010-06-14 Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC 0 None
2010-06-14 Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS 0 None
2010-06-14 Chiasma successfully completes Phase I clinical study of Octreolin 0 None
2010-06-11 Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010 0 None
2010-06-11 Phase II study results of riociguat for CTEPH and PAH published online 0 None
2010-06-11 Trevena's scientists present research data on GPCR biased ligands at two scientific conferences 0 None
2010-06-11 Otonomy completes $10 million Series A financing with Avalon Ventures 0 None
2010-06-11 AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting 0 None
2010-06-11 Clinical data from investigational study of patients with multiple myeloma presented at ASCO 0 2
2010-06-11 Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma 0 None
2010-06-11 Repros receives FDA confirmation on lifting of full clinical hold on Proellex 0 None
2010-06-11 Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL 0 None
2010-06-11 Helix BioPharma third-quarter revenues increase 20.6% 0 None
2010-06-11 Bevacizumab effective for treatment of wet AMD: Study 0 None
2010-06-11 AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics 0 None
2010-06-11 Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy 0 5
2010-06-11 FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS 0 4
2010-06-10 Idenix initiates IDX320 proof-of-concept study for HCV infection 0 None
2010-06-10 FDA grants Collegium Fast Track designation for COL-172 opioid formulation 0 None
2010-06-10 MAP Pharmaceuticals to present new analyses from LEVADEX Phase 3 trial for acute migraine at 52nd AHS 0 None
2010-06-10 Allopurinol exhibits potential benefits for CKD patients 0 5
2010-06-10 Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin 0 5
2010-06-10 Preclinical data of VB-201 to be presented at EULAR Annual European Congress of Rheumatology 0 None
2010-06-10 Sucampo announces completion of lubiprostone phase 3 trial for CIC in Japanese patients 0 None
2010-06-10 Study suggests potential of ARC man-made compound in combination with Abbott's ABT-737 for cancer 0 None
2010-06-10 Lantheus presents preliminary Phase 2 data of flurpiridaz F18 injection PET MPI at 57th SNM 0 5
2010-06-10 Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer 0 None
2010-06-10 TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer 0 None
2010-06-10 CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks 0 None
2010-06-10 Combination therapy appears to improve outcome of women with late-stage ovarian cancer 0 None
2010-06-10 Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metastatic breast cancer 0 None
2010-06-09 NIH awards Aestus $2M SBIR grant for clinical trials of treatment for chronic neuropathic pain 0 None
2010-06-09 Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy 0 5
2010-06-09 Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting 0 None
2010-06-09 S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis 0 None
2010-06-09 First clinical trial among African women to test vaginal ring that prevents HIV transmission 0 None
2010-06-09 Repligen's fiscal 2010 total revenue decreases to $20,971,000 0 None
2010-06-09 Discovery Labs reports preliminary results from Surfaxin Phase 2 trial in children with Acute Respiratory Failure 0 None
2010-06-09 Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol 0 None
2010-06-09 Update on Phase II clinical study of CH-4051 in rheumatoid arthritis 0 None
2010-06-09 Human Genome Sciences reports results of mapatumumab Phase 2 trial for multiple myeloma 0 None
2010-06-09 Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO 0 4
2010-06-09 Vital Therapies commences enrollment in ELAD SILVER trial for acute-on-chronic liver failure 0 None
2010-06-09 Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors 0 5
2010-06-09 Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting 0 None
2010-06-09 Lantheus Medical Imaging reports Phase 1 data of LMI 1195 heart failure PET imaging agent 0 None
2010-06-09 Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010 0 None
2010-06-09 GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting 0 3.5
2010-06-09 Merck's MK-4305 improves overall sleep efficiency in primary insomnia patients 0 5
2010-06-09 Pharnext closes €4.8-million Series A funding round 0 None
2010-06-09 Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study 0 2
2010-06-09 Helix BioPharma reports Phase II clinical results of Topical Interferon Alpha-2b for ano-genital warts 0 None
2010-06-09 PharmaMar commences Aplidin Phase III registration trial for multiple myeloma 0 None
2010-06-09 Lubiprostone phase 3 clinical trial in Japan for chronic idiopathic constipation meets primary endpoint 0 None
2010-06-08 Argos presents positive AGS-003 Phase 2 data for newly diagnosed advanced renal cell carcinoma at ASCO 0 None
2010-06-08 NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates 0 None
2010-06-08 Immunomedics reports encouraging results from TF2 Phase I studies for colorectal cancer 0 None
2010-06-08 Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma 0 None
2010-06-08 GTx reports positive results from toremifene Phase III clinical trial 0 None
2010-06-08 Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases 0 None
2010-06-08 Protalix BioTherapeutics reports positive results from PRX-105 Phase I clinical trial 0 None
2010-06-08 Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010 0 None
2010-06-08 TG-MV-006 study: Microplasmin shows promise for treatment of VMA, MH 0 None
2010-06-08 Experimental drug that targets genetic makeup of tumor shows early signs of efficacy against medulloblastomas 0 None
2010-06-08 Scientists combine two agents to treat patients with multiple myeloma 0 None
2010-06-08 Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer 0 None
2010-06-08 Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO 0 None
2010-06-08 Chemotherapy drug sunitinib promising for HIV-positive cancer patients 0 None
2010-06-08 Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL 0 None
2010-06-08 Aeterna Zentaris presents data of perifosine Phase 1 trial for recurrent pediatric solid tumors at ASCO 0 None
2010-06-08 Polaris' ADI-PEG 20 novel anticancer drug inhibits growth of metastatic melanoma cells: Study 0 None
2010-06-08 Genta presents tesetaxel dose-ranging trial results at ASCO 2010 0 None
2010-06-08 Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010 0 None
2010-06-08 Clinical data from two separate Phase 2a combination drug studies of Azixa presented at ASCO 2010 0 None
2010-06-08 GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010 0 None
2010-06-08 Interim results from Micromet's MT110 BiTE antibody Phase 1 trial presented at ASCO 0 None
2010-06-08 Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010 0 None
2010-06-08 Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO 0 5
2010-06-08 ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO 0 None
2010-06-08 Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer 0 None
2010-06-08 Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010 0 None
2010-06-08 ZIOPHARM presents positive data from PICASSO Phase II trial for soft tissue sarcoma at 46th ASCO 0 None
2010-06-08 Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010 0 None
2010-06-08 First clinical data for ImmunoGen's IMGN388 anticancer compound presented at ASCO Annual Meeting 0 None
2010-06-08 Erlotinib can reduce lung cancer death by 26% : Study 0 None
2010-06-08 Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO 0 None
2010-06-08 Cyclacel reports positive interim data from sapacitabine Phase 2 study for myelodysplastic syndromes 0 None
2010-06-07 Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer 0 None
2010-06-07 XCell-Center GmbH announces approval of clinical trial in patients with chronic spinal cord injury 0 None
2010-06-07 Preliminary outcomes and trends from Phase III pivotal study of Generex Oral-lyn reported 0 None
2010-06-07 Promising clinical data on CDX-011 in metastatic melanoma presented at ASCO Annual Meeting 0 None
2010-06-07 Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010 0 None
2010-06-07 Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010 0 None
2010-06-07 Clinical trial data of XP19986, XP13512 to be presented at Associated Professional Sleep Society meeting 0 None
2010-06-07 Phase 1 study data of Keryx' perifosine for recurrent pediatric solid tumors presented at ASCO 0 None
2010-06-07 Clivatuzumab tetraxetan shows promising results in patients with metastatic pancreatic cancer 0 None
2010-06-07 OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors 0 None
2010-06-07 Fovea's initiation of Prednisporin Phase 2b clinical testing triggers milestone payment to CombinatoRx 0 None
2010-06-07 EDEMA4 study results of KALBITOR for treatment of acute attacks of HAE published 0 None
2010-06-07 Oncolytics reports updated results from U.K. Phase I/II combination REOLYSIN trial at ASCO 2010 0 None
2010-06-07 Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010 0 None
2010-06-07 Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes 0 5
2010-06-07 Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting 0 None
2010-06-07 Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer 0 None
2010-06-07 Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis 0 5
2010-06-07 Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma 0 None
2010-06-07 Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease 0 None
2010-06-07 Cytheris completes €12 million Series D financing 0 None
2010-06-07 Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations 0 None
2010-06-07 Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis 0 None
2010-06-07 AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer 0 None
2010-06-07 Genta reports combined data from Genasense Phase 3 trials for advanced melanoma 0 None
2010-06-07 Bevacizumab extends progression-free survival in women with advanced ovarian cancer 0 None
2010-06-07 Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL 0 None
2010-06-07 The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug 0 None
2010-06-07 Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients 0 None
2010-06-07 Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR 0 None
2010-06-07 Ipilimumab extends survival of metastatic melanoma patients: Study 0 None
2010-06-07 Updated phase II study results of OPAXIO in patients with advanced esophageal cancer 0 None
2010-06-07 Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO 0 None
2010-06-07 MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy 0 None
2010-06-07 Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs 0 None
2010-06-07 Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer 0 None
2010-06-07 Positive results from Phase 3 trial of ipilimumab in patients with metastatic melanoma 0 None
2010-06-07 Array BioPharma presents positive Phase 1 clinical data of ARRY-520 KSP inhibitor for multiple myeloma 0 None
2010-06-07 Endocyte presents interim results from phase II trial of EC145 plus Doxil for platinum-resistant ovarian cancer 0 None
2010-06-07 Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma 0 None
2010-06-07 Phase III trial comparing PHP with melphalan to BAC for hepatic metastases highlighted at ASCO 2010 0 None
2010-06-07 Poniard reports positive data from Phase 3 SPEAR trial of picoplatin for SCLC 0 None
2010-06-07 Addition of sorafenib to chemotherapy regimen not effective against advanced melanoma: Study 0 None
2010-06-07 OXiGENE presents updated data from ZYBRESTAT Phase 2 study in NSCLC at 2010 ASCO 0 None
2010-06-07 Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO 0 None
2010-06-07 Microplasmin exhibits potential to cure 50% of patients with macular hole 0 None
2010-06-07 Incyte presents additional results from INCB7839 Phase I/II trial for HER2-positive metastatic breast cancer 0 None
2010-06-07 Phase II study results of pomalidomide, dexamethasone for multiple myeloma presented at ASCO 0 None
2010-06-07 Selenium not beneficial in reducing risk of lung cancer development 0 None
2010-06-07 AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment 0 None
2010-06-07 Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO 0 None
2010-06-07 ArQule, Daiichi Sankyo present positive data from Phase 2 combination ARQ 197 trial for lung cancer at ASCO 0 None
2010-06-07 ZymoGenetics' IL-21 Phase 2 clinical trial in metastatic melanoma meets primary endpoint 0 None
2010-06-07 Celldex Therapeutics reports mature data from CDX-011 Phase 1/2 study in advanced breast cancer 0 None
2010-06-07 Alder Biopharmaceuticals reports positive data from ALD518 Phase 2a clinical trial for NSCLC 0 None
2010-06-07 Phase Ib/II trial data for trastuzumab-DM1 in combination with pertuzumab presented at ASCO 2010 0 None
2010-06-07 ChemGenex reports positive safety findings from two OMAPRO clinical trials at ASCO 2010 0 None
2010-06-05 Positive results from new analyses of denosumab Phase 3 trials 0 None
2010-06-05 Celgene reports initial data from investigator-initiated study of REVLIMID 0 None
2010-06-05 Millennium announces data on VELCADE in treatment of patients with amyloidosis 0 None
2010-06-05 Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway targeting antibody 0 None
2010-06-05 Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO 0 None
2010-06-05 Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC 0 None
2010-06-05 Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer 0 None
2010-06-05 Green tea component reduces leukemia cells in patients with CLL 0 4
2010-06-05 Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma 0 None
2010-06-05 Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010 0 None
2010-06-05 RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa 0 3.3
2010-06-04 Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO 0 None
2010-06-04 Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC 0 None
2010-06-04 Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND 0 None
2010-06-04 Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy 0 None
2010-06-04 Boehringer Ingelheim to present new data on BIBW 2992 for NSCLC and head-and-neck cancer at ASCO 2010 0 None
2010-06-04 Study of methylphenidate for cancer-related fatigue benefits patients with stage III/IV disease 0 None
2010-06-04 Oxycyte perfluorocarbon emulsion demonstrates marked neuroprotective effect in rat model of spinal cord injury 0 None
2010-06-04 Ongoing clinical development program for NX-1207 for treatment of BPH highlighted 0 None
2010-06-04 Merrimack's Phase 1/2 trial design of MM-111 in HER2 positive cancer to be presented at 2010 ASCO 0 None
2010-06-04 R-Tech Ueno announces completion of Phase II clinical study of UF-021 for retinitis pigmentosa 0 None
2010-06-04 Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress 0 None
2010-06-04 PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids 0 None
2010-06-04 Tioga commences dosing in Phase 3 trial of asimadoline for diarrhea-predominant irritable bowel syndrome 0 None
2010-06-03 Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix 0 1
2010-06-03 Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon 0 None
2010-06-03 Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint 0 None
2010-06-03 NCCTG study testing methylphenidate in treatment of cancer-related fatigue completed 0 None
2010-06-02 Data on ImmunoCellular Therapeutics' ICT-107 for GBM to be presented at 46th ASCO 0 None
2010-06-02 Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH 0 None
2010-06-02 ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study 0 None
2010-06-02 ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C 1 None
2010-06-02 Shionogi Pharma presents study results of PSD502 for treatment of primary PE at AUA 2010 0 None
2010-06-02 Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer 0 None
2010-06-02 Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea 0 None
2010-06-02 Curemark commences clinical trial enrollment for CM-AT autism treatment at two more sites 0 None
2010-06-02 Azithromycin as effective as penicillin for early-stage syphilis: Study 0 3
2010-06-02 Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA 0 None
2010-06-02 Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress 0 None
2010-06-02 Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer 0 None
2010-06-02 HTDS commences clinical trials for MEVAC-A vaccine in Vietnam 0 None
2010-06-02 Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online 0 None
2010-06-01 Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting 0 None
2010-06-01 Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers 0 None
2010-06-01 Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed 0 None
2010-06-01 BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients 0 None
2010-06-01 Centocor Ortho Biotech acquires RespiVert 0 None
2010-06-01 Shionogi Pharma presents data on PSD502 pivotal studies for primary premature ejaculation at 2010 AUA 0 None
2010-06-01 Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting 0 None
2010-05-31 FAIR-HF study: Ferinject improves renal function in patients with CHF and iron deficiency 0 None
2010-05-31 Mucosis receives € 3M innovation credit line from Dutch Ministry for development of FluGEM influenza vaccine 0 None
2010-05-31 Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients 0 None
2010-05-31 Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010 0 None
2010-05-29 Sunitinib not effective in patients with papillary RCC: Researchers 0 None
2010-05-29 CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia 0 None
2010-05-28 Advaxis doses first patient in FDA-approved phase II CIN trial 0 None
2010-05-28 Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress 0 None
2010-05-28 VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010 0 None
2010-05-28 Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's 0 None
2010-05-28 Nymox Pharmaceutical announces symposium and panel discussion on NX-1207 drug for BPH 0 None
2010-05-28 CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial 0 None
2010-05-28 ARCA receives approval to begin enrollment of first therapeutic trial with GeoVax vaccine 0 None
2010-05-27 NOXXON Pharma closes €33 million Series D round of financing 0 None
2010-05-27 Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy 0 None
2010-05-27 YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC 0 None
2010-05-27 Pfizer plans recruitment halt to EMPHASIS-HF trial 0 None
2010-05-27 FDA, EMA approve Repligen's proposal for Phase 3 re-read in RG1068 trial for pancreatic imaging 0 None
2010-05-27 Shark cartilage extract shows no benefit for patients with advanced non-small cell lung cancer 0 None
2010-05-27 Patients with transformed lymphoma show positive response to lenalidomide: Research 0 None
2010-05-27 New study holds promise for patients with LCA 0 None
2010-05-27 Logical Therapeutics closes $16.9 million Series C equity financing round 0 None
2010-05-26 CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer 0 None
2010-05-26 Presidio Pharmaceuticals to advance PPI-1301 inhibitor from HCV NS5A program into clinical development 0 None
2010-05-26 Study demonstrates efficacy of CONCERTA in treating ADHD in presence of comorbid learning disability 0 5
2010-05-26 Positive results from 3 year follow-up of BPH patients treated with NX-1207 in Study NX02-0016 0 None
2010-05-26 Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH 0 None
2010-05-26 Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept 0 None
2010-05-26 Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen 0 5
2010-05-26 GTx reports top line results from toremifene Phase III clinical trial for prostate cancer 0 None
2010-05-25 Rockwell Medical's SFP Phase IIb data accepted for presentation at XLVII ERA-EDTA Congress 0 None
2010-05-25 CoDa Therapeutics reports positive results from Phase 2 study of NEXAGON for chronic venous leg ulcers 0 5
2010-05-25 Cytochroma reports positive Phase 1/2 results for CTAP101 Capsules in non-dialysis CKD patients 0 None
2010-05-25 Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010 0 None
2010-05-25 REDUCE trial data published in the online version of European Urology 0 4
2010-05-25 DMC recommends ARIAD continue Phase 3 trial of oral ridaforolimus for metastatic sarcomas to final analysis 0 None
2010-05-25 ImmunoGen to present clinical data on IMGN388 solid tumor compound at 2010 ASCO 0 None
2010-05-25 NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo 0 None
2010-05-25 Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS 0 None
2010-05-25 Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting 0 None
2010-05-25 Neuralstem updates progress of ongoing Phase I human clinical trial for ALS 0 5
2010-05-25 Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC 0 None
2010-05-24 Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA 0 None
2010-05-24 Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed 0 None
2010-05-24 Phase 1 clinical trial of OXY111A initiated 0 None
2010-05-24 Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA 0 None
2010-05-24 Bayer Healthcare Pharmaceuticals presents Phase 3 clinical data on gadobutrol 0 None
2010-05-21 Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC 0 None
2010-05-21 New data on ARIAD's AP24534 and ridaforolimus accepted for presentation at ASCO 2010 0 None
2010-05-21 ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO 0 None
2010-05-21 Clinical data evaluating CAL-101 in patients with hematologic malignancies to be presented at ASCO 2010 0 None
2010-05-21 Ligand Pharmaceuticals secures milestone and royalty interest in IL-9 antibody program 0 None
2010-05-21 ArQule announces presentations on ARQ 197 c-Met inhibitor at 2010 ASCO 0 None
2010-05-21 Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO 0 None
2010-05-21 PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting 0 None
2010-05-21 Combination of reovirus and carboplatin/paclitaxel shows promising anticancer activity in SCCHN 0 None
2010-05-21 Interim data from Phase 2 clinical trial of sapacitabine in patients with MDS to be presented at ASCO 2010 0 None
2010-05-21 New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting 0 None
2010-05-21 Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome 0 4.5
2010-05-21 Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO 0 None
2010-05-21 Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO 0 None
2010-05-21 ZIOPHARM Oncology to present phase II data from PICASSO trial for soft tissue sarcoma at ASCO meeting 0 None
2010-05-21 Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting 0 None
2010-05-21 Phase III PRIMA study data of Rituxan to be featured at 46th ASCO 0 None
2010-05-21 Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation 0 None
2010-05-21 Genentech to present new data for targeted cancer medicines at 46th ASCO 0 None
2010-05-21 Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO 0 None
2010-05-21 Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010 0 None
2010-05-21 Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO 0 None
2010-05-21 ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting 0 None
2010-05-21 Positive results from Phase 1 study evaluating IV administration of JX-594 to metastatic cancer patients 0 None
2010-05-21 Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010 0 None
2010-05-21 Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010 0 None
2010-05-21 Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO 0 None
2010-05-21 Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer 0 None
2010-05-20 Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma 0 None
2010-05-20 Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial 0 None
2010-05-20 Update on Phase I clinical trials of Oncopore for treatment of cancer 0 None
2010-05-20 Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever 0 None
2010-05-20 Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies 0 None
2010-05-19 Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD 0 None
2010-05-19 Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010 0 None
2010-05-19 Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients 0 None
2010-05-19 Discovery Labs revalidates optimized BAT in program to gain FDA approval of Surfaxin for RDS 0 None
2010-05-19 Cell Therapeutics reports cardiac safety results from phase II trial of pixantrone in CHOP-R regimen 0 None
2010-05-19 Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials 0 None
2010-05-19 Pre-menopausal women with HSDD report clinically meaningful improvement with flibanserin 2 2
2010-05-19 Pearl Therapeutics presents data supporting development of PT003 combination bronchodilator product 0 None
2010-05-19 New multi-center follow-up study of NX-1207 for treatment of BPH to be completed 0 None
2010-05-19 Generex Biotechnology's Phase I study data of AE37 for prostate cancer published 0 None
2010-05-19 Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA 0 None
2010-05-19 Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder 0 4
2010-05-19 Aprea to present poster on phase I/II clinical trial of APR-246 anticancer compound at ASCO Meeting 0 None
2010-05-19 Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer 0 None
2010-05-18 Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting 0 None
2010-05-18 Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial 0 None
2010-05-18 KaloBios Pharmaceuticals' KB001 promising in prevention of serious lung infection 0 None
2010-05-18 Thai AIDS vaccine trial: Risk of HIV infection can be reduced with a vaccine 0 None
2010-05-18 Cerenis' CER-001 Phase 1 study data supports continued clinical development for acute coronary syndromes 0 None
2010-05-18 Phase II ALSTAR trial: Talampanel is safe for ALS patients 0 5
2010-05-18 UMPIRE trial of Red Heart Pill launched to combat cardiovascular problems 0 5
2010-05-18 FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis 0 4.2
2010-05-17 BaroFold licenses PreEMT Technology to Nuron Biotech for development of BaroFeron 0 None
2010-05-17 Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting 0 None
2010-05-17 FDA grants NeoPharm's IL13-PE38QQR orphan-drug designation for treatment of IPF 0 None
2010-05-17 Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data at 19th CAHR 0 None
2010-05-17 Hemispherx Biopharma to conduct study of Ampligen antiviral in China 0 None
2010-05-17 ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial 0 None
2010-05-17 Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review 0 None
2010-05-17 Celldex Therapeutics commences screening in CDX-1307 Phase 2 study for bladder cancer 0 None
2010-05-17 Tranzyme Pharma to present data on prokinetic agent TZP-101 in GI recovery at ASCRS 2010 0 None
2010-05-17 Polypill to be tested in new heart disease trial 1 None
2010-05-17 Roche to commence clinical study of TB-403 in patients with colorectal and ovarian cancer 0 None
2010-05-17 Treatment with MP-376 reduces P. aeruginosa in CF patients: Research 0 None
2010-05-15 Inhibitex commences trials on INX-189 for treatment of Hepatitis C infections 0 5
2010-05-15 Merck, Cardiome Pharma show superiority of BRINAVESS to amiodarone injection 0 None
2010-05-14 Data from RGN-259 study published in Archives of Ophthalmology 0 None
2010-05-14 Phase 2a study results of Aerosurf for prevention of RDS in premature infants published 0 None
2010-05-14 Inhibitex reports net loss of $4.8M for first-quarter 2010 0 None
2010-05-14 International study to test effectiveness of celecoxib in preventing growth of precancerous polyps 0 None
2010-05-14 DMC recommends Celsion to continue enrollment in ThermoDox clinical study for primary liver cancer 0 None
2010-05-14 Jennerex to present key data on JX-594 Phase 1 dose escalation clinical study at ASGCT Annual Meeting 0 None
2010-05-14 Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010 0 None
2010-05-14 Transdel Pharmaceuticals reports lower net loss of $0.9 million for first-quarter 2010 0 None
2010-05-14 RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug 0 None
2010-05-14 Derma Sciences first-quarter net sales up 23% to $12,844,382 0 None
2010-05-14 Chimerix commences first-in-human study of CMX157 for HIV 0 None
2010-05-13 Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED 0 None
2010-05-13 ARYx Therapeutics decreases first-quarter net loss to $6.4 million 0 None
2010-05-13 Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia 1 5
2010-05-13 Genta first-quarter net loss increases to $166.6 million 0 None
2010-05-13 Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010 0 None
2010-05-13 Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087 0 None
2010-05-13 Amarin reports cash balance of $44 million for first-quarter 2010 0 None
2010-05-13 Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates 0 None
2010-05-13 CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer 0 None
2010-05-13 Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule 0 None
2010-05-12 Avexa halts HIV drug trials 0 None
2010-05-12 GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010 0 None
2010-05-12 NovaBay first-quarter net loss increases to $1.6 million 0 None
2010-05-12 Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010 0 None
2010-05-12 Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials 0 None
2010-05-12 FDA approves Aeterna Zentaris' AEZS-108 IND for bladder cancer 0 None
2010-05-12 Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD 0 None
2010-05-12 Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients 0 None
2010-05-12 Evotec first-quarter operating loss decreases 93% to € 1.5 m 0 None
2010-05-12 COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate 0 None
2010-05-12 NiKem Research receives Italian authorization to perform toxicology studies of NCEs in rodents 0 None
2010-05-12 Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs 0 None
2010-05-12 Oncos Therapeutics completes € 4 million investment from HealthCap 0 4
2010-05-12 Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients 0 None
2010-05-12 Gilead Sciences board authorizes $5 billion common stock repurchase program 0 None
2010-05-12 Pacira Pharmaceuticals receives $11.25M credit facility from GE Capital, Healthcare Financial Services 0 None
2010-05-12 Update on Nymox Pharmaceutical's Phase 3 program for NX-1207 0 None
2010-05-12 Tianyin third-quarter revenue up 60% 0 None
2010-05-12 Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease 0 None
2010-05-12 Exelixis first-quarter revenues increase to $42.2 million 0 None
2010-05-12 Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients 0 None
2010-05-12 Preliminary data from Achillion Pharmaceuticals' Phase 1b clinical trial of ACH-1625 reported 0 None
2010-05-11 Pro-Pharmaceuticals completes $6 million private placement with 10X Fund 0 None
2010-05-11 EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer 0 None
2010-05-11 China Pharma first-quarter revenue up 16% to $15.1 million 0 None
2010-05-11 DUSA Pharmaceuticals first-quarter total product revenues up 22% 0 None
2010-05-11 MediciNova announces $15 million senior secured term loan with Oxford Finance 0 None
2010-05-11 Scancell signs worldwide licensing agreement with NIH for TRP-2 and gp100 melanoma antigens 0 None
2010-05-11 Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference 0 None
2010-05-11 Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010 0 None
2010-05-11 Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million 0 None
2010-05-11 CrystalGenomics completes European Phase I SAD study of CG400549 antibiotic candidate 0 None
2010-05-10 Generex Biotechnology enrolls over 400 subjects in global Phase III study of Generex Oral-lyn 0 None
2010-05-10 Enzon reports income from continuing operations of $20.8M for first-quarter 2010 0 None
2010-05-10 QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain 0 None
2010-05-10 Harbor BioSciences reports encouraging results from Triolex Phase IIa trials 0 None
2010-05-10 Immunomedics third-quarter revenues increase to $10.7 million 0 None
2010-05-10 European patent strengthens Soligenix' topically active steroid intellectual property portfolio 0 None
2010-05-10 Achillion reports lower net loss of $5.6M for first-quarter 2010 0 None
2010-05-10 MicroStockProfit.com features investment report on ARIAD Pharmaceuticals 0 None
2010-05-10 Lexicon Pharmaceuticals first-quarter revenues down 61% 0 5
2010-05-10 Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei 0 None
2010-05-07 Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting 0 5
2010-05-07 Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010 0 None
2010-05-07 Osiris Therapeutics reports net income of $2.4M for first-quarter 2010 0 None
2010-05-07 Nile Therapeutics completes dose escalation in CD-NP Phase II study for acute decompensated heart failure 0 None
2010-05-07 Halozyme Therapeutics first-quarter net loss decreases to $11.8 million 0 None
2010-05-07 MicroStockProfit.com releases NexMed investment report 0 None
2010-05-07 Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010 0 None
2010-05-07 Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting 0 None
2010-05-07 Genzyme to initiate $2 billion stock buyback 0 None
2010-05-07 Nabi Biopharmaceuticals reports first-quarter net income of $5.5 million from continuing operations 0 None
2010-05-07 Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule 0 None
2010-05-06 Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex 0 None
2010-05-06 Cytochroma reports positive results from Phase I trial for CTAP201 Injection in hemodialysis patients 0 None
2010-05-06 PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis 0 5
2010-05-06 Momenta Pharmaceuticals first-quarter net loss decreases to $16.1 million 0 None
2010-05-06 Vical reports net loss of $8.5 million for first-quarter 2010 0 None
2010-05-06 Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin 0 None
2010-05-06 Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease 0 None
2010-05-06 CU-Boulder develops inhalable vaccine for measles prevention 0 None
2010-05-06 Pharmasset reports net loss of $16.1 million for fiscal second-quarter 2010 0 None
2010-05-06 ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE 0 None
2010-05-06 Positive results from Phase 2 clinical study of LX1031 in IBS patients presented at DDW 2010 0 None
2010-05-06 Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010 0 None
2010-05-06 Positive results from Phase IIa clinical study of LIPO-102 0 None
2010-05-06 Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416 0 None
2010-05-06 Update on CEL-SCI's Phase III clinical trial of Multikine 0 None
2010-05-06 Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX 0 None
2010-05-05 Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients 0 None
2010-05-05 Rockwell Medical first-quarter sales up 17.1% 0 None
2010-05-05 Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma 0 None
2010-05-05 Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin 0 None
2010-05-05 AMRI first-quarter total revenue down 9% to $49.3 million 0 None
2010-05-05 Cadence Pharmaceuticals resubmits OFIRMEV NDA 0 None
2010-05-05 Merck acquires development, commercialization rights of ridaforolimus 0 None
2010-05-05 ARIAD restructures collaboration with Merck for ridaforolimus mTOR inhibitor 0 None
2010-05-05 Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine 0 None
2010-05-05 Archivel Farma to start phase II clinical trials of RUTI vaccine for Latent Tuberculosis 0 None
2010-05-05 UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine 0 None
2010-05-05 Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study 0 None
2010-05-05 StemCells first-quarter total revenue up 307% 0 None
2010-05-05 Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010 0 None
2010-05-05 ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial 0 None
2010-05-05 Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies 0 None
2010-05-05 S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors 0 None
2010-05-05 Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010 0 None
2010-05-05 Additional pivotal Phase 3 trial data for MoxDuo IR released 0 None
2010-05-05 Nymox Pharmaceutical announces new positive results from long term outcome study of NX-1207 for BPH 0 None
2010-05-05 Second fidaxomicin Phase 3 clinical study data in patients with CDI to be presented at DDW 2010 0 5
2010-05-05 BELLUS Health to discontinue NC-503 diabetes development program 0 None
2010-05-04 MAP Pharmaceuticals reports net loss $14.1 million for first-quarter 2010 0 None
2010-05-04 Celldex reports net loss of $6.6 million for first-quarter 2010 0 None
2010-05-04 Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010 0 None
2010-05-04 Celsion reports $4.6 million net loss from operations for first-quarter 2010 0 None
2010-05-04 Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI 0 None
2010-05-04 Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com 0 None
2010-05-04 MicroStockProfit.com releases investment report on Vical 0 None
2010-05-04 Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS 0 None
2010-05-04 ADVENTRX Pharmaceuticals announces 6-month stability data for Exelbine 0 None
2010-05-04 Hologic commences enrollment in European trial of Gestiva for prevention of recurrent preterm birth 0 None
2010-05-04 Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010 0 None
2010-05-04 Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010 0 None
2010-05-04 Researchers present positive results of Phase II clinical trial of eliglustat tartrate 0 None
2010-05-04 Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010 0 None
2010-05-03 NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12 0 None
2010-05-03 NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis 0 None
2010-05-03 Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells 0 None
2010-05-03 Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting 0 None
2010-05-03 Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease 0 None
2010-05-03 ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM 0 5
2010-05-03 Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor 0 None
2010-05-03 BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development 0 None
2010-05-03 Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010 0 None
2010-05-03 AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010 0 None
2010-05-03 Omeros announces additional data from Phase 2 trial of OMS103HP for arthroscopic meniscectomy surgery 0 None
2010-05-03 Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments 0 None
2010-05-03 TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH 0 None
2010-05-03 SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit 0 None
2010-05-03 Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH 0 None
2010-05-03 Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study 0 3
2010-05-03 Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure 0 None
2010-05-03 Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials 0 None
2010-05-03 Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference 0 None
2010-05-03 FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer 0 None
2010-04-30 GeNOsys sponsors Phase I safety trial in collaboration with Nitric Solutions 0 None
2010-04-30 Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound 0 None
2010-04-30 Celtic Pharma commences enrolment in Phase III trial of TDT 067 for onychomycosis 0 None
2010-04-30 Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder 0 None
2010-04-30 Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex 0 None
2010-04-30 Novavax reports positive results from Phase II study of trivalent VLP influenza vaccine in older adults 0 None
2010-04-30 TenX Biopharma signs Clinical Trial Agreement with NCI 0 None
2010-04-30 Lotus Pharmaceuticals receives Chinese SFDA approval to commence Laevo-Bambuterol clinical trials 0 None
2010-04-30 EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout 0 None
2010-04-30 Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan 0 None
2010-04-30 Artisan Pharma enrolls 750 patients in Phase 2b study of ART-123 in sepsis patients with DIC 0 None
2010-04-29 Celgene's first-quarter non-GAAP total revenue up 31% to $789 million 0 None
2010-04-29 Provectus reports on end-of-Phase 2 meeting with FDA on licensure of PV-10 for metastatic melanoma 0 None
2010-04-29 Human Genome Sciences reports net loss of $47.9M for first-quarter 2010 0 None
2010-04-29 AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010 0 None
2010-04-29 Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment 0 None
2010-04-29 Gilead announces bioequivalence of Truvada in combination with Tibotec Pharmaceuticals' TMC278 NNRTI 0 None
2010-04-29 Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting 0 None
2010-04-29 CINJ trial targets new combination therapy for advanced solid tumors 0 None
2010-04-29 Pain Therapeutics reports net loss of $1.0 million for first-quarter 2010 0 None
2010-04-29 Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics 0 None
2010-04-29 Geron reports net loss of $16.6M for first-quarter 2010 0 None
2010-04-29 Multicenter NIH trial finds combination antibiotics effective against Chlamydia-induced reactive arthritis 0 5
2010-04-29 Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients 0 None
2010-04-29 Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint 0 None
2010-04-29 Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease 0 None
2010-04-29 Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated 0 None
2010-04-28 Positive results from interim analysis of ongoing Phase 2a study of BCX4208 0 None
2010-04-28 Diamyd Medical to focus on completion of Diamyd Phase III studies and preparation for market launch 0 None
2010-04-28 BiondVax announces successful conclusion of second Phase I/II trial of Multimeric-001 Universal Flu Vaccine 0 None
2010-04-28 Seattle Genetics reports revenues of $46.5M for first-quarter 2010 0 None
2010-04-28 Diamyd Medical reports group net sales of MSEK 0.2 for second-quarter 2010 0 None
2010-04-28 Update on ICA-105665 clinical development plans for treatment of epilepsy and pain 0 None
2010-04-28 ChronSeal multi-center study in Sweden and Norway finalized 0 None
2010-04-28 DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients 0 None
2010-04-28 NCCTG to conduct Phase II study of brostallicin in combination with cisplatin for mTNBC cancer 0 None
2010-04-28 Lexicon Pharmaceuticals to present Phase 2 study results of LX1031 for non-constipating IBS at DDW 2010 0 None
2010-04-28 Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets 0 None
2010-04-28 Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress 0 None
2010-04-27 Debiopharm commences treatment in Phase I clinical trial for Debio 0932 small molecule Hsp90 inhibitor 0 None
2010-04-27 Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS 0 None
2010-04-27 Interim results from Phase I clinical trial of PLX-PAD for treatment of CLI 0 None
2010-04-27 ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE 0 None
2010-04-27 Prime-boost malaria vaccine regimen provides sterile protection: Vical 0 5
2010-04-27 UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV 0 None
2010-04-27 LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand 0 None
2010-04-27 Evotec to receive EUR 1.5M from German BMBF for advancing H3 receptor antagonist programme 0 None
2010-04-27 Patient preference study results of Kristalose to be presented at 2010 Digestive Disease Week meeting 0 None
2010-04-27 Phase 2b clinical study initiated to evaluate GI safety of LT-NS001 0 None
2010-04-27 FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco 0 None
2010-04-26 OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva 0 None
2010-04-26 First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD 0 None
2010-04-26 Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer 0 None
2010-04-26 Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting 0 None
2010-04-24 Recent business progress at Penwest Pharmaceuticals 0 None
2010-04-24 Study finds AFREZZA comparable to standard of care insulin therapy 0 None
2010-04-24 Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study 0 None
2010-04-24 Urigen Pharmaceuticals requests FDA meeting for advancing URG101 clinical program 0 None
2010-04-24 AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing 0 None
2010-04-23 Oncolytics Biotech completes Phase I enrollment in Phase I/II trial of REOLYSIN for recurrent malignant gliomas 0 None
2010-04-23 Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010 0 1
2010-04-23 Affymax institutes quiet period in connection with Hematide Phase 3 result analysis 0 None
2010-04-23 Amira Pharmaceuticals granted UK patent covering novel small molecule inhibitors of DP2 receptor 0 None
2010-04-23 Gelesis presents Attiva data at AACE 19th Annual Meeting & Clinical Congress 0 None
2010-04-23 Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research 0 None
2010-04-23 Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting 0 5
2010-04-23 Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation 0 None
2010-04-23 Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC 0 None
2010-04-23 Aragon Pharmaceuticals raises $22M through Series B financing 0 None
2010-04-22 Karo Bio reports net loss of MSEK 40.5 for January–March 2010 0 None
2010-04-22 Valor Medical's European cerebral aneurysm clinical trial finalized with 30 patients treated 0 None
2010-04-22 Vical presents Phase 2 trial results of TransVax CMV vaccine at World Vaccine Congress 0 None
2010-04-22 Cancers deficient in ASS enzyme allow ADI-PEG 20 to inhibit cancer cell growth 0 None
2010-04-22 Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium 2 None
2010-04-22 Positive results from preclinical EP-302 program presented at AACR 2010 0 None
2010-04-22 AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR 0 None
2010-04-22 PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting 1 None
2010-04-22 ImmunoCellular Therapeutics, UPENN sign research agreement 0 None
2010-04-22 Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting 0 None
2010-04-22 Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR 0 None
2010-04-22 NO-naproxen blocks molecular changes leading to colorectal cancer development 0 None
2010-04-22 Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients 0 None
2010-04-22 Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer 0 None
2010-04-22 Delcath Systems' trial meets primary endpoint of extended hPFS in patients with melanoma metastases 0 None
2010-04-21 Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs 0 None
2010-04-21 HemaQuest Pharmaceuticals closes $12M Series B financing 0 None
2010-04-21 Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing 0 None
2010-04-21 Curis presents data on CU-906 compound designed to inhibit HDAC and PI3K/mTOR targets simultaneously 0 None
2010-04-21 Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010 0 None
2010-04-21 Positive preclinical pharmacokinetic data for XMT-1001 presented at AACR 2010 0 None
2010-04-21 Initial results of gallium-containing compound to treat serious infection presented at AACR 2010 0 5
2010-04-21 ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting 0 None
2010-04-21 Preclinical data in neuroblastoma for perifosine to be presented at AACR 2010 Meeting 0 None
2010-04-21 Plexxikon presents promising preclinical data from PLX3397 in vivo cancer studies 0 None
2010-04-21 Roche's progress of RG7348 into Phase I clinical trial triggers $6.5M milestone payment to Ligand 0 None
2010-04-21 Lotus Pharmaceuticals' asthma drug Laevo-Bambutero to receive Chinese SFDA Fast Track Approval 0 None
2010-04-21 Celsion's ThermoDox Phase I trial data presented at 9th IHPBA World Congress 0 None
2010-04-21 IMPACT trial shows improvement in OS for metastatic CRPC 0 None
2010-04-21 Stemedica receives FDA IND approval for ischemic stroke clinical trial using allogeneic stem cells 0 None
2010-04-21 Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS 0 None
2010-04-20 Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus 0 None
2010-04-20 NeoPharm commences enrollment in Phase II clinical trial of LE-DT for pancreatic cancer 0 None
2010-04-20 Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients 0 None
2010-04-20 Acorda Therapeutics to initiate Phase 1 clinical trial of GGF2 for heart failure in mid-2010 0 None
2010-04-20 Teva Pharmaceutical Industries presents ADAGIO study results at AAN Annual Meeting 0 None
2010-04-20 Interim results from QLT's Phase 1b study of QLT091001 for Leber congenital amaurosis 0 None
2010-04-20 NanoBio to develop intranasal vaccine for HBV 0 None
2010-04-20 Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy 0 None
2010-04-20 XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels 0 None
2010-04-20 Boston Biomedical to present updated Phase I study data of BBI608 cancer drug at 101st AACR 0 None
2010-04-20 On-going phase II trial of octagam in AD to be discussed at ICAD 2010 0 None
2010-04-20 Statin use may increase risk of developing benign colorectal tumors: APC trial 0 None
2010-04-20 ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint 0 None
2010-04-20 Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy 0 None
2010-04-20 Cornerstone Pharmaceuticals obtains clearance for CPI-613 human clinical trial for hematologic malignancies 0 None
2010-04-20 Gilead Sciences halts Phase II trial of GS 9450 for chronic hepatitis C 0 None
2010-04-19 Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer 0 None
2010-04-19 Raloxifene, tamoxifen remain effective options in prevention of breast cancer, finds 19,490-patient study 0 None
2010-04-19 Epix Pharmaceuticals' MRI imaging intellectual properties to be auctioned on May 28, 2010 0 None
2010-04-19 Jennerex presents positive interim data from Phase 2 clinical trial of JX-594 for HCC at 45th EASL 0 None
2010-04-19 Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals 0 None
2010-04-19 Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood 0 None
2010-04-19 Amylin Pharmaceuticals announces $174.1M total revenue for first-quarter 2010 0 None
2010-04-19 Encouraging early data from Bellicum Pharmaceuticals' Phase I/II study of BPX-101 for mCRPC 0 4
2010-04-19 Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus 0 None
2010-04-19 Stallergenes' US phase III clinical trial of Oralair achieves primary endpoint 0 5
2010-04-19 Amgen announces results from pivotal Phase 3 "408" trial of Vectibix 0 None
2010-04-19 Results of BATTLE Trial presented at AACR 2010 0 None
2010-04-19 Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress 0 None
2010-04-17 G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks 0 None
2010-04-17 Ocera Therapeutics presents data on prevalence of neurocognitive impairment in cirrhotic patients 0 None
2010-04-17 Multinational phase II study: GS-9450 can reduce markers of liver damage in patients with NASH 0 None
2010-04-17 New data on Cladribine Tablets presented at AAN annual meeting 0 None
2010-04-17 Tikcro Technologies reports net loss of $1.8M for fourth-quarter 2009 0 None
2010-04-17 Knopp Neurosciences to initiate Phase 3 studies of KNS-760704 in AL 0 3.7
2010-04-17 RegeneRx Biopharmaceuticals proposes common stock public offering 0 None
2010-04-16 Repligen expects total revenue of $21.0M for fiscal year 2010 0 None
2010-04-16 VisEn Medical expands FMT imaging platform 0 None
2010-04-16 Results of study comparing REMICADE to azathioprine for Crohn's disease published 0 None
2010-04-16 InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL 0 None
2010-04-16 Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment 0 None
2010-04-16 Promising pharmacokinetic data from Idenix Pharmaceuticals' Phase I study of IDX320 for HCV 0 None
2010-04-16 Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting 0 None
2010-04-16 Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL 0 None
2010-04-16 Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial 0 None
2010-04-16 Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate 0 None
2010-04-16 Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting 0 None
2010-04-16 Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting 0 5
2010-04-16 LOTS results of Myozyme in older children and adults with Pompe disease published 0 None
2010-04-16 Novartis Pharma AG initiates second Phase I trial for oral PTH1-34: Emisphere Technologies 0 None
2010-04-16 Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066 0 None
2010-04-16 Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222 0 None
2010-04-16 Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN 0 None
2010-04-15 Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422 0 None
2010-04-15 Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting 0 None
2010-04-15 Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine 0 None
2010-04-15 AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting 0 1
2010-04-15 Investment report on MIPI 0 None
2010-04-15 Phase 1 clinical trial results of Achillion Pharmaceuticals' ACH-1625 to be presented at EASL meeting 0 None
2010-04-15 Interim results from Pharmasset's phase 2a combination study of PSI-7977 with Pegasys and Copegus for HCV 0 None
2010-04-15 Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting 0 None
2010-04-15 Phase I clinical trial of DFMO initiated to treat children with neuroblastoma 0 None
2010-04-15 Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients 0 None
2010-04-15 Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights 0 None
2010-04-15 Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients 1 None
2010-04-15 Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting 0 None
2010-04-15 Kenta Biotech presents positive Phase IIa results of panobacumab 0 None
2010-04-15 Targeted therapy MDV3100 is effective for patients with CRPC: Study 0 None
2010-04-15 Opexa Therapeutics presents key efficacy data on Tovaxin 0 None
2010-04-15 Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD 0 None
2010-04-15 Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction 0 None
2010-04-15 Phase IIa clinical trial results of Serdaxin for treatment of MDD 0 None
2010-04-15 Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced 0 None
2010-04-15 ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals 0 None
2010-04-15 Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors 0 None
2010-04-15 First patient enrolled in Endologix percutaneous EVAR pivotal clinical trial 0 None
2010-04-15 Trevena commences Phase I trial of TRV120027 biased ligand for acute decompensated heart failure 0 None
2010-04-13 EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer 0 None
2010-04-13 Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting 0 None
2010-04-13 VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings 0 None
2010-04-13 Investment report on Rexahn Pharmaceuticals 0 None
2010-04-13 NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS 0 None
2010-04-13 Gilead Sciences doses first patient in Quad Phase III clinical program 0 None
2010-04-12 Angiochem to highlight oncology program data at 101st American Association for Cancer Research meeting 0 None
2010-04-12 XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting 0 None
2010-04-12 Rib-X Pharmaceuticals to present delafloxacin Phase 2 study data at 20th ECCMID 0 None
2010-04-12 Inhibitex provides update on ongoing Phase II clinical trial of FV-100 for shingles 0 None
2010-04-12 Results of Phase I ThermoDox dose escalation trial to be discussed in a press conference 0 None
2010-04-12 Clinical and preclinical malaria vaccine data presented at Keystone Symposium 0 None
2010-04-12 Phase I study of Affinium Pharmaceuticals' AFN-1252 for MRSA initiated 0 None
2010-04-12 Optimer Pharmaceuticals announces results from second Phase 3 clinical study of fidaxomicin 0 None
2010-04-09 Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference 0 None
2010-04-09 Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting 0 None
2010-04-09 ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor 0 None
2010-04-09 Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting 0 None
2010-04-09 Combination telaprevir treatment beneficial for retreatment of hepatitis C 0 None
2010-04-09 Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis 0 None
2010-04-09 Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease 0 5
2010-04-09 Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine 0 None
2010-04-09 University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma 0 None
2010-04-09 Æterna Zentaris commences perifosine Phase 3 registration trial 0 None
2010-04-09 ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer 0 None
2010-04-08 Cubist Pharmaceuticals initiates dosing in Phase 2 trial with CB-183,315 for diarrhea due to CDAD 0 None
2010-04-08 Phase 1 SAD study of PSI-938 for HCV initiated 0 5
2010-04-08 OncoGenex Pharmaceuticals recognized with BIOTECanada's Gold Leaf Award 0 None
2010-04-08 Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine 0 None
2010-04-08 Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection 0 None
2010-04-08 Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated 0 None
2010-04-08 Results of M118 EMINENCE clinical trial published in Circulation 0 None
2010-04-08 Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme 0 None
2010-04-08 Encouraging results from OptiNose's sumatriptan Phase II study for migraine 0 None
2010-04-08 MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE 0 None
2010-04-08 Avid Radiopharmaceuticals, PETNET Solutions collaborate in manufacture of Florbetapir F 18 0 None
2010-04-07 King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain 0 1
2010-04-07 Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda 0 None
2010-04-07 Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer 0 4
2010-04-07 MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting 0 None
2010-04-07 Nile Therapeutics to fund ongoing Phase II clinical trial of CD-NP with proposed public offering 0 None
2010-04-07 Nationwide Phase III clinical trial of OncoVEX for advanced melanoma 0 None
2010-04-07 Optimer Pharmaceuticals to present data from fidaxomicin Phase 3 studies at 20th ECCMID 0 None
2010-04-07 MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone 0 None
2010-04-06 Three scientific posters featuring Zenvia to be presented at AAN Annual Meeting 0 None
2010-04-05 Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation 0 None
2010-04-05 Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD 0 None
2010-04-05 Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing 0 None
2010-04-05 Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure 0 None
2010-04-05 Spectrum Pharmaceuticals reports $15.7M revenue from ZEVALIN sales in 2009 0 None
2010-04-03 Clinical utility and pharmacological action of MN-166 in treatment of MS 0 None
2010-04-03 CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer 0 None
2010-04-02 Serenity Pharmaceuticals enters agreement with Allergan for nocturia product candidate 0 None
2010-04-01 Allergan, Serenity Pharmaceuticals announce global agreement for nocturia drug development 0 5
2010-04-01 Cipher Pharmaceuticals' enrollment milestone in CIP-ISOTRETINOIN study triggers $2.0M milestone payment 0 None
2010-04-01 BELLUS Health initiates Phase I clinical study for NRM8499 0 None
2010-04-01 Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US 0 3
2010-04-01 Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study 0 None
2010-04-01 Positive results from Phase 2 clinical trial of OMS103HP 0 None
2010-04-01 Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout 0 None
2010-03-31 Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer 0 5
2010-03-31 ViroPharma initiates Phase 2 clinical study to evaluate Cinryze 0 None
2010-03-31 DSMB for DIGNITY trial recommends Celsion continue enrollment 0 None
2010-03-31 ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC 0 None
2010-03-31 Investment report on Sunesis Pharmaceuticals 0 None
2010-03-31 SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference 0 3
2010-03-31 Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data 0 None
2010-03-31 PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic 0 None
2010-03-31 QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations 0 None
2010-03-31 YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387 0 None
2010-03-31 Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction 0 None
2010-03-30 FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine 0 1
2010-03-30 NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss 0 None
2010-03-30 CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN 0 None
2010-03-30 Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD 0 None
2010-03-30 GenVec announces discontinuation of TNFerade PACT trial for pancreatic cancer 0 None
2010-03-30 Trius Therapeutics' Phase 1 trial establishes safety and tolerability of IV torezolid phosphate for MRSA 0 None
2010-03-29 NexMed files IND with FDA for Phase II trial of PrevOnco for HCC 0 None
2010-03-29 Interim data comparing Cervista HPV HR to Hybrid Capture 2 presented at 4th Biennial Meeting of AOGIN 0 None
2010-03-29 Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced 0 None
2010-03-29 Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress 0 4
2010-03-29 Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD 0 None
2010-03-29 Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC 0 None
2010-03-29 Genta reports net loss of $11.7M for fourth-quarter 2009 0 None
2010-03-29 ARYx Therapeutics reports net loss of $5.8M for fourth-quarter 2009 0 None
2010-03-26 Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy 0 None
2010-03-26 Avid, Cardinal Health partner to detect Alzheimer's disease in living patients 1 None
2010-03-26 Muscular dystrophy: $1M grant for study of erectile dysfunction drugs in improving muscle blood flow 0 None
2010-03-26 NellOne's lead candidate for skeletal muscle wound healing and myocardial infarction demonstrates potential efficacy 0 None
2010-03-26 Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV 0 None
2010-03-26 Oramed Pharmaceuticals completes Phase 2b study of ORMD-0801 oral insulin capsule 0 None
2010-03-26 Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced 0 None
2010-03-26 FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD 0 None
2010-03-26 Positive results from Stage A pivotal study of 2009 A/H1N1 VLP pandemic influenza vaccine 0 None
2010-03-26 Santarus enrolls 510 patients in Phase III clinical program for budesonide MMX 0 None
2010-03-26 Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C 0 None
2010-03-26 Independent DMC recommends continuance of enrollment in Eisai's Phase III ACCESS trial 0 None
2010-03-26 Aastrom Biosciences' RESTORE-CLI trial: Final patient treated 0 None
2010-03-26 DARA BioSciences announces the initiation of Phase I clinical study for DB959 0 None
2010-03-25 Arena Pharmaceuticals initiates patient screening for phase 1 clinical trial of APD916 0 None
2010-03-25 Scott & White seeks breast cancer patients for Phase II clinical trial 0 None
2010-03-25 Biogen Idec and Elan begin comparative trial of MS treatments 0 5
2010-03-25 Clinic sites seek gay men to participate in HIV vaccine study 0 None
2010-03-25 Clinical data of dendritic cell based vaccine to be presented at Cancer Stem Cells Conference 0 None
2010-03-24 Shingles drug receives clearance for final stage of testing 0 None
2010-03-24 Single dose of Pain Therapeutics' PTI-188 decreased melanoma tumors: Study 0 None
2010-03-23 Garnet BioTherapeutics commences treatment in GBT009 trial for incisional wounds following breast reconstruction surgery 0 None
2010-03-23 Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases 0 None
2010-03-23 Merck Serono, EMD Serono suspend global clinical development program for Stimuvax temporarily 0 None
2010-03-23 Inhibitex announces net loss of $4.7M for fourth-quarter 2009 0 None
2010-03-23 Aradigm reports net loss of $3.4M for fourth-quarter 2009 0 None
2010-03-23 Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands 0 None
2010-03-23 CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval 0 None
2010-03-23 Advaxis' ADXS11-001 Phase 1 study for cervix cancer failures: 13.3% of treated patients alive at over 3 years 0 None
2010-03-22 Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated 0 None
2010-03-22 Pevion Biotech commences Phase 1 clinical trial of PEV7 vaccine 0 None
2010-03-22 ChemoCentryx undertakes Phase II clinical trial of CCX140 0 None
2010-03-22 First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat 0 None
2010-03-22 Simcere Pharmaceutical completes Phase IV clinical study of Endostar 0 None
2010-03-22 Vical awarded contract to conduct Phase 1 clinical trial of Vaxfectin-formulated DNA vaccine against A/H1N1 0 None
2010-03-22 PharmAthene suspends work on SparVax research and development contract with BARDA 0 None
2010-03-22 Formatech selects Tracon Pharmaceuticals’ TRC102 inhibitor as next Fillanthropy Program candidate 0 None
2010-03-22 Phase II Topical Interferon Alpha-2b trial for AGW: Helix BioPharma achieves last-patient-out 0 None
2010-03-19 Major study shoots for personalized breast cancer drugs 0 5
2010-03-19 CPEX Pharmaceuticals' Phase 2a Nasulin trial fails, Arcadia Capital Advisors issues statement 0 None
2010-03-19 Synergy Pharmaceuticals commences dosing in Phase IIa clinical trial of SP-304 in CC patients 0 None
2010-03-19 A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter 0 None
2010-03-19 Abstract about Phase I/II trial of ThermoDox in RCW accepted for presentation at ASCO 2010 0 None
2010-03-19 FDA drafts new rules for testing, approving drug cocktails; Public-private partnership for TB treatment development launched 0 None
2010-03-19 Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056 0 None
2010-03-19 ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation 0 None
2010-03-18 Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints 0 None
2010-03-18 Achillion Pharmaceuticals receives NIH SBIR grant for study of novel antibacterial compound series 0 None
2010-03-18 Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Study 0 None
2010-03-18 Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD 0 None
2010-03-18 Findings from Study 305 evaluating the effect of Northera reported 0 None
2010-03-18 Agendia to participate in groundbreaking clinical trial for breast cancer 0 None
2010-03-18 Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin 0 None
2010-03-17 Nabi Biopharmaceuticals commences second Phase III study of NicVAX for treating nicotine addiction 0 None
2010-03-17 ONGLYZA-metformin combination: FDA accepts NDA for review 0 2
2010-03-17 Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC 0 None
2010-03-17 Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002 0 None
2010-03-17 Prevenar 13: Immunogenic and well tolerated in young children previously vaccinated with Prevenar 0 None
2010-03-17 Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD 0 None
2010-03-17 Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint 0 None
2010-03-17 Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications 0 None
2010-03-17 Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC 0 None
2010-03-17 TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene 0 None
2010-03-17 Human Genome Sciences to deploy Aegis Analytical's Discoverant manufacturing intelligence solution 0 None
2010-03-17 Booster shot appears to improve TB resistance in previously vaccinated adults 0 None
2010-03-17 Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting 0 None
2010-03-16 PCI Biotech completes treatment of third dose group in phase I/II study of Amphinex in cancer patients 0 None
2010-03-16 Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients 1 2.5
2010-03-16 Lantheus Medical Imaging announces preliminary data on flurpiridaz F 18 PET MPI agent 0 3
2010-03-16 Iverson Genetic Diagnostics to conduct WARFARIN clinical study 0 None
2010-03-16 Promedior raises $12M in Series C financing 0 None
2010-03-16 EXPLORE-Xa study: Betrixaban reduces CRNM bleeds compared to dose-adjusted warfarin 0 3
2010-03-16 Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint 0 None
2010-03-16 Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis 0 5
2010-03-16 Positive results from Phase IIa epilepsy study of ICA-105665 0 None
2010-03-15 Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development 0 None
2010-03-15 CytRx plans five Phase 2 clinical trials with oncology drug candidates 0 None
2010-03-15 YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR 0 None
2010-03-15 Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis 0 None
2010-03-15 Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study 0 None
2010-03-15 Data from ACCORD Lipid study: Abbott issues statement 0 None
2010-03-15 Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly 0 None
2010-03-15 Regadenoson drug is safe for heart transplant patients: Study 0 None
2010-03-15 XOMA 052 reduces adverse consequences that lead to development of congestive heart failure 0 None
2010-03-15 ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes 0 None
2010-03-12 XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients 0 5
2010-03-12 TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints 0 None
2010-03-12 Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009 0 None
2010-03-12 CBio recruits 75th patient into XToll phase II clinical trial, achieves milestone under agreement with Novo Nordisk 0 None
2010-03-12 Tranzyme Pharma's ulimorelin Phase 2 trial data selected for presentation at DDW 2010 0 None
2010-03-12 AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy 0 None
2010-03-12 Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints 0 None
2010-03-12 Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy 0 None
2010-03-12 Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC 0 None
2010-03-12 Neoprobe meets with FDA to review Phase 3 clinical trial results of Lymphoseek drug 0 None
2010-03-12 Genentech announces topline results from Phase III trial of Avastin 0 None
2010-03-12 PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS 0 None
2010-03-12 Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL 0 None
2010-03-11 FDA provides guidance on Restanza clinical program in treatment of CABP 0 4.7
2010-03-11 Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45% 0 None
2010-03-11 Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study 0 None
2010-03-11 Evotec completes first-in-human Phase I study of EVT 103 for treatment-resistant depression 0 None
2010-03-11 Clinical research trial of new treatment to restore brain cells damaged by stroke passes safety stage 0 None
2010-03-11 NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil 0 4
2010-03-11 Lithera announces positive results from Phase IIa clinical study of LIPO-102 0 None
2010-03-10 Positive results from Limerick BioPharma's LIM-0705 Phase 1a trial 0 None
2010-03-10 NeoPharm seeks Orphan Drug Designation for IL13-PE38QQR in treatment of IPF 0 None
2010-03-10 Affymax initiates Phase 3 clinical testing of Hematide in Japan, receives $5M milestone payment 0 None
2010-03-10 Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009 0 None
2010-03-10 Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide 0 None
2010-03-10 AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B 0 None
2010-03-10 Helix BioPharma reports 29.9% increase in total revenues for second-quarter fiscal 2010 0 None
2010-03-10 Diamyd Medical enrolls over 430 children with newly diagnosed type 1 diabetes in global Phase III program 0 None
2010-03-10 Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes 0 None
2010-03-10 Cellectar completes enrollment in (131)I-CLR1404 Phase I dosimetry trial for advanced solid malignancies 0 None
2010-03-09 Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV 0 None
2010-03-09 Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury 0 None
2010-03-09 Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK 0 None
2010-03-09 JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK 0 None
2010-03-09 Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray 0 None
2010-03-08 ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC 0 None
2010-03-08 Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009 0 None
2010-03-08 Rexahn Pharmaceuticals granted Japanese patent for Archexin 0 None
2010-03-08 Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer 0 None
2010-03-08 NOVAVAX' Stage B 2009 H1N1 VLP pandemic influenza vaccine study in Mexico: Enrollment complete 0 None
2010-03-08 Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC 0 None
2010-03-08 VIVUS granted three additional patents for Qnexa 0 None
2010-03-08 Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals 0 None
2010-03-08 DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test 0 None
2010-03-08 Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting 0 None
2010-03-06 Presentation of results from open-label extension study of Xenazine 0 None
2010-03-06 Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results 0 None
2010-03-05 LEO Pharma presents Phase III study results of PEP005 Gel 0.05% for treatment of AK at 68th AAD meeting 0 None
2010-03-05 Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced 0 4
2010-03-05 Apixaban superior to enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients 0 5
2010-03-05 Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented 0 None
2010-03-04 BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine 0 3.2
2010-03-04 Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs 0 None
2010-03-04 Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue 0 None
2010-03-04 Belatacept drug can prevent graft rejection in kidney transplant recipients 0 None
2010-03-04 Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments 0 None
2010-03-04 Allergan, Bristol-Myers Squibb sign global exclusive license agreement for EHT/AGN 0001 0 None
2010-03-04 Endocyte's PRECEDENT study: DSMB recommends enrollment to continue 0 None
2010-03-04 Androxal Type C meeting: Repros Therapeutics receives FDA’s version of minutes 0 None
2010-03-04 Negative results from latrepirdine Phase III clinical trial: Alzheimer's Association disappointed 0 None
2010-03-04 Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA 0 None
2010-03-03 Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer 0 5
2010-03-03 AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement 0 None
2010-03-03 Pfizer, Medivation announce results of two dimebon Phase 3 trials in AD patients 0 None
2010-03-03 FDA issues new draft guidance for Trius Therapeutics' proposed Phase 3 trial of torezolid phosphate 0 None
2010-03-03 Merck’s MF/F Phase III study data presented at AAAAI annual meeting 0 None
2010-03-03 Merck announces updated late-stage pipeline following its recent merger with Schering-Plough 0 5
2010-03-03 Phase III study results of Merck's allergy immunotherapy tablet 0 None
2010-03-02 Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB 0 None
2010-03-02 Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development 0 None
2010-03-02 Inovio Biomedical's SynCon preventive DNA vaccine receives approval in Korea for Phase I clinical trial 0 None
2010-03-02 Archimedes Pharma raises GBP65 million in new funding 0 None
2010-03-02 IgPro20 protects PI patients against infection 0 None
2010-03-02 PTSD drug: Cannabis Science to file first application for FDA clinical trials 0 None
2010-03-02 Celsion to commence Phase II Study of ThermoDox and RFA for CRLM 0 None
2010-03-02 Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION 0 None
2010-03-01 Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment 0 None
2010-03-01 Synexus recruits 87% of agreed number of patients in major osteoporosis study within deadline 0 None
2010-03-01 [11C]PiB PET neuroimaging exhibits potential for monitoring therapeutics on amyloid beta load during Alzheimer’s disease treatment 0 None
2010-02-27 ADMET tester Absorption Systems joins Society of Toxicology as Affiliate 0 4
2010-02-27 Single submission of orphan drug designation annual report for both FDA and EMA 0 2
2010-02-27 Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090 0 None
2010-02-26 Teva Pharmaceutical announces clinical study results of Copaxone in RRMS patients 0 None
2010-02-26 Antiretroviral therapy reduces mortality rates in patients co-infected with HIV and TB 0 None
2010-02-26 Study confirms efficacy and tolerability of lacosamide for uncontrolled POS 0 None
2010-02-26 Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients 0 5
2010-02-26 Genta initiates new dose-ranging study of tesetaxel drug 0 None
2010-02-25 Kinex Pharmaceuticals announces KX2-391 Phase 2 safety and efficacy clinical trial in men with CRPC 0 None
2010-02-25 Cannabis Science completes selection of initial cannabis-based pharmaceutical for FDA clinical trials 0 None
2010-02-25 OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC 0 None
2010-02-25 Study demonstrates Prochymal treamtent is safe for cardiac patients 0 None
2010-02-25 Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy 0 None
2010-02-25 Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV 0 None
2010-02-24 Welichem commences enrollment in WBI-1001 Phase IIa clinical trial for psoriasis 0 None
2010-02-24 Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients 0 None
2010-02-24 Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint 0 None
2010-02-24 Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting 0 5
2010-02-24 Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference 0 None
2010-02-24 ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI 0 5
2010-02-24 Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy 0 None
2010-02-23 Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction 0 4.5
2010-02-23 Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients 0 None
2010-02-23 Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes 0 None
2010-02-23 TCAD therapy active and synergistic against drug resistant influenza virus strains 0 None
2010-02-23 Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint 0 None
2010-02-23 GlycoVaxyn initiates Phase I clinical study of GVXN SD133 vaccine candidate against Shigella dysenteriae 0 None
2010-02-23 Viamet Pharmaceuticals, Novartis Option Fund partner to develop novel inhibitors against key metalloenzyme target 0 None
2010-02-23 Heartware completes patient enrollment for ADVANCE clinical trial 0 None
2010-02-23 Merrimack Pharmaceuticals commences dosing in MM-121/Tarceva combination Phase 1/2 study for NSCLC 0 None
2010-02-23 Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination therapy development 0 None
2010-02-22 Enzymerx completes enrollment for clinical trial of pegsitacase 0 None
2010-02-22 FDA grants Fast Track designation for Curemark's CM-AT autism treatment 0 None
2010-02-22 Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection 0 None
2010-02-20 Emory School of Medicine to enroll nearly 1,140 people for Phase III clinical trial of progesterone for TBI 0 None
2010-02-19 Polyphor discovers new class of antibiotics effective against multi-drug resistant Gram-negative bacteria 0 None
2010-02-19 BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines 0 None
2010-02-19 Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting 0 None
2010-02-19 BioSante Pharmaceuticals' LibiGel clinical update to be presented at 2010 ISSWSH annual meeting 0 None
2010-02-18 Incyte announces 2009 financial results and key fourth-quarter accomplishments 0 None
2010-02-18 Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME 0 None
2010-02-18 PK/PD data demonstrates clear relationship between TBR-652 plasma concentrations and antiviral activity 0 None
2010-02-18 Aprea's AML treatment receives EMEA recommendation for orphan drug status 0 None
2010-02-18 Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla 0 None
2010-02-18 Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers 0 None
2010-02-18 Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010 0 None
2010-02-17 Roche completes enrollment in RG7128 Phase 2b PROPEL study 0 None
2010-02-17 Tioga Pharmaceuticals to utilize $18M equity funding for Phase 3 clinical trial of asimadoline 0 None
2010-02-17 FDA clears Otonomy's IND for clinical trial of OTO-104 in Meniere's disease patients 0 4.2
2010-02-17 Marcadia Biotech commences Phase 1 clinical trial of MAR701 for type 2 diabetes 0 None
2010-02-17 Fourth-quarter and full-year 2009 results announced by Celsion 0 None
2010-02-17 Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer 0 None
2010-02-17 Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer 0 5
2010-02-17 ITS secures £8.65M Series-A equity funding round extension to fund synthetic flu vaccine study 0 None
2010-02-17 Generx clinical development opportunities: bioRASI to assist Cardium 0 None
2010-02-16 Cancer Research UK, immatics Biotechnologies sign collaboration agreement to trial IMA950 vaccine for GMB 0 None
2010-02-16 Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced 0 None
2010-02-16 Oncolytics Biotech receives U.K. MHRA approval for REOLYSIN combination Phase 3 trial 0 3
2010-02-16 MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial 0 None
2010-02-16 Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency 0 None
2010-02-14 Positive interim results from Helix BioPharma's Topical Interferon Alpha-2b Phase II pharmacokinetic study 0 None
2010-02-12 Debiopharm receives AFSSAPS approval of CTA for Debio 0932 inhibitor, triggers milestone payment to Curis 0 None
2010-02-12 Viral Genetics: Company update 0 None
2010-02-12 Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial 0 None
2010-02-12 Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity 1 5
2010-02-12 Third party reexamination of Phase III study of Ereska meets primary endpoint 0 None
2010-02-12 Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease 0 None
2010-02-12 Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease 0 None
2010-02-12 NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services 0 None
2010-02-12 Second-quarter fiscal 2010 results announced by Pharmacyclics 0 None
2010-02-12 Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented 0 None
2010-02-11 Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease 0 None
2010-02-11 PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study 0 None
2010-02-11 3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA 0 None
2010-02-11 YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference 0 None
2010-02-11 Biodel's VIAject insulin Phase 3 study results to be presented at international diabetes conference in Basel 0 None
2010-02-11 4SC AG announces the first treatment in Phase I clinical study of 4SC-205 0 None
2010-02-11 Micromet outlines the design of registration study for blinatumomab in ALL 0 None
2010-02-11 MUHC commences clinical trial of Exsulin for type 1 diabetes 0 5
2010-02-11 QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR 0 None
2010-02-10 Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium 0 None
2010-02-10 DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer 0 None
2010-02-10 Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint 0 None
2010-02-10 Positive results from Naurex's Phase I clinical trial of GLYX-13 reported 0 None
2010-02-10 Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International 0 None
2010-02-10 DMC recommends JV to continue enrolling patients in Phase III clinical trial of StemEx 0 None
2010-02-10 QR Pharma commences clinical trial of Posiphen in early stage AD patients 0 None
2010-02-10 Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial 0 None
2010-02-10 Johns Hopkins Hospital initiates Phase I trial with Neogenix's NPC-1C 0 4.3
2010-02-10 TI commences Phase IIa clinical trial for its lead molecule in CDH 0 None
2010-02-10 Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction 0 5
2010-02-10 Advaxi to receive fund from CRUK for clinical trial of ADXS11-001 0 None
2010-02-10 FDA expands indication for Crestor 0 None
2010-02-09 Thrombogenics announces publication of positive microplasmin Phase II trial results 0 None
2010-02-09 USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza 0 None
2010-02-09 Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir 0 None
2010-02-09 Resverlogix completes Phase 2 ASSERT trial enrollment 5 months ahead of schedule 0 None
2010-02-09 Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases 0 None
2010-02-09 Novavax announces new data from trivalent seasonal influenza VLP vaccine study 0 None
2010-02-09 GeoVax Labs provides updates on HIV-1 vaccine trials 0 None
2010-02-09 Positive data from Cara Therapeutics' peripherally-restricted kappa opioid agonist Phase II trial 0 None
2010-02-09 Genta commences Phase 2 trial of tesetaxel on first subject 0 None
2010-02-09 Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regions 0 None
2010-02-08 Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial 0 None
2010-02-08 Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study 0 None
2010-02-05 CREON effective in improving CFA and CNA in pediatric patients with EPI due to CF 0 None
2010-02-05 EBMT honours abstract on Defibrotide in Hepatic VOD prevention with the Van Bekkum Award 0 None
2010-02-05 BioTime announces results of independent Hextend study in hemodynamically unstable trauma patients 0 None
2010-02-05 Top-line results from Optimer Pharmaceuticals' second fidaxomicin Phase 3 trial in CDI patients 0 None
2010-02-05 BioMarin announces update on BMN 110 Phase I/II trial for Morquio A Syndrome 0 None
2010-02-05 WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial 0 None
2010-02-05 Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529 0 None
2010-02-04 Data analysis of Delcath Systems' Phase III trial of melphalan to be commenced 0 None
2010-02-04 Results from three phase two studies show the effectiveness of Tanezumab 1 None
2010-02-04 Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium 0 None
2010-02-04 Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced 0 None
2010-02-04 Recent clinical trials in patients with ALBP show that SOMA 250 mg reduces disability 0 None
2010-02-04 Phase 2a clinical trial results of VX-809 in patients with CF announced 0 None
2010-02-03 Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401 0 None
2010-02-03 Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications 0 4
2010-02-03 MV vaccine prevents TB in people with HIV infection 0 None
2010-02-03 Promising results from Soligenix' RiVax vaccine trials against ricin toxin 0 None
2010-02-03 Repros Therapeutics receives FDA confirmation for initiating Androxal IND 0 None
2010-02-03 Artefill could be viable for lipoatrophy and non-surgical anti-aging enhancement 0 None
2010-02-02 GenSpera’s G-115 anti-cancer drug awarded US patent 0 None
2010-02-02 Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia 0 None
2010-02-02 RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation 0 None
2010-02-02 Phase III study evaluating PEP005 Gel for treatment of AK meets primary clinical endpoint 0 None
2010-02-02 Pervasis Therapeutics reaches agreement with FDA on pivotal Phase 3 clinical trial for Vascugel 0 None
2010-02-01 Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza 0 None
2010-02-01 Interim positive data from Phase IIa clinical study of SYN115 for Parkinson’s disease 0 3
2010-01-30 Clinical results of MedImmune's pivotal trial for motavizumab published 0 None
2010-01-30 Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia 0 None
2010-01-29 Positive Phase 2 trial results of Keryx Biopharmaceuticals' KRX-0401 announced 0 None
2010-01-29 New guidance may help minimize risks to patient privacy in clinical trials 0 None
2010-01-29 Diabetes vaccine: Diamyd Medical to file for market approval in 2011 0 None
2010-01-29 Merge Healthcare deploys etrials eDiary 5.0 platform for global urology clinical trial 0 None
2010-01-28 Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV 0 None
2010-01-28 ChemoCentryx announces the initiation of Phase I clinical trial of CCX168 0 None
2010-01-28 Zelos Therapeutics commences dosing in clinical study of ZT-034 nasal spray for osteoporosis 0 None
2010-01-28 NIDA supports Omeros' Addiction program 0 None
2010-01-28 Neovasc to fund proceeds of its non-brokered private placement for COSIRA trial 0 None
2010-01-28 Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases 0 None
2010-01-28 Anacor Pharmaceuticals to present data on its PDE4 inhibitor at the Cytokines and Inflammation Conference 0 None
2010-01-28 Men welcome male contraceptive pill currently undergoing trials 0 None
2010-01-28 GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients 0 None
2010-01-27 Positive results from Supernus Pharmaceuticals' SPN 810 Phase IIa trial for ADHD 0 None
2010-01-27 GenSpera commences treatment in G-202 Phase I trial for solid tumors 0 None
2010-01-27 Eribis Pharmaceuticals' cardiovascular therapy program receives new investment from Karolinska Development 0 None
2010-01-27 Cornerstone Pharmaceuticals closes $6.17M Series B-4 private equity financing 0 None
2010-01-27 Suneva Medical to present interim data from its Artefill study for NLF correction at the Maui Derm 2010 0 None
2010-01-27 Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes 0 1
2010-01-27 Dynavax Technologies to present data on its SD-101 Phase 1b trial for chronic HCV infection 0 None
2010-01-27 Curemark commences CM-AT Phase III autism clinical trial enrollment at ten sites 0 None
2010-01-27 YM BioSciences' nimotuzumab Phase II trials: FDA advises patient enrollment 0 None
2010-01-25 Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B 0 None
2010-01-24 Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced 0 None
2010-01-23 Pfizer reports final results from randomized Phase 3 trial of Sutent 0 None
2010-01-22 Biovail comments on Teva Pharmaceutical's proposed Budeprion XL trial 0 None
2010-01-22 Progress in Anadys Pharmaceuticals' Phase II study of ANA598 announced 0 None
2010-01-22 CMO to manufacture Gaia BioPharma's GAI-122 Mitochondria-targeted neuroprotective agent 0 None
2010-01-21 Ipsen and Inspiration Biopharmaceuticals form strategic partnership 0 None
2010-01-21 Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC 0 None
2010-01-21 China Pharma Holdings announces completion of clinical trials for Candesartan 0 None
2010-01-21 Elevation Pharmaceuticals closes $30M tranched Series A financing 0 None
2010-01-21 Pharmasset commences PSI-7977 Phase 2a trial for HCV 0 None
2010-01-21 BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial 0 None
2010-01-21 Results of two pivotal Phase III clinical trials with oral FTY720 published 0 None
2010-01-21 Phase 3 clinical trial results of Inspire Pharmaceuticals' PROLACRIA announced 0 None
2010-01-21 IMUC’s ICT-107 vaccine product candidate targets cancer stem cells 0 5
2010-01-21 EMD Serono announces results from CLARITY Phase III trial in MS patients 0 None
2010-01-21 Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced 0 None
2010-01-20 Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients 0 None
2010-01-20 PROLOR Biotech's hGH-CTP Phase I study data to be presented at the BIO CEO & Investor Conference 0 None
2010-01-20 Telaprevir effective in HCV patients 4 3
2010-01-20 PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD 0 None
2010-01-20 Depomed plans additional Serada Phase 3 trial for treatment of menopausal hot flashes 0 None
2010-01-20 Patient enrollment for Phase 2B clinical study of Oramed Pharmaceuticals' ORMD-0801 completed 0 None
2010-01-20 Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment 0 None
2010-01-20 Preliminary data from Phase 1 study of Sangamo BioSciences' SB-728-T announced 0 5
2010-01-19 CytoDyn commences enrollment in Cytolin clinical trial 0 None
2010-01-19 DURECT commences dosing in its POSIDUR Phase III clinical trial 0 None
2010-01-19 Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies 0 None
2010-01-19 PCI Biotech AS completes second dose group in phase I/II study of Amphinex 0 None
2010-01-19 Enrollment of Phase 2 portion of Cempra Pharmaceuticals' Phase 2/3 clinical trial of TAKSTA completed 0 None
2010-01-18 New neuroprotective drug trial for people with traumatic brain injuries 0 None
2010-01-18 AVIR Green Hills Biotechnology commences deltaFLU Phase II study 1 None
2010-01-18 Treatment for chronic hepatitis C with pegylated-interferon and ribavirin proves effective 0 None
2010-01-17 Results from Bionovo's phase 1B clinical trial of Bezielle published 0 None
2010-01-13 Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1 0 5
2010-01-13 New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic 0 None
2010-01-13 Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials 0 None
2010-01-12 Patient enrollment in Spherix's global Phase 3 clinical trial NEET completed 0 None
2010-01-12 Vion Pharmaceuticals files SPA for Onrigin-LDAC combination Phase II/III trial 0 None
2010-01-12 Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer 0 None
2010-01-12 Phase I clinical trial of XRX-001 for yellow fever initiated 0 None
2010-01-12 Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV 0 None
2010-01-12 HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C 0 None
2010-01-12 Pfizer/Medivation's AD drug Dimebon may garner peak year sales of $1.5 billion 0 None
2010-01-12 Salt Lake City research center joins international drug trial program for painful menstrual cramps 0 None
2010-01-12 CEL-SCI completes validation of its GMP manufacturing facility 0 None
2010-01-12 NicOx, TOPIGEN Pharmaceuticals terminate TPI 1020 collaboration 0 None
2010-01-12 Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine 0 None
2010-01-12 4SC commences treatment in its resminostat Phase II trial for HL 0 None
2010-01-12 Idenix Pharmaceuticals announces significant progress in HCV development programs 0 None
2010-01-12 Second pivotal efficacy study not required for MAP Pharmaceuticals' LEVADEX NDA 0 None
2010-01-12 YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration 0 None
2010-01-12 Pfizer commences SBI-087 Phase 2 clinical trial for RA 0 None
2010-01-12 Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel 0 None
2010-01-12 Positive results from KemPharm's KP106 Phase 1 clinical trial for ADHD 0 None
2010-01-12 Interim results from Phase I clinical trials utilizing PLX-PAD for treatment of CLI reported 0 None
2010-01-12 BioMarin Pharmaceutical commences BMN 195 Phase 1 clinical study for DMD 0 None
2010-01-11 Positive top-line results from Protox Therapeutics' Phase 2b study of PRX302 announced 0 None
2010-01-11 Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics 0 None
2010-01-11 Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease 0 None
2010-01-11 New data from phase 3 study of avanafil for treatment of ED announced 3 5
2010-01-11 Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published 0 None
2010-01-11 Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy 0 None
2010-01-09 Results of randomized, placebo-controlled study of Ambrotose complex announced 0 None
2010-01-09 Acetylon Pharmaceuticals to utilise additional funding in multiple myeloma drug development 0 None
2010-01-09 LFB completes conversion of all acquired preferred stock 0 None
2010-01-09 Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma 0 3.2
2010-01-09 Savient Pharmaceuticals announces filing of KRYSTEXXA BLA resubmission on track 0 None
2010-01-08 Funxional Therapeutics completes Phase I study of FX125L 0 None
2010-01-08 TetraLogic Pharmaceuticals commences its TL32711 SMAC mimetic Phase 1 clinical trial 0 5
2010-01-08 Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer 0 5
2010-01-08 Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study 0 None
2010-01-08 Patient enrollment in Tolerx's Phase 3 clinical study DEFEND-1 completed 0 None
2010-01-08 University Hospitals Case Medical Center conducts Phase 2 clinical trial of gene therapy for AD 0 None
2010-01-08 Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced 0 5
2010-01-08 Initiation of double blind placebo controlled multi-center trial of DAS181 announced 0 None
2010-01-08 Pfizer and Debiopharm Group enter into co-development agreement to conduct Phase 3 trial of tremelimumab 0 None
2010-01-07 Positive results from phase 2 study evaluating the safety and efficacy of Qnexa announced 0 None
2010-01-07 Positive top-line results from Phase III study of aclidinium bromide announced 0 None
2010-01-07 BioVex's Phase 3 melanoma study amended to include first line patients 0 None
2010-01-07 Phase II clinical trial results of Liposome-Entrapped Paclitaxel announced 0 5
2010-01-07 Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective 0 None
2010-01-06 Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38 0 None
2010-01-06 Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206 0 None
2010-01-06 OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427 0 None
2010-01-06 Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results 0 None
2010-01-06 Patient enrolled in Phase I clinical study of two investigational compounds: MK-2206 and AZD6244 0 4
2010-01-06 Keryx Biopharmaceuticals reaches SPA agreement for Phase 3 clinical program for Zerenex 0 None
2010-01-06 Phase I clinical trial for Intellikine's INK128 inhibitor initiated 0 None
2010-01-06 Scott & White's CRI launches two clinical trials targeting cancers 0 None
2010-01-06 Excaliard Pharmaceuticals initiates Phase 2 trials of EXC 001 0 None
2010-01-06 EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124 0 None
2010-01-06 IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090 0 None
2010-01-06 Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4 0 None
2010-01-06 Enrollment for sham-controlled study of radiation therapy for treatment of wet AMD announced 0 None
2010-01-05 DSMB recommends Quark Pharmaceuticals to continue clinical study of QPI-1002 0 None
2010-01-05 Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated 0 None
2010-01-05 Talampanel slows progression of amyotrophic lateral sclerosis 0 None
2010-01-04 Headline results from first phase III study of Balaglitazone announced 0 None
2010-01-04 DSPA submits lurasidone NDA to the FDA 0 None
2010-01-04 BioInvent International begins BI-505 drug study on patients with advanced multiple myeloma 0 None
2010-01-04 Novelos continues NOV-002 Phase 3 combination trial for lung cancer 0 5
2010-01-03 D-Pharm commences enrollment in MACSI Phase III clinical study for acute ischemic stroke 0 5

Total

2792 posts
53 comments
428 raters